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ABSTRACT 
 
Hypertension is one of the major health problems worldwide. Bioactive peptides that 
inhibit angiotensin I-converting enzyme (ACE) in the blood pressure regulation system 
(renin-angiotensin system) can contribute to the prevention and treatment of 
hypertension. Mushroom species studied are high in protein content, which makes them 
potentially a good source of antihypertensive peptides. Among the nine edible 
mushrooms evaluated, protein extracts from Pleurotus cystidiosus (E1Pc and E5Pc) and 
Agaricus bisporus (E1Ab and E3Ab) exhibited high levels of ACE inhibitory activity. 
The protein extracts were fractionated by reverse-phase high performance liquid 
chromatography (RPHPLC) into six fractions each. Fraction 3 from E5Pc (E5PcF3) and 
fraction 6 from E3Ab (E3AbF6) with the highest ACE inhibitory activity were selected 
for proteomic analysis. SDS-PAGE analysis showed E5PcF3 consisted mainly of low 
molecular weight proteins while E3AbF6 contained a variety of high to low molecular 
weight proteins. There were 22 protein clusters detected by SELDI-TOF-MS analysis 
with five common peaks found in E5PcF3 and E3AbF6, which had m/z values in the 
range of 3940 to 11413. Further purification by size exclusion chromatography (SEC) 
yielded seven fractions. SEC fraction 1 of E5PcF3 (E5PcF3C1) as well as SEC fraction 
1 and 4 of E3AbF6 (E3AbF6C1 and E3AbF6C4) showed the highest percentages of 
ACE inhibitory activity. Nine peptides with potential ACE inhibitory activity were 
selected from the list of peptides obtained by LC/MS/MS analysis. Two peptides were 
from E5PcF3C1 (AHEPVK, GPSMR) while five peptides (KVAGPK, FALPC, RIGLF, 
EGEPR, APSAK) and three peptides (AHEPVK, GVQGPM, PSSNK) were selected 
from E3AbF6C1 and E3AbF6C4, respectively. The nine peptides were chemically 
synthesized and tested for their IC50 values and their stability against gastrointestinal 
enzymes (pepsin, trypsin and chymotrypsin). The lowest IC50 value was exhibited by 
AHEPVK, where 50% of ACE activity was reduced at a concentration of 62.6 µM. This 
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was followed by RIGLF and PSSNK, where their IC50 values were 115.9 and 129.3 µM, 
respectively. Interestingly, the ACE inhibitory activity of the peptides was stable at the 
acidic and basic pH of stomach and intestine. Their biological activity was also retained 
after gastrointestinal digestion. BIOPEP analysis predicted AHEPVK was stable 
throughout the digestion process. The remaining eight peptides could be further 
hydrolyzed by the digestive enzymes to produce fragments of peptides, 2-4 amino acids 
in length with enhanced ACE inhibitory activity. The inhibition pattern of the three 
most potent peptides (AHEPVK, RIGLF and PSSNK) was determined by Lineweaver 
Burk plot. AHEPVK and RIGLF exhibited competitive inhibition pattern against the 
ACE while PSSNK showed noncompetitive inhibition pattern. Therefore, the peptides 
tested in the current study, particularly AHEPVK, RIGLF and PSSNK could be 
potential ACE inhibitors from mushroom. The widely available mushroom source and 
rare food allergy cases makes the peptides a potential source to be applied as ingredient 
in functional foods, dietary supplements or produced as pharmaceutical antihypertensive 
drugs. 
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ABSTRAK 
 
Hipertensi merupakan salah satu masalah kesihatan utama di seluruh dunia. Peptida 
bioaktif yang merencat enzim angiotensin-I converting enzyme (ACE) dalam sistem 
pengawalaturan tekanan darah (sistem renin-angiotensin) boleh menyumbang kepada 
pencegahan dan rawatan hipertensi. Cendawan yang dikaji mempunyai kandungan 
protein yang tinggi. Ini menjadikannya sumber yang baik untuk peptida antihipertensi. 
Antara sembilan cendawan yang dikaji, ekstrak protein daripada Pleurotus cystidiosus 
(E1Pc dan E5Pc) dan Agaricus bisporus (E1Ab dan E3Ab) mempunyai aktiviti 
antihipertensi yang tinggi. Setiap ekstrak protein tersebut difraksi kepada enam fraksi 
dengan menggunakan ‘Reverse Phase High Performance Liquid Chromatography’ 
(RPHPLC). Fraksi 3 daripada E5Pc (E5PcF3) dan fraksi 6 daripada E3Ab (E3AbF6) 
dengan aktiviti antihipertensi tertinggi telah dipilih untuk analisis proteomik. Analisis 
SDS-PAGE menunjukkan E5PcF3 terdiri terutamanya daripada protein dengan berat 
molekul rendah manakala E3AbF6 mengandungi protein dengan pelbagai berat molekul 
tinggi dan rendah. Terdapat 22 kelompok protein dikesan oleh analisis SELDI-TOF-MS 
dengan lima puncak yang sama ditemui dalam E5PcF3 dan E3AbF6, yang mempunyai 
nilai m/z dalam lingkungan 3940-11413. Penulenan selanjutnya dengan menggunakan 
‘Size Exclusion Chromatography’ (SEC) menghasilkan tujuh fraksi. Fraksi SEC 1 
daripada E5PcF3 (E5PcF3C1) serta fraksi SEC 1 dan 4 daripada E3AbF6 (E3AbF6C1 
dan E3AbF6C4) menunjukkan peratusan aktiviti antihipertensi tertinggi. Analisis 
LC/MS/MS daripada tiga fraksi SEC tersebut telah mengenalpasti sembilan urutan 
peptida yang berpotensi dalam merencat aktiviti ACE. Dua peptida dari E5PcF3C1 
(AHEPVK, GPSMR) manakala lima peptida (KVAGPK, FALPC, RIGLF, EGEPR, 
APSAK) dan tiga peptida (AHEPVK, GVQGPM, PSSNK) telah dipilih, masing-masing 
dari E3AbF6C1 dan E3AbF6C4. Sembilan peptida tersebut telah disintesis secara kimia 
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dan diuji nilai IC50 dan kestabilan terhadap enzim pencernaan (pepsin, tripsin dan 
kimotripsin). Nilai IC50 terendah ditunjukkan oleh AHEPVK, di mana 50% aktiviti 
ACE telah disekat pada kepekatan 62.6 µM. Ini diikuti oleh RIGLF dan PSSNK, 
dengan nilai IC50 masing-masing ialah 115.9 dan 129.3 µM. Semua peptida 
menunjukkan aktiviti perencatan enzim ACE yang stabil pada pH berasid dan beralkali 
dalam perut dan usus. Aktiviti biologi mereka juga dikekalkan selepas pencernaan. 
Analisis BIOPEP menunjukkan AHEPVK adalah stabil sepanjang proses pencernaan. 
Baki lapan peptida berkemungkinan dihidrolisiskan oleh enzim pencernaan untuk 
menghasilkan serpihan peptida, 2-4 amino asid panjang yang mempunyai aktiviti 
perencatan enzim ACE yang meningkat. Corak perencatan tiga peptida yang paling 
potent (AHEPVK, RIGLF dan PSSNK) ditentukan oleh plot Lineweaver Burk. 
AHEPVK dan RIGLF menunjukkan corak perencatan kompetitif manakala PSSNK 
menunjukkan corak perencatan tak kompetitif. Oleh itu, peptida yang diuji, terutamanya 
AHEPVK, RIGLF dan PSSNK adalah perencat enzim ACE yang berpotensi dari 
cendawan. Sumber cendawan yang senang didapati dan jarang menyebabkan kes alahan 
makanan membuatkan peptida tersebut sumber yang berpotensi untuk digunakan 
sebagai ramuan dalam diet tambahan atau dihasilkan sebagai ubat antihipertensi.  
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1.0 INTRODUCTION 
Hypertension or high blood pressure is defined as persistent elevation of systolic blood 
pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg. 
Hypertension affects about 30% of the adult population in most countries and has 
become one of the leading public health problems worldwide (Lawes et al., 2008). It is 
one of the risk factors for cardiovascular diseases, such as stroke, heart failure, cardiac 
arrhythmia and arteriosclerosis (Yunus et al., 2004). It is estimated that approximately 
7.6 million of premature deaths were attributed to high blood pressure worldwide 
(Lawes et al., 2008). The number of adults with hypertension is predicted to increase to 
a total of 1.56 billion in the year 2025 (Kearney et al., 2005). 
The most common blood pressure regulation mechanism has been associated with 
the renin-angiotensin system. Renin is a protease synthesized by the kidney. It converts 
angiotensinogen from the liver to angiotensin I, which is a biologically inactive 
decapeptide. Later, angiotensin I is converted to an active octapeptide vasoconstrictor, 
angiotensin II, by the action of angiotensin I-converting enzyme (ACE). This reaction 
will cause the contraction of blood vessels and thereby leads to hypertension. Another 
blood pressure regulation pathway involves a peptide called bradykinin. It causes blood 
vessels to enlarge and therefore lowering the blood pressure (Lam et al., 2009). ACE 
inhibitors block the conversion of angiotensin I to angiotensin II and inhibit the 
degradation of bradykinin and thus lowers the blood pressure (Sweitzer, 2003; Tom et 
al., 2002). Therefore, ACE inhibitors have become an important therapeutic approach in 
the development of antihypertensive drugs. 
Many attempts have been made in the production of artificial synthetic ACE 
inhibitors. Currently, synthetic ACE inhibitor drugs such as captopril, enalapril and 
lisinopril are used for hypertension therapy in clinical practice. However, synthetic 
drugs may cause undesirable side effects such as cough, taste disturbances, skin rashes 
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and angioedema in hypertensive patients, who usually require life-long medication 
(Brown & Vaughan, 1998; Murray & Crowther, 1998). Since the first discovery of ACE 
inhibitory peptide from snake venom (Borgheresi et al., 1996), many studies were 
carried out to find ACE inhibitory peptides from natural sources such as high protein 
food. Previous studies have reported on the successful purification of ACE inhibitory 
peptides from foods such as tuna (Lee et al., 2010), buckwheat (Ma et al., 2006), milk 
(Nakamura et al., 1995) and potato (Pihlanto et al., 2008). 
Mushrooms have received increasing attention in recent years because of its 
nutrition with health-stimulating properties and medicinal effects. Beside nutritional 
value, the unique colour, taste and aroma of the mushrooms which can sometimes 
stimulate one’s appetite are also the reasons that attract their consumption by humans 
(Chang, 2008). It is not easy to separate edible and medicinal mushrooms because many 
of the common edible species that are beneficial in the prevention and treatment of 
various human diseases and several medically related mushrooms that are also eaten. 
The most reported medicinal mushroom with blood pressure lowering effect is 
Ganoderma lucidum (Guillamón et al., 2010). Previous studies have also reported on 
the antihypertensive effect of some edible mushrooms. Lentinula edodes, Flammulina 
velutipes and Pleurotus species such as P. cornucopiae, P. nebrodensis and P. sajor-
caju have been reported to possess hypotensive activity (Hagiwara et al., 2005; Kim et 
al., 2002; Miyazawa et al., 2008; Tam et al., 1986; Wasser, 2005). 
Mushrooms are rich in protein content. The amount of crude protein in 
mushrooms is ranked below most animal meats but above most other foods, such as 
milk, vegetables and fruits (Chang & Miles, 2004). The high protein content of 
mushrooms makes them a potential source of antihypertensive peptide. Besides, the 
mushroom industry is becoming popular in Malaysia. Hence, a large amount of 
mushrooms can be obtained from the mushroom farms in Malaysia for protein 
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extraction. Previous studies have shown successful purification of ACE inhibitory 
peptides from fruiting bodies of edible mushrooms, Tricholoma giganteum (Lee et al., 
2004), Grifola frondosa (Choi et al., 2001), Pholiota adiposa (Koo et al., 2006) and P. 
cornucopiae (Jang et al., 2011). 
Thus, based on the reasons mentioned above, the objectives of this study are  
1. To evaluate the antihypertensive activity of crude water extracts and proteins 
from fruiting bodies of nine selected species of edible mushrooms. 
2. To carry out bioassay-guided purification of angiotensin I-converting enzyme 
(ACE) inhibitory peptide from the selected active protein fractions. 
3. To test the effect of gastrointestinal digestion on the ACE inhibitory activity of 
the selected peptides and to determine their ACE inhibition pattern. 
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2.0 LITERATURE REVIEW 
2.1 Hypertension 
Blood pressure is the force created by the heart as it pushes blood into the arteries 
through the circulatory system. It is recorded in two numbers. A normal blood pressure 
has a reading below 120/80 mm/Hg. The “120” is the systolic blood pressure 
representing the pressure while the heart contracts to pump blood to the body. The “80” 
is the diastolic blood pressure representing the pressure when the heart relaxes between 
beats. A person diagnosed with high blood pressure or hypertension usually has blood 
pressure reading above 140/90 mm/Hg (Lewis, 2009). It occurs when the arteries 
become narrowed because of blood clots or cholesterol and plaque build-up in the 
arteries. Thus, the heart has to pump harder to force the blood to pass through them 
(Valeo, 2013).  
There are two categories of hypertension, primary and secondary hypertension. 
Primary hypertension, which is also called essential hypertension, is the most common 
type of hypertension, affecting 95% of hypertensive patients. The cause of primary 
hypertension is unknown. It is usually linked to genetics, race, unhealthy diet, lack of 
exercise and obesity (Carretero & Oparil, 2000). Thus, the diagnosis of primary 
hypertension is made after excluding known causes that comprise secondary 
hypertension. Secondary hypertension is less common compared to primary 
hypertension. It affects only 5% of hypertensive patients (Mayet & Coats, 1998). It can 
be caused by conditions that affect the kidneys, arteries, heart or endocrine system and 
can be a side effect of many medications. It can also occur during pregnancy (Chiong et 
al., 2008).  
Hypertension has been on the rise worldwide. According to World Health 
Organization (WHO), it is estimated that nearly one billion people globally have high 
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blood pressure (Chockalingam et al., 2006). Kearney et al. (2005) predicted that the 
number of adults with hypertension would increase to approximately 1.56 billion in the 
year 2025. In Malaysia, four out of ten adults suffer from hypertension (Yunus et al., 
2004). Hypertension is one of the major risk factors for cardiovascular diseases, such as 
atherosclerosis, myocardial infarction, stroke and renal failure (Whitworth, 2003). 
Cardiovascular disease has been the principal cause of death in government hospitals in 
Malaysia. It accounted for about 23-26% of deaths from 1994 to 2001 (Zambahari, 
2004). This high rate is most probably due to the low awareness, low rates of treatment 
and poor control rates of hypertension among the Malaysians (Lim & Morad, 2004). 
Hypertension is a ‘silent killer’ because it usually causes no symptoms until the 
people who had it measure their blood pressure (Moser, 2007). Some of the symptoms 
may develop in people with markedly elevated blood pressure, which includes headache, 
dizziness, blurred vision, nausea and chest pain. People often do not seek medical care 
until they have symptoms arising from the organ damage caused by long-term high 
blood pressure. Examples of organ damage commonly seen in chronic high blood 
pressure are heart attack, heart failure, stroke, kidney failure, vision loss and leg pain 
when walking. Thus, besides measuring blood pressure, doctors will also inspect the 
eyes of hypertensive patients for thickening or narrowing blood vessels, examination of 
the heart for unusual sounds or beats, examination of the enlargement of kidneys and 
swelling in the neck (goiter) which is caused by overactive or underactive thyroid, a 
condition that can elevate blood pressure (Moser, 1992). 
There are different ways to treat hypertension, which involves lifestyle 
modification alone or with pharmacological treatment. Lifestyle changes, such as losing 
weight, exercise, limit alcohol intake, reduce sodium intake, stop smoking and taking a 
well balanced diet rich in fresh fruits and vegetables are able to control the blood 
pressure level and prevent hypertension (Barbosa-Filho et al., 2006). Meta-analysis 
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carried out by Neter and coworkers showed that weight loss makes an important 
contribution to the treatment of hypertension, especially in subjects taking 
antihypertensive medication (Neter et al., 2003). Based on the findings by Geleijnse et 
al. (2003) and Bray et al. (2004), a great reduction in blood pressure level was observed 
among adults with high potassium and reduced sodium intake. A control trial on 2234 
participants have shown a dose-response relationship between the mean percentage of 
alcohol reduction and the mean blood pressure reduction (Xin et al., 2001). In addition, 
The National Heart, Lung and Blood Institute (NHLBI), U.S. has developed a diet plan 
known as DASH diet (Dietary Approaches to Stop Hypertension) to prevent and control 
hypertension. The diet is rich in fruits, vegetables, whole grains and low-fat dairy foods. 
The diet plan has been proven to significantly lower the blood pressure (Svetkey et al., 
1999). Beside blood pressure lowering effect, a cohort study among middle-aged 
women during 24 years of follow-up showed association of DASH diet with a lower 
risk of coronary heart disease and stroke (Fung et al., 2008). Lifestyle changes may 
effectively lower the blood pressure, however it requires patience and motivation.  
Previous study has reported on the successful reduction of blood pressure and its 
associated symptoms by massage therapy (Hernandez-Reif et al., 2000). Other 
treatments such as acupuncture (Weil et al., 2007), Qigong (Cheung et al., 2005), Tai 
Chi (Tsai et al., 2003) and yoga (Cohen et al., 2011) have also been reported to show 
hypotensive effect.  
Beside lifestyle changes and drug medication, botanical medicines can also help 
to normalize blood pressure. Yarnell and Abascal (2001) have reported on the 
effectiveness of rauwolfia, garlic and hibiscus to reduce the blood pressure reading. Oral 
administration of extracts from fruiting bodies of reishi has been proven to show 
hypotensive effect in spontaneously hypertensive rats (Kumakura et al., 2008). Non-
herbal supplements such as fish oil (Knapp & FitzGerald, 1989), co-enzyme Q10 
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(Hodgson et al., 2002), green algae (Merchant et al., 2002), vitamin C (Duffy et al., 
1999) and combination of vitamins and minerals (Farvid et al., 2004) had also shown 
successful blood pressure lowering effect. Ernst (2005) had summarized the clinical trial 
reports on the treatment of hypertension by lifestyle modification, herbal medicines and 
non-herbal supplements. Therefore, people have to be alerted about the importance of 
consuming dietary supplements from natural products to maintain their health and 
prevent diseases; “prevention is better than cure”.  
 
2.2 Antihypertensive drugs 
There are many classes of antihypertensive drugs, which lower blood pressure by 
different means. The most widely used are diuretics, beta-blockers, alpha-blockers, 
alpha2-agonists, calcium channel blockers, angiotensin II receptor antagonists and ACE 
inhibitors (Barbosa-Filho et al., 2006). 
Diuretics help the kidneys to eliminate excess salt and water from the body’s 
tissues and blood, thereby, cause vasodilatory effect and reduce the blood pressure 
(Ernst & Mann, 2011). It is recommended for patients with mild to moderate 
hypertension. Three main classes of diuretics are thiazide-diuretics, loop diuretics and 
potassium sparing diuretics (Shah et al., 2004). The increase of serum uric acid 
concentration induced by diuretics can trigger a gouty attack. Besides formation of gout, 
other side effects of diuretics include interstitial nephritis, ototoxicity, sun sensitivity 
and urinary frequency (Ernst & Mann, 2011).  
Alpha-blockers and beta-blockers are antihypertensive drugs that reduce the blood 
pressure by blocking the action of the sympathetic nervous system and reduce the force 
of heart muscle’s contractions. Alpha-blockers and beta-blockers are not recommended 
to be used as first-line therapy for hypertension. They can be considered as second-line 
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or third-line agents when drugs from other classes are not sufficient to achieve target 
blood pressure (Bangalore & Messerli, 2008; Rossitto et al., 2010). Consumption of 
beta-blockers have undesirable adverse effects, such as drowsiness, sleep disturbance, 
visual hallucinations, depression, blurring of vision and reducing the physical 
performance of body (Bangalore & Messerli, 2008; Bengtsson, 1984). Side effects of 
alpha-blockers include dizziness, fatigue and somnolence (Rossitto et al., 2010). 
Furthermore, National Institute for Health and Clinical Excellence in the UK has 
downgraded the role of beta-blockers due to their risk of provoking type 2 diabetes 
(NICE, 2006).  
Alpha2-agonist can help to treat hypertension by stimulating the brain to open 
peripheral arteries and ease the blood flow. They are usually administered in 
combination with a diuretic. Clonidine, a type of alpha2-agonist has been used as an 
antihypertensive agent since the late sixties. Administration of clonidine may cause side 
effects such as drowsiness, dry mouth, increase of blood glucose concentration and 
impotence (Basker et al., 2009).  
Another type of antihypertensive drug, calcium channel blockers or also known as 
calcium antagonists work by blocking the entry of calcium into muscle cells in artery 
walls and thus reduce the arterial pressure and decrease the blood pressure (Hernández-
Hernández et al., 2002). Opie and Schall (2002) had reported that calcium channel 
blockers gave a higher risk of myocardial infarction. Besides myocardial infarction, 
consumption of calcium channel blockers had also been associated to the higher risk of 
mortality and cancer (Cheng & Behar, 1997).  
ACE inhibitors regulate the blood pressure through the renin-angiotensin system 
and the kallikrein-kinin system (Murphey et al., 2003). Its mechanism of action will be 
discussed in detail in the next part of the thesis (Section 2.3). 
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The different classes of antihypertensive drugs mentioned above have been shown 
to effectively lower blood pressure in hypertensive patients. The frequency of 
antihypertensive agents used differs according to countries. For example, calcium 
channel blocker is preferred in Japan whereas beta-blockers and diuretic are the most 
widely prescribed antihypertensive drugs in the U.S. and Europe (Higashi et al., 2000; 
Muratani et al., 1996). National Institute for Health and Clinical Excellence in the UK 
has recommended ACE inhibitor as the first choice for the treatment of hypertension 
(NICE, 2006). According to Forni et al. (2010), the choice of the antihypertensive drug 
prescribed should depend on its side-effect profile. Some antihypertensive drugs are 
better than others in specific groups of patients. For example, ACE inhibitors are 
preferred to be prescribed to treat hypertension in patients with diabetes (Opie & Schall, 
2002). Some studies have reported on the benefits of combination therapy compared to 
monotherapy. The treatment involving the combination of two or more antihypertensive 
agents requires less time to achieve target blood pressure and better tolerability 
compared to higher dose monotherapy (Frank, 2008). Example of combination therapy 
include ACE inhibitor and calcium antagonists (Forni et al., 2010).  
 
2.3 ACE inhibitors 
Blood pressure is controlled by a number of different interacting biochemical pathways. 
It can be increased or decreased depending on the pathway that predominates at any 
given time (Hong et al., 2008). The most common blood pressure control has been 
associated with the renin-angiotensin system. Renin is a protease synthesized by the 
kidney. It converts the angiotensinogen from the liver to angiotensin I, which is a 
biologically inactive decapeptide. Later, angiotensin I is converted to an active 
octapeptide vasoconstrictor, angiotensin II, by the action of ACE. This reaction will 
cause the contraction of blood vessels and thereby raising the blood pressure (Kumar et 
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al., 2010). Another blood pressure pathway involves a peptide called bradykinin. It can 
cause the enlargement of blood vessels and thereby lowering the blood pressure. In this 
pathway, ACE has a promoting effect in the degradation and inactivation of bradykinin 
(Lam et al., 2009; Pina & Roque, 2008). ACE inhibitors have the effect to suppress the 
conversion of angiotensin I to angiotensin II and inhibit the degradation of bradykinin 
and further lowering the blood pressure (Kumar et al., 2010; Sweitzer, 2003). Thus, 
ACE inhibitors have become an important therapeutic approach in the development of 
antihypertensive drugs. 
Besides being used as a drug for patients with hypertension, ACE inhibitor also 
plays a role in the regulation of other types of diseases. According to O'Keefe et al. 
(2001), ACE inhibitor is effective in the treatment of patients with atherosclerosis. 
There is also an improvement in diagnosis when ACE inhibitors were supplied to 
patients who have diabetes but with normal blood pressure. It reduces the new-onset of 
type 2 diabetes through unknown mechanisms (O'Keefe et al., 2001). The Heart 
Outcomes Prevention Evaluation Study Investigators (HOPE) reported that ramipril, a 
type of ACE inhibitor, is effective in the reduction of death rate, myocardial infarction, 
stroke revascularization, cardiac arrest, heart failure and complications related to 
diabetes (HOPE, 2000). Another type of ACE inhibitor, captopril has also been tested to 
be effective in the protection against deterioration in renal function in insulin-dependent 
diabetic nephropathy (Lewis et al., 1993). 
There is a correlation between cardiovascular diseases, diabetes and hypertension. 
Cardiovascular diseases are the major causes of mortality in persons with diabetes and 
hypertension (Sowers et al., 2001). Pharmacologic therapy that interrupts the renin-
angiotensin system may reduce cardiovascular and renal diseases in diabetic patient 
with hypertension (Sowers & Haffner, 2002). This was supported by a report showing 
ACE inhibitor therapy reduced the probability of hypertensive patients to develop type 
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2 diabetes (Sowers et al., 2001). In contrast, hypertensive patients who were taking 
another type of antihypertensive medication, beta-blockers had a higher risk of getting 
diabetes (Gress et al., 2000). Therefore, ACE inhibitors are prescribed as the first line 
treatment for hypertensive patients with diabetes (Vivian & Rubinstein, 2002).  
Basically, ACE inhibitors can be divided into three groups based on their reactive 
moiety that binds with ACE. The first group consists of captopril and zofenopril which 
binds with ACE by a sulfhydryl (SH) linkage. In vitro studies suggest that the presence 
of SH may confer properties other than ACE inhibition to these drugs. For instance 
captopril and zofenopril has exhibited cardioprotective and free radical scavenging 
abilities in animal studies (Liu et al., 1992). The second group of ACE inhibitor 
contains a phosphinyl (PO2) as its reactive moiety. Fosinopril is the only ACE inhibitor 
that was categorized in this group (Brown & Vaughan, 1998). The largest group of ACE 
inhibitor contain a carboxyl (CO2). It consists of enalapril, ramipril, quinapril, 
perindopril, lisinopril, imidapril and trandolapril (Buttar, 1997). 
Various synthetic ACE inhibitors such as captopril, ramipril, enalapril, cilazapril, 
pentopril, trandolapril, perindopril, lisinopril, alacepril and imidaprilat may effectively 
block the conversion of angiotensin I to angiotensin II or inhibit the breakdown of 
bradykinin. However, these pharmaceutical products may have side effects such as 
cough, taste disturbances, angioedema, skin rashes and fetal anomalies in pregnant 
woman (Brown & Vaughan, 1998). The incidence of cough has been reported in 
patients receiving captopril, enalapril, lisinopril and ramipril (Salami & Katibi, 2005). 
This side effect was higher during captopril and enalapril treatment (Yesil et al., 1994). 
The presence of SH group in captopril has been reported to confer toxicity such as taste 
disturbance, skin rashes and proteinuria (Reid, 1997). Administration of benazepril has 
been proven to develop hyperkalemia whereas captopril, lisinopril and enalapril may 
cause the incidence of angioedema (Ahuja et al., 2000; Jason, 1992; Kharasch, 1992). 
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Thus, this has raised the awareness among the scientists to search for ACE inhibitors 
from natural sources to replace the chemically synthesized drugs and to reduce the cost 
of current drug therapy.  
The ACE inhibitory activity can be quantified with methods that include 
colorimetric, fluorometric, radiochemical and chromatographic method (Murray et al., 
2004). In general, most of the ACE inhibitory assays rely on the principle of 
determining hippuric acid formation from hippuryl-histidyl-leucine (HHL) resulted 
from the removal of the C-terminal dipeptide histidylleucine by the action of ACE. The 
hippuric acid formed is extracted with ethyl acetate and measured at 228 nm by a 
spectrophotometer (Cushman & Cheung, 1971). However, the unhydrolyzed HHL or 
the presence of other compounds in the sample extracts were also easily extracted into 
the ethyl acetate and absorbed at 228 nm. Thus, this may cause the overestimation of the 
ACE activity. To overcome these problems, Lam et al. (2007) had introduced a 
colorimetric method using a new synthetic substrate, 3-hydroxybutyrylglycyl-glycine 
(3HB-GGG) for measuring ACE inhibiting activity. The substrate, 3HB-GGG is 
cleaved into amino acids (Gly and Gly-Gly) and 3-hydroxybutyric (3HB) by the actions 
of ACE (Lam et al., 2007). The ACE inhibitory activity is measured 
spectrophotometrically according to the amount of cleaved 3-hydroxybutyric (3HB) 
from 3HB-GGG (Lam et al., 2009). This assay kit is available commercially and known 
as ACE Kit-WST (Dojindo Laboratories, Kumamoto, Japan). The ACE inhibitory 
activity in the current study was tested using the ACE-kit WST. 
 
2.4 Edible mushrooms and antihypertensive effect 
Mushrooms are defined as macrofungi with distinctive and visible fruiting bodies which 
can be either epigeous or hypogeous (Chang, 2008). Edible mushrooms are used 
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extensively in culinary especially among the Chinese, European and Japanese (Chang, 
2008). Beside nutritional value, the unique colour, taste and aroma of mushrooms are 
the reasons that attract their consumption by humans (Guillamón et al., 2010). 
Mushrooms contain large amount of protein, carbohydrates, fibre and low in fat (Chang 
& Miles, 2004). Besides, mushrooms can be a good source of vitamins B1, B2, B12, C 
and D as well as mineral elements, such as calcium, potassium, magnesium, phosphorus, 
copper, iron and selenium. (Chang, 2008; Chang & Buswell, 1996). Thus, they are a 
good diet for people with hypertension (Moura et al., 2007).  
It is not easy to differentiate edible and medicinal mushrooms because many of 
the common edible species are beneficial in the prevention and treatment of various 
human diseases and several medically related mushrooms are also eaten (Guillamón et 
al., 2010). Among 14,000-15,000 species of mushrooms in the world, about 1800 
species of mushrooms have been estimated to contain potential medicinal properties 
(Chang, 2008). Edible mushrooms which are widely cultivated by the local mushroom 
growers and sold in the supermarkets in Malaysia are oyster mushrooms (Pleurotus 
spp.), shiitake [Lentinula edodes (Berk.) Pegler], jelly mushroom (Auricularia spp.) and 
paddy straw mushroom [Volvariella volvacea (Bull.) Singer] (Chang & Lee, 2004). 
Besides the locally cultivated mushroom, some imported mushrooms are also found in 
the supermarkets in Malaysia. Examples are Portabella, white button mushroom 
[Agaricus bisporus (J.E. Lange) Imbach] and shimeji (Hypsizygus sp.). Others are 
edible mushrooms collected in the wild e.g. Schizophyllum commune Fr. and 
Termitomyces spp. which are sometimes available at wet markets. Truffles (Tuber spp.), 
maitake [Grifola frondosa (Dicks.) Gray] and monkey’s head [Hericium erinaceus 
(Bull.) Pers.] are normally found in speciality shops or in selected restaurants (Lee et al., 
2009b). 
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Many mushrooms have been reported to possess antihypertensive effect. The most 
reported medicinal mushroom with blood pressure lowering effect is Ganoderma 
lucidum (Curtis) P. Karst. (Guillamón et al., 2010; Paterson, 2006). Mycelium extract of 
G. lucidum has exhibited blood pressure lowering effect in animal studies (Lee & Rhee, 
1990). Ten triterpenes isolated from G. lucidum have been shown to have ACE 
inhibitory activity (Morigiwa et al., 1986). Besides G. lucidum, some common edible 
mushrooms have also been reported to show hypotensive effect, namely maitake and 
oyster mushroom (Agrawal et al., 2010; Talpur et al., 2002).  
Some studies suggested that hypotension can be induced by the mushroom 
extracts as an impact resulting from the primary effect. For instance, suppression of 
sympathetic nervous system was reported to be involved in hypotension (Sato et al., 
1987). According to an in vivo study carried out by Lee and Rhee (1990), extract of G. 
lucidum showed a decreased in the systolic and diastolic blood pressure as well as 
inhibition of renal efferent sympathetic nerve activity in the animals. However, it did 
not decrease the heart rate. Therefore, it was suggested that the hypotensive action of G. 
lucidum was due to its suppression effect on the sympathetic nerve activity (Lee & Rhee, 
1990). Another example, seaweeds were reported to exhibit marked antihyperlipidemic 
activity (Ren et al., 1994a). Enhanced excretion of cholesterol into faeces that resulted 
from consumption of seaweed has been suggested as an important factor for reducing 
blood pressure (Ren et al., 1994b). Mushrooms, such as L. edodes and H. erinaceus 
have been reported as potent hypolipidemic agents (Yang et al., 2003a; Yoon et al., 
2011). Thus, the reduction of cholesterol due to the consumption of mushrooms can 
help to reduce blood pressure in hypertensive patients. 
Mushrooms can be a good source of antihypertensive drugs. Compared to most 
pharmaceuticals, the biologically active compounds that are extracted from mushrooms 
have extraordinarily low toxicity, even at high doses (Chang & Miles, 2004). The 
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antihypertensive effects reported in the previous studies on the nine edible mushroom 
species tested in the current study are as follows:    
 
2.4.1 Agaricus bisporus 
Agaricus bisporus is commonly known as button mushroom. It grows naturally in 
grasslands, fields and meadows in North America and Europe. It is the most cultivated 
mushroom globally and the most consumed mushroom in Western countries (Jeong et 
al., 2010). It is cultivated in more than 100 countries, which produced about 2 million 
metric tons of fresh weight in 1997 (Chang & Miles, 2004). Its fruiting body is either 
white or brown colour according to variety.  
In hypercholesterolemic rats, consumption of A. bisporus had decreased their 
plasma total cholesterol, low density lipoprotein, hepatic cholesterol and triglyceride 
concentration (Jeong et al., 2010). This is in line with the study conducted by Chen et al. 
(2012c), which reported that the fruiting body of A. bisporus having high amount of 
lovastatin, a compound with cholesterol lowering effect. Lovastatin has been proven to 
reduce the risk of coronary heart disease (Furberg et al., 1994). Beside lovastatin, A. 
bisporus also contains γ-aminobutyric acid (GABA) which has been demonstrated to 
have hypotensive effect in in vivo studies (Tanaka et al., 2009).  
 
2.4.2 Flammulina velutipes 
Flammulina velutipes (Curtis) Singer is commonly known as enoki in Japan or golden 
needle mushroom (Jin zhen gu) in China. It is sometimes called winter mushroom. It 
grows naturally on the stumps of the Chinese Hackberry tree, called enoki in Japanese 
and also on some other trees such as mulberry and persimmon trees. China, Japan, 
Korea and Taiwan are the major producers of F. velutipes with worldwide production of 
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284,000 metric ton in 1997 (Chang & Miles, 2004). There is a difference in appearance 
between wild and cultivated F. velutipes. Cultivated F. velutipes have white colour 
fruiting bodies with long and thin stem while their wild types usually have a dark brown 
colour with shorter and thicker stem. Supermarkets usually sell cultivated form of F. 
velutipes.  
Flammulina velutipes has been reported to contain fibrinolytic enzyme which 
exhibits a remarkable degree of fibrinolytic activity (Park et al., 2007). Fibrin is formed 
from fibrinogen by the action of protease thrombin and it is then polymerized to form 
clot over a wound site (Falvo et al., 2010). Fibrinolysis is an important process in the 
body that keeps fibrin blood clots from growing. Fibrin clot formation and fibrinolysis 
are normally well balanced in the body system (Cesarman-Maus & Hajjar, 2005). 
However, factors such as dysfunction or disease of the liver could lead to impaired 
fibrinolysis, which would subsequently cause the occurrence of cardiovascular diseases 
(Tabak et al., 2009). Clinical studies have demonstrated a positive correlation in the 
increased level of plasma fibrinogen and prevalence of hypertension (Poli et al., 2000; 
Shankar et al., 2006). This could be due to the relation of fibrinogen to cause the 
increase in blood viscosity (Letcher et al., 1981), hyperinsulinemia (Válek et al., 1995) 
and inflammation (Engstrom et al., 2002) which are among the factors involved in the 
elevation of blood pressure. Therefore, F. velutipes could exhibit its blood pressure 
lowering effect through fibrinolytic activity. Besides fibrinolytic enzyme, high amount 
of GABA and lovastatin have been detected in the fruiting body of F. velutipes (Chen et 
al., 2012c). GABA and lovastatin is a potent hypotensive and cholesterol lowering 
compound, respectively (Furberg et al., 1994; Tanaka et al., 2009).  
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2.4.3 Hericium erinaceus 
Hericium erinaceus is commonly known as Hou tou gu or Monkey’s head in China due 
to its fruiting body that looks like the head of a baby monkey. It is known as 
Yamabushitake in Japan and sometimes referred to as the bear’s head or lion’s mane 
mushroom. Its fruiting body is white in colour but tends to be yellowish. Initially, it was 
available only in the wild where it grows on old and dead wood in the deep forest but 
now it is being grown on substrates in plastic bag cultures. The largest producer of H. 
erinaceus is China with the annual production of approximately 2800 metric ton in 1998 
(Chang & Miles, 2004).  
Hericium erinaceus was found to have the ability to reduce serum triglyceride and 
total cholesterol levels as well as decrease the body weight and fat weight (Hiwatashi et 
al., 2010; Wang et al., 2005). Besides, it also showed to have hypolipidemic effects in 
in vivo study (Yang et al., 2003a). Thereby, it is an ideal food for hypertension and 
cardiovascular disease patients. 
 
2.4.4 Lentinula edodes 
Lentinula edodes is commonly known as shiitake. It is a Japanese name derived from 
the mushroom associated tree, shii tree (Castanaopsis cuspidate Schottly) and take, 
Japanese word for mushroom (Wasser, 2005). It is the second most cultivated 
mushroom worldwide, which produce 1,564,000 metric ton in 1997 (Chang & Miles, 
2004). Initially, it is grown mainly in Asian countries but now it has spread to the 
United States, Australia, Canada, Brazil and a few European countries (Chang & Miles, 
2004).  
Lentinula edodes has been reported to contain therapeutic properties for treating 
cardiovascular disease where it can lower cholesterol level in plasma and remove lipids 
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in liver (Rai et al., 2005). Kabir et al. (1987) had reported on the blood pressure 
lowering effect in spontaneously hypertensive rats fed with shiitake. A compound 
known as eritadenine was found in L. edodes which is a hypocholesterolemic agent 
(Yoon et al., 2011). Eritadenine can accelerate the excretion of ingested cholesterol and 
its metabolic decomposition (Sugiyama et al., 1995). Besides, L. edodes was also found 
to contain high amount of ergothioneine (Chen et al., 2012c). Dietary consumption of 
ergothioneine has been associated with reduced risk of cardiovascular disease (Martin, 
2010). A high amount of vitamin D has been detected in L. edodes that were grown 
under exposure to ultraviolet lights (Lee et al., 2009a; Mattila et al., 2002a). Several 
clinical studies have shown association between vitamin D and hypertension. 
Hypertensive patients who received ultraviolet B (UVB) exposure 3 times weekly for 6 
weeks have shown significant reduction in systolic and diastolic blood pressure (Krause 
et al., 1998). Elderly women who received dietary supplement of vitamin D showed 
significant reduction of blood pressure after 8 weeks (Pfeifer et al., 2001). Interestingly, 
the blood pressure lowering effect of vitamin D has been associated to the renin-
angiotensin system (Li, 2003). Vitamin D was reported to increase the productions of 
intracellular calcium which is a suppressor to the renin activity (Burgess et al., 1990). 
Furthermore, vitamin D induces relaxation of vascular smooth muscle cells which 
would improve dilation of arterial blood vessels and subsequently decreases blood 
pressure (Tarcin et al., 2009).  
 
2.4.5 Pleurotus species 
Pleurotus spp. is commonly known as oyster mushroom. The word Pleurotus derives 
from Greek which means ‘side ear’. About 875.6 thousand metric ton of Pleurotus spp 
were produced in 1997 (Chang & Miles, 2004). Various species of this wood-rotting 
fungus are found globally. It is cultivated in many countries in Europe and Asia. One of 
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the reasons for its popularity is its ability to grow on a wide range of substrates due to 
its characteristic that secrete a wide range of enzymes, which can degrade 
polysaccharides, such as lignin, cellulose and hemicelluloses found in the biomass of 
forest and agricultural crop residues. This mushroom fruits at a relatively high 
temperature. Thus, it can be grown in tropical and subtropical areas, as well as in 
temperate regions during the summer season (Chang & Miles, 2004). There are five 
Pleurotus spp cultivated in Malaysia, which includes P. citrinopileatus Singer (yellow 
oyster mushroom), P. cystidiosus O.K. Mill. (abalone mushroom), P. flabellatus (Berk 
and Br.) Sacc (pink oyster mushroom), P. florida (Mont.) Singer (white oyster 
mushroom) and P. pulmonarius (Fr.) Quél (a.k.a. P. sajor-caju) (grey oyster mushroom).  
A significant reduction in blood pressure was observed in hypertensive patients 
after the consumption of oyster mushroom (Agrawal et al., 2010). In vivo studies have 
also shown Pleurotus spp contain effective lipid lowering properties (Alam et al., 2011; 
Schneider et al., 2011), cholesterol lowering effect (Rai et al., 2005) and 
antihypertensive effects (Miyazawa et al., 2008). The results found in the in vivo studies 
were in line with the results of the bioactive compounds found in Pleurotus spp. D-
mannitol, a phytochemical from Pleurotus spp was reported to exhibit hypotensive 
effect (Hagiwara et al., 2005). Fruiting body of Pleurotus spp. also have high amount of 
ergothioneine (Chen et al., 2012c). Dietary consumption of ergothioneine has been 
associated with reduced risk of cardiovascular disease (Martin, 2010). Similarly, a 
cholesterol lowering compound, lovastatin was also detected in large amount in the 
fruiting bodies of Pleurotus spp (Chen et al., 2012c). 
 
2.5 Mushrooms proteins and ACE inhibitory peptides 
According to Chang and Miles (2004), the protein content of cultivated mushrooms 
ranges from 1.75-5.9% of their fresh weight. This is in line with the report by Manzi et 
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al. (1999), who reported the protein content of P. ostreatus, P. eryngii, P. pulmunarius 
and L. edodes in the range of 1.26 to 5.75 g/100 g of fresh weight (Manzi et al., 1999). 
On a dry weight basis, the protein content in mushrooms may vary from as little as 4-8% 
for species of Auricularia to as high as 43% for Volvariella volvacea (Chang, 1999). 
The protein content in mushroom is about 2-12 times of the amount found in vegetables 
and fruits. Milk has been reported to have 2.9-3.3% protein. On the other hand, the 
protein content of various meat is as follows: pork (9-16%), beef (12-20%), chicken 
(18-20%), fish (18-20%) (Chang, 1999). Thus, it can be concluded that the amount of 
crude protein in mushrooms rank below animal meats but well above most other foods, 
such as vegetables, fruits and milk.  
The role of proteins as physiologically active components in the diet is being 
increasingly recognized (Iwaniak & Dziuba, 2009). A previous study had reported on 
the inverse relationship of dietary protein with blood pressure (Stamler et al., 1996). 
This could be due to the bioactive peptides encrypted within the sequence of proteins. 
Bioactive peptides have been defined as specific fragment that have a positive impact 
on the body systems upon administration, namely the cardiovascular, digestive, immune 
and nervous systems (Kitts & Weiler, 2003). Bioactive peptides are inactive within the 
sequence of the parent protein and can be released in three ways, which are enzyme 
hydrolysis by digestive enzyme, hydrolysis by proteolytic microorganisms and through 
food processing (Korhonen & Pihlanto, 2006). Some natural or synthesized peptides 
which act on the renin-angiotensin system have the ability to prevent and treat 
hypertension through inhibition of  angiotensin I, angiotensin converting enzyme (ACE) 
and Ang II type 1 receptor (AT1) (Hong et al., 2008; Korhonen & Pihlanto, 2003; 
Korhonen & Pihlanto, 2006). Since the first discovery of ACE inhibitory peptide in 
snake venom, there has been an increased interest in finding ACE inhibitory peptides 
from food proteins.  
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Many food proteins or artificial synthetic products are a good source of these 
inhibitory peptides (Korhonen & Pihlanto, 2003). Examples of the successful 
purification of ACE inhibitors from food proteins are shown in Table 2.1. Most of the 
peptides listed in Table 2.1 consist of short amino acid sequences and low molecular 
masses. This is in line with the report by Natesh et al. (2003), which stated low 
molecular weight peptides have added advantage as ACE inhibitor because large 
peptide molecules are restricted from fitting into the active site of ACE.  
Although ACE inhibitory peptides from food proteins may have lower ACE 
inhibitory activity in vitro compared to the ACE inhibitory drugs, they do not have the 
harmful side effects and also lower the cost of healthcare (Hong et al., 2008). Besides in 
vitro studies, several tests in spontaneously hypertensive rats also suggest a significant 
suppression of the development of hypertension with a diet rich in ACE inhibitory 
peptides (Lee et al., 2010; Wang et al., 2008). Thus, ACE inhibitory peptides are not 
only effective for treatment of hypertension, it can also be used as functional food for 
prevention of hypertension. There are several ACE inhibitory peptides from bonita and 
sardine which have been commercialized in Japan and Canada. Examples of the product 
names are Valtyron
®
, PeptAce, Vasotensin
®
 and Levenorm
®
 (Harnedy & FitzGerald, 
2012). These products are claimed to be suitable for consumption as functional food by 
individuals with mild hypertension. Additionally, these products were reported to be 
free of side effects (EFSA Panel on Dietetic Products Nutrition and Allergies, 2010a; 
EFSA Panel on Dietetic Products Nutrition and Allergies, 2010b). Therefore, this has 
increased the interest among researchers in finding ACE inhibitory peptides in other 
commonly consumed foods. 
Previous studies have showed successful purification of ACE inhibitory peptides 
from fruiting bodies of edible mushrooms, Grifola frondosa (Choi et al., 2001), 
Tricholoma giganteum (Lee et al., 2004), Pholiota adiposa (Koo et al., 2006) and 
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Pleurotus cornucopiae (Jang et al., 2011). The comparison of their peptide sequences, 
molecular masses, IC50 values and kinetic mode of inhibition are illustrated in Table 2.2. 
Peptides purified from G. frondosa, T. giganteum and P. adiposa have short amino acid 
sequences, which was in the range of 3-6 amino acids in length whereas ACE inhibitory 
peptides from P. cornucopiae consist of 14-17 amino acids in length. The IC50 values 
for the ACE inhibitory activity were in the range of 3.2-539.9 µM. 
 
Table 2.1: ACE inhibitory peptides derived from food protein. 
Food 
source 
Peptide 
sequence 
Molecular 
mass (Da) 
b 
IC50  
(µM) 
Reference 
Bonita fish LKPNM 601.7 2.4 Fujita and Yoshikawa (1999) 
Broccoli YPK 
a
NM 23.7  Lee et al. (2006) 
Buckwheat GPP 270.56 23.1 Ma et al. (2006) 
Clam VKP NM 3.7 Tsai et al. (2006) 
VKK NM 1045 
Cuttlefish VYAP 448.2 6.1 Balti et al. (2010) 
VIIF 491.1 8.7 
MAW 407.2 16.32 
Egg RVPSL 571.6 20 Liu et al. (2010a) 
Garlic 
 
SY 269 66.3 Suetsuna (1998) 
SF 253 130.2 
Milk PYVRYL 809.9 2.4 Quiros et al. (2005) 
Mung bean KDYRL 693.8 26.5 Li et al. (2006) 
VTPALR 655.8 82.4 
Oyster DLYDY 687.7 143 Shiozaki et al. (2010) 
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Table 2.1 (Continued) 
Rice TQVY NM 18.2 Li et al. (2007) 
Salmon AP 186.18 0.322 Gu et al. (2011) 
VR 273.30 1.214 
Sea squirt AHIII 565.7 37.1 Ko et al. (2011) 
Soy meal DLP NM 4.8 Wu and Ding (2002) 
DG NM 12.3 
Soybean LVQGS 495.70 43.7 Rho et al. (2009) 
Spinach MRWRD 762.8 2.1 Yang et al. (2003b) 
MRW 473.6 0.6 
LRIPVA 667.8 0.38 
Sweet 
potato 
GTEKC NM 275.8 Huang et al. (2008) 
VKAGE NM 141.56 
KIEL NM 849.7 
SNIP NM 228.3 
VRL NM 208.6 
RF NM 392.2 
VVGAK 472.5 1.14 Huang et al. (2011a) 
GPCSR 518.5 61.67 Huang et al. (2011b) 
Wakame AIYK 494 213 Suetsuna and Nakano (2000) 
YKYY 636 64.2 
KFYG 514 90.5 
YNKL 537 21 
a
 NM=Not mentioned 
b 
IC50 denotes the concentration of an ACE inhibitor required to inhibit 50% of ACE 
activity. 
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Table 2.2: ACE inhibitory peptides derived from edible mushrooms.  
Mushroom 
sp 
Peptide sequence Molecular 
mass (Da) 
a 
IC50 
(µM) 
Inhibition 
pattern 
Reference 
Grifola 
frondosa 
VIEKYP 747.8 129.7 Competitive Choi et al. 
(2001) 
Tricholoma 
giganteum 
GQP 301 3.2  Competitive Lee et al. 
(2004) 
Pholiota 
adiposa 
GQGGP  414 254 Competitive Koo et al. 
(2006) 
Pleurotus 
cornucopiae 
RLPSEFDLSAFL
RA  
1622.85 277.3  Competitive Jang et al. 
(2011) 
RLSGQTIEVTSE
YLFRH  
2937.26 539.9  Noncompetitive 
a 
IC50 denotes the concentration of an ACE inhibitor required to inhibit 50% of ACE 
activity. 
 
2.6 Purification of ACE inhibitory peptide 
2.6.1 Extraction of proteins from mushroom 
Proteins can be recovered from inside (intracellular proteins) and outside (extracellular 
proteins) of the cell. Most of the proteins studied in the early days were isolated from 
extracellular fluids because it was easy to obtain and extracellular proteins are more 
stable (Scopes, 1994). Intracellular proteins were obtained by disrupting the cells and 
the proteins will be released into the aqueous extract. Various cell disruption methods 
have been developed which include physical, chemical, enzymatic and mechanical 
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methods (Middelberg, 1995). Table 2.3 showed the principles of cell disruption 
techniques commonly used in the laboratory. 
Plant cells are difficult to disrupt because they have cellulosic cell walls. 
Mushrooms also contain cell walls which are made of chitin (Vetter, 2007). Hence, they 
require vigorous mechanical techniques to break up the cell wall. Previous studies had 
reported on the higher concentration of proteins obtained from fungi using sonicator, 
bead milling and homogenization (Klimek-Ochab et al., 2011; Taskova et al., 2006). In 
the current study, homogenization using a waring blender was used to extract proteins 
from mushroom.  
 
Table 2.3: Principles of cell disruption methods. 
Cell disruption methods Principle 
Physical 
Osmotic shock 
This method involved suspension of cells in hypotonic 
solution which would cause the rupture of cells and 
release its cellular content (Klimek-Ochab et al., 
2011). 
Freeze-thaw 
This technique involves freezing of cells in freezer 
followed by thawing at room temperature. Multiple 
cycles of freezing-thawing are necessary for efficient 
lysis of cells (Ward & Swiatek, 2009). 
Chemical Detergent 
Suspension of cells in solution containing detergent to 
solubilise the cell membrane. Commonly used 
detergents include Triton-X and Tween series. 
However, proteins could be denatured in the presence 
of detergents and an additional purification polishing  
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Table 2.3 (Continued) 
Chemical 
 
step has to be carried out to remove the detergent from 
the product. Hence, this method is avoided where 
possible (Klimek-Ochab et al., 2011). 
Solvents 
Suspension of cells in organic solvents such as 
acetone and toluene which acts on the cell membrane 
by solubilising its phospholipids and release the 
integral proteins and subcellular components (Dey et 
al., 1997). Limitation of using solvents is similar to 
detergent i.e. they have to be removed from samples 
after the cell disruption process (Scopes, 1994).  
Enzymatic 
 
Suspension of cells in solution containing enzymes 
that digest the cell wall. The enzymes commonly used 
include lysozyme, zymolase, cellulase, pectinase, etc. 
The disadvantage of enzymatic method is the 
instability of enzyme which will subsequently cause 
the method to be irreproducible (Taskova et al., 2006). 
Mechanical 
Bead mill 
Sample is placed in a vessel containing small beads. 
Cell disruption of sample is due to the grinding action 
of the rolling beads and the impact resulting from the 
cascading beads (Taskova et al., 2006). 
Homogenizer 
Homogenizing of samples in a blender will break up 
large cells and shears apart smaller ones (Scopes, 
1994).  
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Table 2.3 (Continued) 
Mechanical 
Sonicator 
Sample is subjected to high frequency ultrasound 
(above 16kHz). Tiny bubbles formed by the high 
frequency vibration will release mechanical energy in 
the form of shock waves equivalent to several 
thousand atmosphere of pressure (Scopes, 1994). 
French press 
The device consists of a cylinder fitted with a plunger. 
Sample placed in the cylinder is pressurized using the 
plunger (Scopes, 1994).  
 
2.6.2 Protein separation by ammonium sulphate 
The distribution of hydrophilic and hydrophobic residues at the surface of the protein 
molecule will determine its solubility in various solutions. Hence, different types of 
proteins in a solution can be separated by causing some of the proteins to precipitate by 
altering some properties in the solution, such as by changing the ionic strength, pH and 
by adding miscible organic solvents, inert solutes or polymers (Scopes, 1994). 
Precipitation by organic solvents such as alcohol or acetone is not commonly used 
because of its tendency to denature protein at room temperature. Precipitation with 
polyethylene glycol (PEG) is also not commonly used due to the difficulty to remove it 
from the protein solutions (Ahmed, 2005). Salting out of proteins by ammonium 
sulphate precipitation is usually used because ammonium sulphate has high solubility 
even at lower temperatures which is important as proteins have to be maintained in cold 
condition. Addition of salt to the solution will increase the surface tension of water and 
subsequently increase the hydrophobic interaction between protein and water 
(Wingfield, 2001). Proteins in the solution tend to fold to decrease their surface area in 
an attempt to minimize contact with the solution. This will cause the aggregation and 
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precipitation of proteins. The precipitate can be collected by centrifugation. Proteins 
with larger amount of hydrophobic surface precipitate at lower salt concentrations. 
Table 2.4 showed the amount of ammonium sulphate required to precipitate proteins at 
a certain salt saturation. 
 
Table 2.4: Amount of ammonium sulphate (in grams) required per litre of solution from 
initial percentage saturation to target percentage saturation at 4
o
C. 
  Target % saturation 
  10 20 30 40 50 60 70 80 90 100 
  Amount of ammonium sulphate (g) required per litre of solution 
In
it
ia
l 
%
 s
at
u
ra
ti
o
n
 
0 56 114 176 243 313 390 472 561 662 767 
10  57 118 183 251 326 406 494 592 694 
20   59 123 189 262 340 424 520 619 
30    62 127 198 273 356 449 546 
40     63 132 205 285 375 469 
50      66 137 214 302 392 
60       69 143 227 314 
70        72 153 237 
 80         77 157 
 90          79 
(Source: http://www.encorbio.com/protocols/AM-SO4.htm) 
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2.6.3 Pooling of protein fractions by Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is a useful method to separate he components of a protein mixture. It can 
also be used to estimate the molecular weight of proteins. In the SDS-PAGE analysis, 
proteins were denatured by boiling. SDS, an anionic detergent which was added to the 
samples would bind to the proteins and further denature secondary and non disulfide 
linked tertiary structures of the proteins (Scopes, 1994). A negative charge was applied 
to each protein in proportion to its mass. The proteins were then loaded onto a gel 
consisting of acrylamide and bisacrylamide. An electric field is applied across the gel 
causing the negatively charged proteins to migrate across the gel towards the positive 
electrode. Each protein will move differently through the gel matrix. Small proteins will 
migrate easily through the pores in the gel. Therefore they are able to travel farther 
down the gel. Larger proteins will have more difficulties to move in the gel matrix. 
Therefore, they will remain closer to the point of origin (Manz et al., 2004; Westermeier, 
2011). After electrophoresis, the gel is stained either with Coomassie Brilliant Blue or 
silver staining to allow visualization of the separated proteins. In the current study, 
proteins precipitated by ammonium sulphate were visualised by SDS-PAGE to 
determine the similarity of protein profiles in the salt fractions. Fractions with similar 
protein profiles were pooled in the same group. 
  
2.6.4 Protein separation by column chromatography 
Column chromatography is the most common method used for protein separation. A 
solution containing protein mixtures is flowed through a column which is packed with 
stationary phase material. There are a wide range of stationary phase materials, which 
include silica, dextran or cellulose (Janson, 2011). Different proteins interact differently 
with the stationary phase material. Therefore, they are separated based on their degree 
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of adsorption to the column material where each protein will require different time to 
pass through the column. Usually protein purification protocol involves with one or 
more chromatographic steps. The chromatographic steps used in the current study were 
reverse phase chromatography (RPHPLC) and size exclusion chromatography (SEC). 
The column material used in the RPHPLC is usually silica based. Proteins are 
eluted according to their hydrophobicity by a gradient of increasing concentrations of 
mobile phase, i.e. organic solvent containing an ionic modifier. The most commonly 
used mobile phase is acetonitrile containing trifluoroacetic acid (TFA). More 
hydrophobic protein will be eluted later from the column (Aguilar, 2004). 
In SEC, proteins are separated according to size and shape. The SEC column 
consists of beads with different pore sizes. The separation depends on the ability of the 
proteins to enter the channels in the porous beads. Small proteins have more potential 
channels that they can access but larger proteins are excluded from the channels and 
will pass quickly between the beads. Therefore, proteins are separated in order of 
decreasing molecular weight, with the largest protein eluting from the column first 
(Stanton, 2004). 
 
2.7 Mass spectrometry analysis of ACE inhibitory peptides 
Biological activities of proteins are related to the amino acid composition, sequence and 
size of peptides. Mass spectrometry (MS) has been established as the primary method 
for protein identification from biological origin. It is an analytical technique that 
measures the mass to charge ratio of charged particles. MS instruments consist of three 
modules; an ion source, a mass analyzer and a detector (Manz et al., 2004).  
An ion source is an electro-magnetic device that is used to ionize the sample to be 
analyzed. The ionization methods commonly used in proteomics are Matrix Assisted 
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Laser Desorption Ionization (MALDI), Surface-Enhanced Laser Desorption Ionization 
(SELDI) and Electrospray Ionization (ESI). MALDI uses a solid plate where a UV 
active matrix is spotted on the plate together with the protein sample. The laser hits the 
spot on the crystallized matrix and transfers energy from the matrix molecule to the 
sample which will then vaporizes the sample and sending a plume of ions into the 
MALDI source. These plumes of ions are collected and sent out simultaneously to a 
mass analyzer. The principle of SELDI is similar to MALDI. It involves the ionization 
of samples that have been co-crystallized with a matrix on a target surface. However, 
unlike MALDI which has a single target surface, SELDI has different ProteinChip 
chromatographic surfaces that are uniquely designed to retain proteins from complex 
mixtures according to their specific properties, such as hydrophobic, anionic, cationic or 
metal ions. These ProteinChips array are commercially known as H50, Q10, CM10 and 
IMAC30 arrays, respectively. Proteins were left to interact with the spot surface by 
letting it to incubate for a period of time. Proteins and contaminants that do not bind to 
the spot surface are then removed by washing followed by the addition of energy-
absorbing matrix to the spot. Samples are ionized by a pulsed-UV laser beam and their 
molecular masses were measured by mass analyzer (Seibert et al., 2004; 
Vorderwülbecke et al., 2005). In ESI, initially protein samples were injected through a 
charged capillary. This will allow charged particles to be formed at the capillary tips. 
Evaporation of the particles increases the charge of the particles and explodes into 
smaller droplets. Repeated evaporation and fission will lead to the formation of small 
charged droplets. These ions will then travel into the analyzer to be scanned one mass at 
a time (Aebersold & Mann, 2003; Manz et al., 2004). ESI coupled with liquid 
chromatography (LC) is usually used for the detection of peptides from a complex 
mixture. Prior separation by LC enables the detection of peptides with similar masses 
by distinct resolution. According to Zhang et al. (2013), attempting to electrospray a 
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mixture of analytes simultaneously without prior separation would result in the 
ionization of only the most hydrophobic molecules. A more sensitive application, 
nanoLC-ESI/MS/MS has been developed and widely used in proteome analysis. The 
separation of peptides by LC at a flow rate of nanolitre per minute followed by direct 
electrospray into the mass spectrometer has been proven to improve the sensitivity of 
peptide separations and subsequently increased the amount of proteins detected, 
especially the low abundant proteins (Wilm & Mann, 2001). 
The mass analyzer is the component that separates the ions created from the ion 
sources by their mass-to-charge ratios. Usually MALDI and SELDI are attached to a 
Time of Flight (TOF) mass analyzer. Ions generated in the MALDI and SELDI source 
are held for a brief time and pulsed into the TOF mass analyzer at the same time. Ions 
with lower mass and higher velocity will hit the detector first. On the other hand, 
quadrupole mass analyzer is widely used together with ESI. It acts as a mass-selective 
filter. Only the ions in a certain range of mass to charge ratio are passed through the 
system at a time (Trauger et al., 2002; Vorderwülbecke et al., 2005). 
The detector records the charged or current produced when an ion hits a surface. 
The signals from these charged or currents will produce a mass spectrum. For each mass 
spectrum, software is used to determine the peptide masses by matching it with the 
protein database (Wiśniewski, 2008).  
Prior to MS analysis, protein was digested with a proteolytic enzyme, usually 
trypsin that will cleave the protein at specific sites to create a complex peptide mixture. 
The peptides are subjected to mass spectrometric analysis. The masses of these peptides 
provide a peptide mass fingerprinting which can be used in database searches to identify 
the protein of interest. This protein profiling technique is known as ‘bottom-up’ 
approach and has been widely used in proteomic research (Aebersold & Mann, 2003). 
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NanoLC-ESI/MS/MS has been used by previous studies for protein identification 
of ACE inhibitory peptide after purification by reversed phase and size exclusion 
chromatography (Balti et al., 2010; Ghassem et al., 2011; Zhao et al., 2009). Thus, in 
the current study, this method has been selected to study the protein profiling of ACE 
inhibitors in mushrooms. 
According to Vermeirssen et al., (2004), the bioactivity of protein or peptide is 
inversely correlated to chain length. Previous studies had reported on the higher ACE 
inhibitory activity exhibited by lower molecular weight peptides. Guang and Phillips 
(2009) had summarized a list of potent low molecular weight ACE inhibitory peptides 
derived from plant foods. SELDI-TOF-MS has been reported as the most effective 
method in profiling low molecular weight proteins and peptides (<20 kDa), providing a 
complementary visualization technique to 2D-PAGE (Issaq et al., 2003). Thus, SELDI-
TOF-MS has been used for the protein profiling analysis of low molecular weight 
proteins in the current study. Hydrophobic ACE inhibitor has been reported to be more 
effective than hydrophilic ACE inhibitor (Moskowitz, 2002; Moskowitz & Johnson, 
2004). Therefore, ProteinChip Array H50 with hydrophobic surface was used in the 
SELDI-TOF-MS analysis in the current study.  
 
2.8 Structure-activity relationship of ACE inhibitory peptides 
There are two isoforms of human ACE, somatic (sACE) and testicular (tACE) forms. 
Somatic ACE and tACE is composed of 1277 and 701 amino acid, respectively (Pina & 
Roque, 2008). Somatic ACE is expressed in most tissues and it has two homologous 
catalytic domains (N- and C-domains). Testicular ACE exhibits only one domain that is 
identical to the C-domain of sACE (Pina & Roque, 2008). The N-domain is involved in 
the control of hematopoietic stem cell proliferation. The C-domain is the dominant site 
involved in blood pressure regulation and it consists of three subsites, S', S1' and S2' 
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(Phelan & Kerins, 2011). ACE hydrolyses peptides by the removal of a dipeptide from 
the C-terminus, as in the cleavage of His-Leu from angiotensin-I to convert it to the 
vasoconstrictor angiotensin-II (Coates, 2003). Accordingly, the C-terminal of the 
inhibitory peptides is important for the inhibitory effect of the ACE enzyme.  
Some authors have proposed structural requirements for potent ACE inhibitory 
peptide. Curtis et al. (2002) reported that peptides with potent ACE inhibitory activity 
usually consist of 2-5 amino acids in length and contain one or a combination of an 
aromatic amino acid, a branched-chain amino acid and an imino proline. There were 
also reports which suggested that potent ACE inhibitors contain hydrophobic amino 
acid residues such as proline, phenylalanine, tryptophan and tyrosine at the C-terminal 
whereas the N-terminal usually consists of branched aliphatic amino acid such as valine, 
isoleucine and arginine (Byun & Kim, 2002; Cheung et al., 1980).  
More recent studies have involved the utilisation of quantitative structure activity 
relationship (QSAR) model. This computational method is a useful tool to search 
information relating chemical structure of peptides to biological activities. It has been 
applied for predicting potential ACE inhibitor by peptide structures. According to the 
QSAR model established by Pripp and co-workers, increased side chain hydrophobicity 
in the C-terminal and decreased side chain size of the penultimate amino acid enhanced 
ACE inhibitory potential of peptides up to six amino acids in length (Pripp et al., 2004; 
Pripp et al., 2005). QSAR model reported by Wu et al. (2006a) showed that amino acid 
with bulky side chain and hydrophobic side chain is preferred for dipeptides. For 
tripeptides, aromatic amino acids were preferred for the C-terminal, while positively 
charged amino acids were preferred for the middle position and hydrophobic amino 
acids were preferred for the N-terminal (Wu et al., 2006a). For tetrapeptides, tyrosine 
and cysteine are preferred for the first position from the C-terminus, histidine, 
tryptophan and methionine for the second position with isoleucine, leucine, valine and 
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methionine for the third position and tryptophan for the fourth position (Wu et al., 
2006b). He et al. (2012) had built a QSAR model with an artificial neural network. 
Their finding shows that protein with high content of hydrophobic amino acid, 
especially aromatic amino acids is suitable to produce ACE inhibitory peptides. 
Small molecular weight peptides have been reported to be more effective in ACE 
inhibitory activity. Several studies had shown the optimum molecular weight of ACE 
inhibitory peptides are less than 3 kDa (He et al., 2006; Jiang et al., 2010; Miguel & 
Aleixandre, 2006). This is due to the capability of small peptides to pass the 
gastrointestinal tract, easily absorbed and reach the peripheral target sites (Quiros et al., 
2005). In addition, large peptide molecules are restricted from fitting into the active site 
of ACE (Natesh et al., 2003).  
 
2.9 Effect of gastrointestinal digestion on the ACE inhibitory peptides 
Proteins or peptides delivered by the oral route have to be able to withstand the strong 
pH and maintain their biological activities throughout the digestion processes in the 
gastrointestinal tracts before they reach their target site inside the body. The most 
important sites for the digestion of proteins and peptides are the stomach and the small 
intestine. Gastric juice in the stomach contains mainly hydrochloric acid (HCl) and 
protease enzyme, pepsin. The approximate pH of the gastric juice is about pH 2.0. The 
low pH of the gastric juice will denature the ingested proteins, making them easier to be 
digested enzymatically. Besides, the acidic condition in the stomach is required for 
activation of pepsin. Pepsin prefers to cleave proteins at N-terminal of aromatic amino 
acid, such as phenylalanine, tryptophan and tyrosine (Fruton et al., 1961). 
Although the chemical digestion of protein is initiated by pepsin in the stomach, 
most of the digestion and absorption processes of protein take place in the small 
intestine (Mahato et al., 2003). It is a tube-like structure consisting of three major 
 36 
 
regions, duodenum, jejunum and ileum (McClements & Li, 2010). Proteolytic enzymes 
in the small intestine include trypsin and chymotrypsin. They are secreted by the 
pancreas. In contrast to pepsin, the pancreatic enzymes function optimally at moderate 
alkaline pH, approximately pH 8.0. Trypsin preferentially cleaves peptide bonds on the 
C-terminal side of lysine and arginine side chains (Olsen et al., 2004). Chymotrypsin is 
less specific than trypsin. They cleave proteins at C-terminal of a variety of amino acid, 
mostly those of aromatic or large hydrophobic amino acid residues, such as 
phenylalanine, tyrosine and tryptophan (Okada et al., 2008). 
Some peptides with potent in vitro ACE inhibiting activity failed to show 
antihypertensive activity after oral administration due to the possible hydrolysis of these 
peptides by gastrointestinal enzymes (Fujita et al., 2000). However some peptides 
showed higher ACE inhibitory activity after gastrointestinal digestion. They are known 
as pro-drug type inhibitor (Li et al., 2004). These peptides are expected to show long 
lasting antihypertensive activity after oral administration (Vercruysse et al., 2010). 
Preliminary experiment by gastrointestinal enzyme incubation in vitro provides an easy 
method to evaluate the fate of these peptides after oral administration. 
 
2.10 Inhibition pattern of inhibitors against ACE enzyme 
Theoretically, the inhibition pattern of enzyme inhibitor can be separated into 
three groups: competitive, noncompetitive and uncompetitive. In the competitive 
inhibition, both the substrate (S) and inhibitor (I) compete for the same active site of 
enzyme (E). Only the ES complex leads to product formation. In the noncompetitive 
inhibition, the inhibitor tends to bind to the enzyme at a site other than the active site 
while in the uncompetitive inhibition, the inhibitor binds only to the ES complex. The 
ESI complex formed in the noncompetitive and uncompetitive inhibition mode will 
cause the inactivation of enzyme, hence it is unable to produce product (Copeland, 2005; 
 37 
 
Jao et al., 2012). The inhibition mode of ACE inhibitory peptides can be evaluated by 
performing Lineweaver-Burk plots of 1/absorbance change per minute (1/V) versus 
1/substrate concentration (1/[S]). ACE inhibition was measured by varying the 
concentration of substrate in the absence and presence of different concentrations of 
inhibitor. The example of graphs obtained for competitive, noncompetitive and 
uncompetitive inhibition mode is shown in Figure 2.1. Competitive inhibitors have the 
same y-intercept as uninhibited enzyme but different x-intercepts. Noncompetitive 
inhibition produces plots with the same x-intercepts as uninhibited enzyme but different 
y-intercepts whereas uncompetitive inhibition produces different intercepts on both the 
y- and x-axes (Chang, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Lineweaver Burk plot of (A) competitive, (B) noncompetitive and (C) 
uncompetitive inhibition. 
N: No inhibitor; RI: With inhibitor at concentration I; RII: With inhibitor at 
concentration II 
1/[S] 
1/V 
RI 
N 
RII 
1/[S] 
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RI 
N 
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3.0 MATERIALS AND METHODS 
3.1 Fruiting body of edible mushrooms 
The nine selected species of fresh mushroom fruiting bodies: Agaricus bisporus (button 
mushroom), Flammulina velutipes (golden needle) and Lentinula edodes (shiitake) were 
purchased from the local grocery store, Aeon Co. (M) Bhd. while Hericium erinaceus 
(monkey’s head mushroom), Pleurotus citrinopileatus (yellow oyster mushroom), P. 
cystidiosus (abalone mushroom), P. flabellatus (pink oyster mushroom), P. florida 
(white oyster mushroom) and P. pulmonarius (grey oyster mushroom) were purchased 
from a local mushroom farm, Ganofarm Sdn Bhd. The fruiting bodies of the nine edible 
mushrooms tested are shown in Figures 3.1. 
 
  
  
Figure 3.1: Fruiting bodies of edible mushrooms studied. 
A: Agaricus bisporus; B: Flammulina velutipes; C: Hericium erinaceus; D: Lentinula 
edodes;  
A B 
C D 
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Figure 3.1 (Continued). 
E: Pleurotus citrinopileatus; F: Pleurotus cystidiosus; G: Pleurotus flabellatus; H: 
Pleurotus florida; I: Pleurotus pulmonarius 
.  
3.2 Protein extraction from fruiting bodies of edible mushrooms 
Fruiting bodies of the nine edible mushrooms were cleaned and sliced. Each mushroom 
species was blended with distilled water at a ratio of 1:2 (w/v). The mixture was filtered 
and centrifuged to remove unwanted debris. Proteins were precipitated out from the 
I 
E 
G H 
F 
 40 
 
mushroom extracts using ammonium sulphate precipitation method. The whole process 
of protein precipitation was carried out with continuous stirring on a magnetic stirrer. 
The beaker containing 100 ml water extract of mushroom was kept chilled by placing it 
in an ice bucket. First, 5.6 g of ammonium sulphate (Merck, Darmstadt, Germany) was 
weight out and added slowly to the water extract. After the last bit of salt has dissolved, 
the solution was left to stir for another 30 min to allow complete equilibration between 
dissolved and aggregated proteins. The solution was then centrifuged at 10,000 rpm (ca. 
8400 x g) for 15 min at 4
o
C. The pellet was dissolved in distilled water and kept for 
further analysis. The supernatant was used for precipitation of proteins at 20% salt 
saturation by the addition of 5.7 g ammonium sulphate followed by the same steps 
mentioned above. The concentration of ammonium sulphate was increased stepwise 
until it reached 100% salt saturation. The amount of ammonium sulphate required for 
each targeted percentage of salt saturation was illustrated in Table 2.4 (page 28). The 
protein extracts obtained from 10-100% salt saturation were then dialysed using 
snakeskin dialysis tubing with a cut-off of 3,500 Da (Thermo Scientific, Rockford, IL, 
USA) to remove the salt from the sample. The protein extracts were dialyzed in a cold 
room (4 °C) against distilled water under continuous stirring with a magnetic stirrer for 
48 hours. Water was changed four times throughout the process. Dialyzed protein 
extracts were freeze-dried and stored at -20 
o
C for further analysis. 
 
3.3 Estimation of protein content in the crude water extracts and protein 
extracts of edible mushrooms 
Protein content was estimated using Pierce® Bicinchoninic Acid (BCA) Protein Assay 
Kit (Thermo Scientific, Rockford, IL, USA). It is a colorimetric method measured with 
a microplate reader. First, the reagent A and reagent B provided in the assay kit was 
mixed at a ratio of 1:50 to produce working reagent. Twenty five microlitre of each 
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sample was then mixed with 200 µl of the working reagent in a microplate well by 
shaking the plate on a plate shaker for 30 seconds. The plate was then covered and 
incubated at 37 
o
C for 30 minutes. After the plate was cooled to room temperature, the 
absorbance of the colour formed was measured with a Sunrise™ ELISA microplate 
reader (Tecan, Grödig, Austria) at 562 nm. Protein content of the samples was estimated 
by comparing their absorbance values against the standard curve of bovine serum 
albumin (BSA). The volume used for the preparation of each diluted BSA standards 
from the initial stock solution of 2000 µg/ml was shown in Table 3.1. A batch 
consisting of the nine concentrations of diluted BSA standards was prepared and tested 
alongside the protein samples each time the assay was performed.  
 
Table 3.1: Volume (µl) used for the preparation of diluted BSA standards from the 
initial stock 2000 µg/ml.  
Vial dH2O (µl) BSA (µl) Final BSA concentration (µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B 750 
E 325 325 of vial C 500 
F 325 325 of vial E 250 
G 325 325 of vial F 125 
H 400 100 of vial G 25 
I 400 0 0 (Blank) 
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3.4 SDS-PAGE analysis of protein extracts from edible mushrooms 
SDS-PAGE was used as a parameter to pool the protein extracts precipitated from 
different percentages of salt saturation. It was also used to visualize the molecular 
weights of the proteins in RPHPLC fractions exhibiting the highest ACE inhibitory 
activity. The method was carried out in a vertical slab gel apparatus according to the 
modified method of Laemmli (1970). The gel consists of separating gel (16% 
polyacrylamide) and stacking gel (4% polyacrylamide) was prepared by mixing the 
solutions according to the protocol given in Appendix A (I). Protein sample was mixed 
with SDS-PAGE sample buffer at a ratio of 3:1 (v/v) and boiled for 5 minutes. The 
mixture and broad range SDS-PAGE standard markers (Bio-Rad Laboratories, Hercules, 
USA) were then loaded into the wells of the gel. Electrophoresis was conducted at a 
constant current of 60 V to move the proteins through the stacking gel followed by 100 
V to resolve the proteins in the separating gel.  
The protein bands were then stained by silver staining according to the method by 
Heukeshoven and Dernick (1988). Protocols for the preparation of solutions for silver 
staining were illustrated in Appendix A (II). A hundred millilitre of solution was used 
per gel. All washing and incubation steps were carried out with constant gentle shaking 
on a shaker. Following electrophoresis, the gel was immersed immediately in the fixing 
solution for at least 30 min. Fixation will restrict protein movement from the gel matrix 
and remove interfering ions and detergent from the gel. Fixing solution was then 
replaced with sensitizing solution to increase the sensitivity and contrast of the staining. 
After incubated for 30 min, the gel was washed three times with distilled water, 5 min 
each time. This was followed by incubation of the gel in silver solution for 20 min. The 
gel was then rinsed with distilled water twice, 1 min each time to remove the excess of 
unbound silver ions. After that, the gel was left to incubate in the developing solution 
until the bands become visible. The colour development was stopped by replacing the 
 43 
 
developing solution with stopping solution and left shaken for 10 min. The gel was then 
washed three times in distilled water for 10 min each time and kept in preserving 
solution. 
      
3.5 Estimation of ACE inhibitory activity 
Antihypertensive activity of crude water extracts and protein fractions were tested using 
ACE inhibitory assay kit (ACE kit-WST, Dojindo Laboratories, Kumamoto, Japan). 
The assay kit was supplied with substrate buffer, enzyme working solution and indicator 
working solution. The crude mushroom extracts and the protein fractions were tested at 
10 mg/ml and 10 µg/ml protein, respectively. The RPHPLC and SEC fractions were 
tested at 1 µg/ml. First, 20 µl of sample solution was added into the 96-well plate 
followed by 20 µl of substrate buffer. There were two blanks required for the assay, 
blank 1 (positive control without ACE inhibition) and blank 2 (reagent blank). 
Deionized water was added in the blank 1 and blank 2 wells instead of sample solution. 
Then, 20 µl of enzyme working solution were added into sample wells and blank 1. 
Deionized water was added in blank 2 well instead of enzyme working solution. The 
amount of each solution for sample, blank 1 and blank 2 were summarized in Table 3.2.  
 
Table 3.2 Amount of each solution (µl) added in the well for sample, blank 1 and blank 
2 in the ACE inhibitory assay. 
Solutions (µl) Sample Blank 1 Blank 2 
Sample solution  20 - - 
Deionized water  - 20 40 
Substrate buffer  20 20 20 
Enzyme working solution  20 20 - 
Indicator working solution  200 200 200 
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The plate was then covered and incubated in waterbath at 37 
o
C. After 60 minutes of 
incubation, 200 µl of indicator working solution was added into each well. The plate 
was incubated at room temperature for 10 minutes. The absorbances of the samples 
were measured with a Sunrise
TM
 ELISA microplate reader (Tecan, Grödig, Austria) at 
450 nm. The ACE inhibitory activity of the samples tested was calculated using the 
following equation: 
ACE inhibitory activity (%) = [(Ablank 1 – Asample) / (Ablank 1 – Ablank 2)] X 100 
where Asample is the absorbance of the solution containing ACE and the sample, Ablank 1 
is the absorbance of positive control (without ACE inhibition) and Ablank 2 is the 
absorbance of reagent blank. 
The concentration of the ACE inhibitor required to inhibit 50% of the ACE activity 
under the above assay condition was defined as IC50. 
 
3.6 Purification of selected active protein extracts from P. cystidiosus and A. 
bisporus by RPHPLC 
Purification of four selected protein extracts (E1Pc, E5Pc, E1Ab and E3Ab) with active 
ACE inhibitory activity was carried out using an HPLC system equipped with a SCL-
10AVP system controller, LC-10ATVP solvent delivery unit, SPD-M10AVP UV-Vis 
diode array detector and DGU-12A degasser (Shimadzu, Kyoto, Japan). The column 
used in the current study was a Chromolith® SemiPrep RP-18 column (100-10 mm, 
Merck, Darmstadt, Germany). First, the protein extracts were filtered through a 
whatman syringe filter (13 mm x 0.45 µm) before being injected into the column. The 
crude proteins were eluted with an increasing gradient of HPLC grade acetonitrile 
(Merck, Darmstadt, Germany) containing 0.05% TFA (Sigma-Aldrich, St. Louis, MO, 
USA), from 0% to 50% in 10 min at a flow rate of 3.5 ml/min. The UV absorbance of 
the eluent was monitored at 220 nm. All the protein extracts were fractionated according 
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to the peaks obtained. The fractions were then freeze-dried and their percentages of 
ACE inhibitory activity were determined at a concentration of 1 µg/ml protein. 
 
3.7 Proteomic analysis of RPHPLC fractions with active ACE inhibitory 
activity 
RPHPLC fractions from P. cystidiosus (E5PcF3) and A. bisporus (E3AbF6) were 
analysed using SDS-PAGE and SELDI-TOF-MS. SDS-PAGE was performed based on 
the method described in Section 3.4 (page 42) while SELDI-TOF-MS analysis was 
carried out using hydrophobic H50 ProteinChip® arrays (Bio-Rad Laboratories, 
Hercules, CA, USA). The arrays were first equilibrated with binding buffer, which 
consisted of 0.5% TFA in 50% acetonitrile (v/v). Then, 5 µl samples containing 0.5 µg 
of protein were spotted on the arrays. After the arrays were air-dried, 2 µl of CHCA in 
0.5% TFA in 50% acetonitrile (v/v) was added onto the arrays and they were left to air-
dry. The analyses were carried out on the Bio-Rad ProteinChip SELDI system PCS4000 
(Bio-Rad Laboratories, Hercules, CA, USA). Data collection was carried out in positive 
ion mode using the following acquisition settings: mass range of 0 to 20 kDa, focus 
mass of 10 kDa. Laser energies used for the shot sequences were based on the following 
settings: warming shots 1000 nJ and data shots 900 nJ. Spectra were calibrated using an 
external calibration against a mixture of standards consisting of somatostatin (1637.9 
Da), arg-insulin (5969.0 Da) and cytochrome c (12263.3 Da). 
Expression Difference Map (EDM) analysis on the SELDI-TOF-MS spectra was 
performed using the ProteinChip Data Manager 3.5 (Bio-Rad Laboratories, Hercules, 
CA, USA). Peaks with mass to charge ratio (m/z) between 2000 and 30000 were 
analysed. Mean peak intensities from four replicate samples were used to determine the 
p-value. Peak clusters were done using second-pass peak selection with S/N > 2, within 
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0.1% of the mass window and allowing estimated peaks to be included; p<0.01 was 
considered statistically significant.  
 
3.8 Purification of active RPHPLC fractions by SEC 
RPHPLC fractions from P. cystidiosus (E5PcF3) and A. bisporus (E3AbF6) were 
further purified by SEC using Biosep SEC-S2000 column (300 x 7.8 mm, Phenomenex, 
Torrance, CA, USA). Analysis was performed on a HPLC system equipped with SCL-
10AVP system controller, LC-10ATVP solvent delivery unit, SPD-M10AVP UV-Vis 
diode array detector and DGU-12A degasser (Shimadzu, Kyoto, Japan). The mobile 
phase consists of 45% acetonitrile containing 0.1% TFA. The flow rate was 1.0 ml/min 
and the effluent was monitored at 214 nm. The RPHPLC fractions were fractionated 
according to the peaks obtained. The fractions were then freeze-dried and their 
percentages of ACE inhibitory activity were determined according to the method 
described in Section 3.5 (page 43). 
 
3.9 Identification of peptide sequence by Liquid Chromatography Mass 
Spectrometry (LC/MS/MS) 
Identification of the peptides present in E5PcF3C1, E3AbF6C1 and E3AbF6C4 were 
carried out by LC/MS/MS. The analysis was conducted by Proteomics International, 
Perth, Australia. Basically, the SEC fractions were digested with trypsin and the 
peptides extracted were analysed by electrospray ionisation mass spectrometry using the 
Ultimate 3000 nano HPLC system (Dionex, Sunnyvale, CA, USA) coupled to a 4000 
QTRAP mass spectrometer (Applied Biosystems, Foster City, CA, USA). Peptides were 
loaded onto a C18 PepMap100, 3 µm (LC Packings) and separated with a linear 
gradient of water/acetonitrile/0.1% formic acid (v/v). Protein identification was carried 
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out using Mascot sequence matching software (Matrix Science) with Ludwig NR 
database. 
 
3.10 Peptide synthesis 
Based on the LC/MS/MS data, nine potential ACE inhibitory peptides were selected 
from E5PcF3C1, E3AbF6C1 and E3AbF6C4. The peptide sequences selected were 
AHEPVK, GPSMR, KVAGPK, FALPC, RIGLF, EGEPR, APSAK, GVQGPM and 
PSSNK. They were chemically synthesized by Peptron, Inc., Republic of Korea. The 
purity of the synthesized peptides were >98% measured by RPHPLC and MS analysis. 
 
3.11 Effect of simulated gastrointestinal digestion on the ACE inhibitory 
activity of selected peptides 
Simulated gastrointestinal digestion of the nine synthesized peptides was carried out in 
vitro by the method of Liu et al., (2010b). The peptide solution (0.1 mg/ml, 0.5 ml) was 
incubated with 0.5 ml of a 0.05% pepsin solution (0.1 M HCl at pH 2.0) for 2.5 h at 
37
o
C. In successive pepsin-pancreatin digestion test, the peptide solution was adjusted 
to pH 8.0 after the pepsin digestion. Then, 0.5 ml of pancreatin solution, i.e. potassium 
phosphate buffer (0.1 M, pH 8.0) containing 0.025% (w/v) chymotrypsin and 0.025% 
(w/v) trypsin were added into the solution. The mixture was incubated for another 2.5 h 
at 37 
o
C. Control consisting of peptide solution incubated in buffer solutions only, i.e. 
HCl and potassium phosphate buffer, were carried out alongside the experiment. Two 
negative controls were also carried out together with the experiment. The first negative 
control comprised only the buffer solutions, i.e. without peptide solution and 
gastrointestinal enzymes. The second negative control consists of buffer solutions with 
gastrointestinal enzymes but void of peptide solution. Protocols for preparation of HCl 
 48 
 
and potassium phosphate buffer were illustrated in Appendix A (III). After the 
enzymatic treatment, the samples were boiled for 10 min to stop the digestion and then 
centrifuged at 10,000 rpm (ca. 8400 x g) for 10 min. The supernatants were freeze-dried 
and used for measurement of ACE inhibitory activity. The stability of the purified 
peptides against gastrointestinal enzymes were analysed by injecting the samples into 
the SEC column. Prediction of proteolytic fragment released after digestion was carried 
out based on the BIOPEP database (www.uwm.edu.pl/biochemia). 
  
3.12 Determination of ACE inhibition pattern 
The inhibition pattern of the most potent peptides, AHEPVK, RIGLF and PSSNK on 
the ACE activity were determined spectrophotometrically using HHL (Sigma-Aldrich, 
St. Louis, MO, USA) as substrate. Basically, 20 µl of ACE solution (0.1 UN/ml; Sigma-
Aldrich, St. Louis, MO, USA) and 50 µl of peptides were incubated with 200 µl of 
various HHL concentrations (0.63, 1.25, 2.50 and 5.00 mM). The enzymatic reaction 
was terminated by the addition of 250 µl of 1.0 M HCl. The liberated hippuric acid was 
extracted with ethyl acetate and evaporated under vacuum condition. The hippuric acid 
residue was re-dissolved in 1.0 ml of distilled water and the absorbance was determined 
at 228 nm using a spectrophotometer (SmartSpec™ Plus Spectrophotometer, Bio-Rad 
Laboratories, Hercules, USA). The kinetics of ACE inhibition in the presence and 
absence of each peptide (0.00, 0.05 and 0.50 mg/ml) was determined by Lineweaver-
Burk plots. 
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4.0 RESULTS AND DISCUSSION 
4.1 Protein content and ACE inhibitory activity of crude water extracts from 
edible mushrooms 
4.1.1 Protein content of crude water extracts 
Mushrooms were reported to have high protein content, which rank above most fruits 
and vegetables (Chang & Miles, 2004). The protein content in the crude water extracts 
of the nine mushroom species tested in the current study was estimated by BCA protein 
assay kit. Referring to Figure 4.1, the protein content was in the range of 0.73 to 2.70 g 
protein/100 g fresh weight. Crude water extracts of L. edodes and P. citrinopileatus had 
the highest protein content. This was followed by P. flabellatus and P. cystidiosus with 
the protein content of 2.47 and 2.07 g protein/100g fresh weight, respectively. The 
protein content of A. bisporus and F. velutipes were 1.70 and 1.53 g protein/100 g fresh 
weight, respectively. Crude water extracts of H. erinaceus contain 0.96 g protein/100 g 
fresh weight. The most commonly cultivated Pleurotus species in Malaysia, P. 
pulmonarius and P. florida contain 0.75 and 0.73 g protein/100 g fresh weight, 
respectively. They had the lowest protein content compared to the other mushroom 
species tested in the current study. 
Agaricus bisporus in the current study had a similar protein content compared to 
samples of A. bisporus from Italy (1.63 g/ 100 g fresh weight) and Northeast Portugal 
(1.23 g/ 100 g fresh weight) (Manzi et al., 2001; Reis et al., 2012). Mattila et al. (2002b) 
has reported slightly higher protein content in A. bisporus, which was 2.09 g/100 g fresh 
weight. Lentinula edodes also showed similar protein content compared to samples of L. 
edodes from Turkey, which had a protein concentration in the range of 2.07 to 2.94 
g/100 g fresh weight (Cağlarirmak, 2007). However, lower protein content for L. edodes 
was reported in samples from Italy (1.53 g/100 g fresh weight) and Northeast Portugal 
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(0.89 g/ 100 g fresh weight) (Manzi et al., 2001; Reis et al., 2012). Pleurotus 
pulmonarius in the current study has a lower protein content compared to P. sajor-caju 
as determined by Cağlarirmak (2007) and Bonatti et al. (2004), who reported 1.76 g and 
1.54 g/ 100 g fresh weight, respectively. Substrates used for mushroom cultivation, 
temperature and humidity during growth as well as the age of the harvested mushroom 
have been reported to influence the chemical composition and nutritional value of 
mushrooms (Chang & Miles, 2004; Dundar et al., 2008). Hence, different pre- and post-
harvest conditions may cause variations in the protein content of mushrooms. 
 
  
Figure 4.1: Protein concentration (g protein/100 g fresh weight) of crude water extracts 
from nine selected species of edible mushrooms. 
All values were expressed as mean ± standard deviation (n=3). Means with different 
lower case alphabet letters are significantly different (p<0.05). 
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4.1.2 ACE inhibitory activity of crude water extracts 
The crude water extracts from the nine edible mushroom species were tested for their 
ACE inhibitory activity at a concentration of 10 mg/ml. This concentration was selected 
as it was the effective concentration at which all the mushroom species tested could 
exert their bioactivity. Referring to the result obtained in Figure 4.2, all the nine 
mushroom species tested inhibited at least 70% of the ACE activity. The highest ACE 
inhibitory activity was exhibited by F. velutipes and L. edodes where both the crude 
water extracts showed 95.5% of ACE inhibition. This is in line with the report by Chen 
et al. (2012c), which showed F. velutipes and L. edodes has high amount of GABA, or 
also known as γ-aminobutyric acid. It is a secondary metabolite present in many 
vegetables and fruits. It has been proven to have blood pressure lowering effect in 
animal studies (Hayakawa et al., 2004; Shizuka et al., 2004). Based on the study by Zhi 
and Omori (2001), GABA has ACE inhibiting ability. This is supported by the report on 
the positive correlation between GABA content and ACE inhibitory activity in cheese 
(Wang et al., 2010). Besides, Watanabe et al. (2002), suggested that peptides and 
GABA in L. edodes played a role in the inhibition of ACE activity. (Chen et al., 2012c). 
In the current study, crude water extract of A. bisporus exhibited 87.2% of ACE 
inhibitory activity. Interestingly, high GABA content was also reported in this 
mushroom. 
Crude water extract of H. erinaceus at concentration of 10 mg/ml showed 90.1% 
of ACE inhibitory activity. There were not many reported studies on the ACE inhibitory 
activity of H. erinaceus. Based on the report by Abdullah et al. (2012), hot water extract 
of H. erinacues inhibited 50% of the ACE activity at a concentration of 580 mg/ml. 
Compared to the current study, the ACE inhibitory activity of the crude water extract of 
H. erinaceus which did not undergo boiling process exhibited higher ACE inhibitory 
activity. This may suggest that cold water extraction is a better technique to extract 
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ACE inhibitors compared to hot water extraction. This is in line with the report by Choi 
et al. (2001), which showed most of the mushrooms tested, especially G. frondosa has 
higher ACE inhibitory activity in cold water extracts compared to hot water extracts. 
Among the Pleurotus spp. tested in the current study, P. florida and P. 
pulmonarius exhibited the highest ACE inhibitory activity with 87.2% and 85.3% of the 
ACE activity inhibited, respectively. The remaining three Pleurotus spp., namely P. 
citrinopileatus, P. cystidiosus and P. flabellatus showed the percentages of ACE 
inhibitory activity in the range of 71.9-81.4%. Aqueous extract from P. sajor-caju (a.k.a. 
P. pulmonarius) has been reported to have hypotensive effect by the regulation of the 
renin-angiotensin system (Chang & Miles, 2004). Previous studies have reported on the 
identification of D-mannitol as one of the main phytochemicals with ACE inhibitory 
effect in P. cornucopiae and P. citrinopileatus (Hagiwara et al., 2005; Suzuki et al., 
2006).  
The ACE inhibitory activity of mushrooms reported in the current study was 
higher compared to previous reports. At a concentration of 25 mg/ml, water extracts of 
A. bisporus and P. sajor-caju were reported to inhibit 27.3% and 38.7% of ACE, 
respectively, while different strains of F. velutipes inhibited ACE activity in the range 
of 13.7-32.9% (Lee et al., 2004). Kim and co-workers (2002) also reported a lower 
ACE inhibitory activity for L. edodes and F. velutipes, where 50% of ACE activity was 
inhibited at concentrations of 18.4 to 39.3 and 7.4 to 22.6 mg/ml, respectively. The 
conditions of extraction of ACE inhibitor from mushrooms have been reported to 
influence the level of ACE inhibitory activity. The optimum extraction conditions for 
Tricholoma giganteum and Pholiota sp. were at 30
o
C for 3 hours and 1 hour, 
respectively (Lee et al., 2004). Grifola frondosa required a longer extraction time, i.e., 
12 hours (Choi et al., 2001). Apparently, the higher ACE inhibitory activity obtained in 
the current study compared to previous studies shows that the extraction technique 
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employed in the current study was sufficient to extract the ACE inhibitors from 
mushrooms. 
According to the study by Barbosa-Filho et al. (2006), natural compounds 
showing active ACE inhibition include proteins, flavonoids, alkaloids, sesquiterpenoids 
and terpenes. Among these, protein was the most reported compound showing ACE 
inhibitory activity. Therefore, further analysis was carried out to study the ACE 
inhibitory activity of proteins in the mushrooms tested in the current study.    
 
 
Figure 4.2:  Percentages of ACE inhibitory activity of crude water extracts from nine 
selected species of edible mushrooms. 
All values were expressed as mean ± standard deviation (n=3). Means with different 
lower case alphabet letters are significantly different (p<0.05). 
ACE inhibitory activity was tested at 10 mg/ml.  
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In the current study, there was no correlation between the protein content and the 
ACE inhibitory activity (R
2
 = 0.1442). This is supported by a report by Apostolidis et al. 
(2006) which also showed no correlation between the two parameters. This may 
indicate that other compounds in the crude water extract could have interfered or 
competed with proteins to bind to the active site of ACE. Therefore, protein purification 
is important to eliminate other compounds that might hinder the true effect of these 
proteins.  
In addition, the disassociation between the ACE inhibitory activity and protein 
content may also show that the type of protein rather than the protein content that could 
have affected the ACE inhibitory activity. Some studies have focused on the 
purification of peptides from protein precursor with known ACE inhibitory activity. 
Examples of these proteins include casein (Jiang et al., 2010; Minervini et al., 2003), 
collagen (Saiga et al., 2008; Sato et al., 2012), elastin (Sato et al., 2012), troponin 
(Katayama et al., 2004), actin (Yokoyama et al., 1992), myosin (Katayama et al., 2007; 
Terashima et al., 2010) and ovalbumin (Miguel et al., 2004). Currently, there is limited 
study reported on the proteomic analysis of proteins present in mushrooms, in particular 
edible mushrooms. Two studies have reported on the proteomics of edible mushrooms, 
P. tuber-regium Fr. (Chen et al., 2012b), H. erinaceus and Sparassis crispa (Wulfen) Fr. 
(Horie et al., 2008). However, these studies were focused on the identification of 
proteins present at different stages of mushroom life cycle instead of their biological 
activity. Referring to the review by Erjavec et al. (2012), the author and co-workers 
have listed a table on the biological activities of bioactive proteins and protein extracts 
from mushrooms. The bioactivities listed include antifungal, antibacterial, antiviral, 
antiparasitic, antitumour and immunomodulatory. Antihypertensive or ACE inhibitory 
activity was not included in the list. Even though there were reports on the ACE 
inhibitory peptides purified from edible mushrooms, such as G. frondosa (Choi et al., 
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2001), T. giganteum (Lee et al., 2004) and P. cornucopiae (Jang et al., 2011), the 
protein precursors for the bioactive peptides were not determined. In view of these 
limitations, the purification of ACE inhibitory peptides in the current study was not 
targeted on certain protein in mushrooms. The protein mixtures in the mushrooms tested 
were fractionated by bioassay-guided purification methods to determine the potent ACE 
inhibitory peptides.           
 
4.2 Comparison of protein contents in the protein extracts precipitated from 
edible mushrooms by ammonium sulphate 
Proteins were precipitated from the water extracts of the nine edible mushrooms by 
different percentages of salt saturation ranging from 10% to 100% (S10 to S100). 
Figure 4.3 shows a comparison of the protein concentrations in the protein extracts of 
each mushroom species tested. Most mushroom species in the current study had the 
highest concentration of protein precipitated at S50 to S70, except for A. bisporus (S40) 
and P. pulmonarius (S90). Theoretically, proteins with large numbers of hydrophobic 
residues should precipitate out first. Hence, mushrooms tested in the current study 
contain high amounts of amphipathic proteins. According to He et al. (2012), proteins 
that contain abundant hydrophobic amino acids are a good source to produce ACE 
inhibitory peptide. This is because peptide with potent ACE inhibitory activity usually 
contain hydrophobic amino acid residues at the C-terminal and branched aliphatic 
amino acid at the N-terminal (Curtis et al., 2002). In addition, Wang et al. (2011a) and  
He et al. (2012) have reported that apricot almond meal and wheat protein isolates 
which contained 50.08% and 42.84% hydrophobic amino acids, respectively are good 
sources of potent ACE inhibitory peptides. Therefore, the high amount of proteins 
precipitated at S50 to S70 in the nine mushroom species tested in the current study 
shows they can be a good source of ACE inhibitory peptides.  
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Figure 4.3: Protein concentration of protein extracts precipitated at ten percentages of salt saturation (S10-S100) from nine selected species of edible 
mushrooms. 
All values were expressed as mean ± standard deviation (n=3). 
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4.3 SDS-PAGE analysis of protein extracts precipitated from edible 
mushrooms by ammonium sulphate 
The ten ammonium sulphate precipitated protein extracts from the nine mushroom 
species were subjected to SDS-PAGE analysis. Figures of the gels were illustrated in 
Appendix B. Protein extracts with similar SDS-PAGE protein band profiles were 
pooled in the same group as shown in Table 4.1. Protein extracts from H. erinaceus and 
P. citrinopileatus were pooled into four groups while A. bisporus, P. flabellatus, P. 
florida and P. pulmonarius were pooled into five groups. Flammulina velutipes, L. 
edodes and P. cystidiosus were divided into six groups. 
 
Table 4.1: Pooling of protein extracts precipitated at 10-100% salt saturation (S10-
S100). 
Mushroom  
species 
*Pooled protein extracts (E) 
1 2 3 4 5 6 
A. bisporus S10-20 S30 S40 S50-60 S70-100 - 
F. velutipes S10-30 S40 S50-60 S70 S80 S90-100 
H. erinaceus S10-30 S40-50 S60-70 S80-100 - - 
L. edodes S10-20 S30-40 S50 S60 S70-80 S90-100 
P. citrinopileatus S10-40 S50 S60-70 S80-100 - - 
P. cystidiosus S10-20 S30-50 S60 S70-80 S90 S100 
P. flabellatus S10-40 S50 S60 S70-80 S90-100 - 
P. florida S10-40 S50 S60-70 S80 S90-100 - 
P. pulmonarius S10-20 S30-50 S60 S70 S80-100 - 
 
* Pooling of protein extracts were based on the similarity of protein bands observed on 
SDS-PAGE profile. 
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4.4 Comparison of ACE inhibitory activity in pooled protein extracts from 
edible mushrooms 
The use of ammonium sulphate precipitation method for purifying protein has the 
advantages of high protein recovery and maintaining proteins in their native state 
(Jiménez et al., 2012). There were a few previously reported studies which have utilized 
ammonium sulphate as their first step in the bioassay-guided method for purification of 
bioactive proteins from plants. Sheih et al. (2009) have purified ACE inhibitory 
peptides from algae at 20% and 80% salt saturation. Arulpandi and Sangeetha (2012) 
have purified protein with antibacterial activity at 40-80% salt saturation. Alpha-
amylase inhibitor have been extracted from tuber at 80% salt saturation (McEwan et al., 
2010). Referring to Table 4.2, the ability of the pooled protein extracts to exhibit ACE 
inhibitory activity at a concentration as low as 10 µg/ml shows that ammonium sulphate 
precipitation method has successfully recovered the proteins from the mushroom 
species without adversely affecting their ACE inhibitory activity.  
As reported in Figure 4.2 (page 53), crude water extracts from all the nine 
mushroom species showed a comparably high ACE inhibitory activity. However, 
referring to Table 4.2, protein extracts from the nine mushroom species showed 
variations of ACE inhibitory activity. Some protein extracts such as E1 to E4 of H. 
erinaceus have exhibited low ACE inhibitory activity. It is possible to suggest that non-
protein ACE inhibitors could play a major role in these mushrooms. Isolation and 
purification of non-protein ACE inhibitors from several mushrooms have been reported. 
Kiyoto et al. (2008) identified L-pipecolic acid from water extract of edible mushroom, 
Sarcodon aspratus (Berk.) as ACE inhibitor with moderate activity (IC50 = 23.7 mg/ml). 
A sugar alcohol, D-mannitol isolated from P. cornucopiae has been identified as the 
active compound that inhibited the ACE activity at IC50 value of 3.0 mg/ml (Hagiwara 
et al., 2005). 
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Based on the percentage of salt saturation, proteins in E1 have the most 
hydrophobic residue, and proteins with less hydrophobicity were precipitated in the 
latter protein extracts. Proteins with high content of hydrophobic amino acid was 
reported to have more potential to produce high ACE inhibitory activity (He et al., 
2012). Referring to the result illustrated in Table 4.2, there was no correlation between 
the ACE inhibitory activity and hydrophobicity of the protein extracts. The percentage 
of ACE inhibitory activity does not decrease proportionally with the reduction of 
hydrophobicity of the protein extracts. For example, theoretically E2 of A. bisporus is 
more hydrophobic than E3. However, E3 has exhibited higher ACE inhibitory activity 
than E2 with 71.4% and 8.3% of ACE inhibited, respectively. This shows that apart 
from hydrophobicity, the presence of other characteristics could also have contributions 
in the ACE inhibition ability of proteins. Pripp and Ardo (2007) have found a positive 
correlation between increased ACE inhibition and bitterness of peptides. Besides, 
several authors have reported on the relationship of the structure and activity of ACE 
inhibitory peptides (Guang & Phillips, 2012; Pripp et al., 2004; Wu et al., 2006b). Juan 
and Cho (2005) have constructed a three dimensional structure-activity relationship 
model to analyse the binding affinity of ACE inhibitor to the active site of ACE.   
The ammonium sulphate precipitation method has fractionated the proteins in the 
crude water extracts according to the hydrophobic interaction between protein and water 
after the addition of salt (Wingfield, 2001). According to the study reported by Gomez-
Ruiz et al. (2002), there could be a synergistic effect among peptides in cheese to 
exhibit potent ACE inhibitory activity. Likewise, this synergistic effect was also 
proposed in the studies on production of ACE inhibitory peptides from fermented milk 
and tilapia (Gobbetti et al., 2000; Raghavan & Kristinsson, 2009). Therefore, in the 
current study, the protein extracts with lower ACE inhibitory activity, such as E1 to E4 
of H. erinaceus may not indicate that the proteins present were not potent ACE 
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inhibitors. There could be a synergistic effect among the proteins or peptides when 
present together in the crude water extracts in inhibiting the ACE activity, where when 
separated, the activity can no longer be observed (Gomez-Ruiz et al., 2002; Raghavan 
& Kristinsson, 2009). However, the aim of the current study is to identify potent ACE 
inhibitory peptides which act individually. Therefore, only protein extracts with 
potentially high ACE inhibitory activity were selected for further analysis.  
Among the protein extracts, E1 from P. cystidiosus (E1Pc) showed the highest 
ACE inhibitory activity, blocking 96.2% of ACE activity in the inhibition assay at 10 
µg/ml. This was followed by E5 of P. cystidiosus (E5Pc) with 86.7% ACE inhibition. 
E1 and E3 of A. bisporus (E1Ab and E3Ab) also showed significantly higher ACE 
inhibitory activity compared to the other protein extracts with 78.4% and 71.4% of ACE 
enzyme inhibited, respectively. Referring to Table 4.1 (page 57), proteins in E1Pc and 
E5Pc were precipitated at 10-20% and 90% salt saturation, respectively. Proteins in 
E1Ab and E3Ab were precipitated at 10-20% and 40%, respectively. Based on the 
percentages of salt saturation, these protein extracts particularly E1Pc and E1Ab most 
probably have higher hydrophobicity. Therefore, they can be a good source of ACE 
inhibitory peptides as indicated by He et al. (2012). Besides high content of 
hydrophobic amino acid, potent ACE inhibitors have preference for certain amino acid 
at their C- and N-termini. For example, proline, phenylalanine, tryptophan and tyrosine 
were preferred at C-terminal whereas valine, isoleucin and arginine were preferred as 
N-terminal residues (Cheung et al., 1980). Therefore, the four protein extracts, i.e. E1Pc, 
E5Pc, E1Ab and E3Ab with the most potent ACE inhibitory activity were selected for 
further purification by RPHPLC to further characterize the ACE inhibitory activity of 
the proteins. 
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Table 4.2: Percentages of ACE inhibitory activity of the pooled protein extracts from the nine selected species of edible mushrooms. 
Mushroom species Pooled protein extracts (E) 
1 2 3 4 5 6 
A. bisporus (Ab) 78.4 ± 4.4 
s
 8.3 ± 3.2 
abcd
 71.4 ± 0.9 
r
 39.3 ± 1.3 
p
 8.1 ± 2.8 
abcd
 - 
F. velutipes 18.3 ± 3.5 
fghi
 15.8 ± 0.8 
efg
 12.6 ± 2.2 
cdef
 13.7 ± 3.2 
def
 16.4 ± 3.7 
efgh
 19.8 ± 0.5 
ghij
 
H. erinaceus 5.4 ± 3.4 
a
 5.9 ± 2.9 
a
 6.3 ± 1.8 
ab
 6.9 ± 4.6 
abc
 - - 
L. edodes 11.7 ± 2.1 
bcde
 16.6 ± 6.3 
efgh
 24.9 ± 2.8 
jkl
 5.7 ± 2.9 
a
 3.3 ± 1.9 
a
 4.6 ± 2.6 
a
 
P. citrinopileatus 41.1 ± 4.4 
p
 20.9 ± 1.6 
ghij
 15.2 ± 4.9 
efg
 20.2 ± 1.5 
ghij
 - - 
P. cystidiosus (Pc) 96.2 ± 0.6 
u
 47.5 ± 2.7 
q
 31.6 ± 6.1 
mno
 31.5 ± 2.3 
mno
 86.7 ± 2.8 
t
 48.3 ± 2.6 
q
 
P. flabellatus 28.4 ± 3.1 
klm
 36.5 ± 4.1 
op
 21.8 ± 3.9 
hij
 19.9 ± 3.0 
ghij
 22.0 ± 3.4 
hij
 - 
P. florida 25.5 ± 2.3 
jkl
 24.2 ± 8.5 
jk
 17.0 ± 3.1 
efgh
 22.9 ± 4.7 
ijk
 4.5 ± 4.2 
a
 - 
P. pulmonarius 41.2 ± 7.3 
p
 30.6 ± 0.8 
lmn
 35.9 ± 2.2 
nop
 32.2 ± 4.2 
mno
 5.5 ± 1.7 
a
 - 
All values are expressed as mean ± standard deviation (n=3). Means with different lower case alphabet letters are significantly different (p<0.05). 
ACE inhibitory activity was tested at 10 µg/ml protein. Protein extracts highlighted in bold were selected for further purification. 
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4.5 Partial purification of ACE inhibitors from selected pooled protein 
extracts of P. cystidiosus and A. bisporus by RPHPLC 
As discussed in Section 4.4, proteins with potent ACE inhibitory activity usually 
contain abundant hydrophobic amino acid (He et al., 2012). Therefore, the four protein 
extracts with the most potent ACE inhibitory activity from P. cystidiosus (E1Pc, E5Pc) 
and A. bisporus (E1Ab and E3Ab) were further fractionated based on hydrophobicity 
by RPHPLC. The RPHPLC chromatograms obtained are shown in Figure 4.4. Both 
protein extracts from P. cystidiosus had different peak patterns. However, both protein 
extracts from A. bisporus showed very similar peak patterns. This could be due to the 
percentages of salt saturation for E1Ab (S10 to S20) and E3Ab (S40) were quite close. 
Thus, some proteins with similar characteristics could be precipitated within these salt 
saturation solutions.  
Six RPHPLC fractions, i.e. F1 to F6 were collected from each protein extract. 
They were freeze-dried and evaluated for ACE-inhibitory activity. Referring to Table 
4.3, RPHPLC fractions collected from E1Pc and E1Ab had higher recovery rate 
percentages compared to E5Pc and E3Ab, respectively. Percentages of proteins 
recovered from RPHPLC fractions of E1Pc and E5Pc were ranging from 6.16-21.78% 
and 4.95-17.48%, respectively. Whilst percentages of proteins recovered from RPHPLC 
fractions of E1Ab and E3Ab ranged from 6.69-19.14% and 5.35-17.18%, respectively. 
RPHPLC utilized hydrophobic stationary phase. Proteins with high net hydrophobicity 
have more tendencies to participate in hydrophobic interactions with the stationary 
phase of RPHPLC (Scopes, 1994). Based on the percentages of salt saturation, proteins 
in E1Pc and E1Ab were more hydrophobic than E5Pc and E3Ab. Therefore, the higher 
hydrophobicity characteristic of the proteins in E1Pc and E1Ab has more affinity to 
bind to the stationary phase of RPHPLC and subsequently caused the higher recovery in 
the two protein extracts. 
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B 
 
C 
 
D 
 
Figure 4.4: RPHPLC chromatograms of protein extracts from (A) E1Pc, (B) E5Pc,      
(C) E1Ab and (D) E3Ab. 
Fractions collected were labelled as F1 to F6. 
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Table 4.3: Percentages of protein recovery yield and percentages of ACE inhibitory activity of RPHPLC fractions from selected protein extracts. 
RPHPLC  
fractions 
Protein extracts 
E1Pc E5Pc E1Ab E3Ab 
% Recovery 
*
% inhibition % Recovery 
*
% inhibition % Recovery 
*
% inhibition % Recovery 
*
% inhibition 
F1 15.75 3.3 ± 0.6 
a
 5.53 19.2 ± 4.5 
de
 9.62 9.2 ± 3.8 
bc
 6.06 7.7 ± 2.2 
abc
 
F2 6.16 7.7 ± 5.0 
ab
 4.95 28.4 ± 5.9 
fg
 12.00 7.4 ± 2.9 
abc
 10.16 12.9 ± 2.3 
cd
 
F3 21.78 10.6 ± 3.2 
abc
 5.36 30.8 ± 5.6 
g
 7.22 1.2 ± 2.7 
a
 6.90 14.4 ± 7.6 
cd
 
F4 9.74 25.9 ± 2.9 
efg
 8.33 21.4 ± 4.5 
def
 19.14 4.4 ± 2.1 
ab
 17.18 12.2 ± 5.7 
cd
 
F5 15.06 21.9 ± 5.4 
def
 14.46 19.1 ± 4.7 
de
 6.69 3.8 ± 4.7 
ab
 5.35 16.8 ± 2.7 
d
 
F6 13.24 14.7 ± 6.8 
bcd
 17.48 17.4 ± 4.1 
cd
 7.84 19.3 ± 6.8 
de
 6.15 25.7 ± 4.2 
e
 
Total 81.73 - 56.11 - 62.51 - 51.80 - 
*
All values are expressed as mean ± standard deviation (n=3). Means with different lower case alphabet letters within the same mushroom species are 
significantly different (p<0.05). 
ACE inhibitory activity of RPHPLC fractions was tested at 1 µg/ml protein. RPHPLC fractions highlighted in bold were selected for further analysis.
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The total percentages of proteins collected in the RPHPLC fractions of E1Pc and 
E5Pc were 81.73% and 56.11%, respectively. On the other hand, a total of 62.51% and 
51.80% of proteins were collected by RPHPLC fractions of E1Ab and E3Ab, 
respectively. This shows that not all the proteins were recovered from the four protein 
extracts. Previous work has shown that proteins denature and lose their bioactivity in 50% 
aqueous-acetonitrile solution (Scopes, 1994). In view of this complication, proteins 
were eluted from the RPHPLC column to a maximum of 50% acetonitrile. Proteins 
eluted by higher than 50% acetonitrile were eliminated from analysis.  
Despite of this drawback, acetonitrile was still utilized as the mobile phase in the 
current study because of its high optical transparency in the detection wavelengths used 
for protein and peptide analysis, which is slightly above 200 nm (Aguilar, 2004). In 
addition, the lower viscosity and lower chemical reactivity of acetonitrile makes it a 
good choice for liquid chromatography (Gekko et al., 1998). Compared to alcohols such 
as methanol and 2-propanol, mobile phases containing acetonitrile was reported to exert 
greater retention (Aguilar, 2004).  
Most of the previously reported studies on the purification of ACE inhibitory 
peptides have used RPHPLC profile with elution of acetonitrile up to not more than 
50%. This could be that the authors were aware of the bioactivity loss of proteins at 50% 
aqueous-acetonitrile solution. There were studies that utilized the same RPHPLC profile 
used in the current study, i.e. elution of proteins using a linear gradient of acetonitrile at 
0-50%. This include studies on the purification of ACE inhibitory peptides from tuna 
(Qian et al., 2007), porcine (Muguruma et al., 2009), cuttlefish (Balti et al., 2010) egg 
white (Asoodeh et al., 2012) and mushroom G. frondosa (Choi et al., 2001). Some 
studies have eluted the proteins at a lower percentage of acetonitrile. For example ACE 
inhibitory peptides were purified from fermented soybean (Kuba et al., 2003), 
freshwater clam (Tsai et al., 2006) and corn gluten (Yang et al., 2007) at a linear 
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gradient of 0-40% acetonitrile. ACE inhibitory peptides from broccoli and buckwheat 
were eluted at a gradient of 5-20% acetonitrile (Lee et al., 2006; Ma et al., 2006). Even 
though some studies on purification of ACE inhibitory peptides have eluted proteins to 
a percentage of acetonitrile higher than 50%, the fraction that exhibited the highest ACE 
inhibitory activity were proteins eluted at lower than 50% acetonitrile. For example, 
ACE inhibitory peptide was purified from grass carp at linear gradient of acetonitrile 
from 5-60% for 60 min. The fraction exhibited the highest ACE inhibitory activity was 
eluted at a retention time of approximately 40 min (Chen et al., 2012a). Likewise, ACE 
inhibitory peptide from salmon was eluted from 0-70% acetonitrile for 33 min. The 
most active fraction was eluted at a retention time of approximately 21 min (Ahn et al., 
2012). Thus, the four protein extracts in the current study was further purified by 
RPHPLC to a maximum of 50% acetonitrile. 
ACE inhibitory activity of the protein fractions collected from RPHPLC are 
shown in Table 4.3 (page 64). The RPHPLC fractions were tested at a lower 
concentration compared to protein extracts, i.e. 1 µg/ml. Approximately 3.3-25.9% of 
ACE was inhibited by the RPHPLC fractions from E1Pc, while the ACE inhibitory 
activity of the RPHPLC fractions from E5Pc was in the range of 17.4-30.8%. RPHPLC 
fractions from E1Ab and E3Ab inhibited ACE activity in the range of 1.2-19.3% and 
7.7-25.7%, respectively. Based on the percentages of ammonium sulphate used, proteins 
in E1Pc and E1Ab have higher hydrophobicity compared to proteins in E5Pc and E3Ab. 
Referring to Table 4.3, mostly RPHPLC fractions collected from E5Pc and E3Ab has 
higher ACE inhibitory activity compared to RPHPLC fractions collected from E1Pc and 
E1Ab, respectively. This shows that proteins with intermediate hydrophobicity in E5Pc 
and E3Ab have higher ACE inhibitory activity. According to He et al. (2012), proteins 
that contain abundant hydrophobic amino acid can be a good source of ACE inhibitory 
peptides. For example, potent ACE inhibitory peptides have been purified from apricot 
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almond meal and defatted wheat germ protein which contain 50.08% and 42.54% of 
hydrophobic amino acids, respectively (He et al., 2012; Wang et al., 2011a). However 
hydrophobicity is not the only characteristic for ACE inhibitor. Apart from abundant 
hydrophobic amino acids, the presence of some amino acids with other characteristic 
can be an added advantage for the proteins to be a good source of ACE inhibitory 
peptides. Some studies have predicted the preference of amino acid with certain 
characteristic for each position in potent ACE inhibitory peptide. For example, a 
tripeptide with potential ACE inhibitory activity was predicted to have preference for 
aromatic amino acids at the carboxyl terminus, a positively charged amino acids for the 
middle position and hydrophobic amino acids for the amino terminus (Wu et al., 2006a). 
Therefore, this may explain the higher ACE inhibitory activity in E5Pc and E3Ab which 
contain proteins with intermediate hydrophobicity compared to E1Pc and E1Ab, 
respectively. 
Referring to Table 4.3, the highest ACE inhibitory activity in P. cystidiosus was 
exhibited by F3 of E5Pc whereas in A. bisporus, it was exhibited by F6 of E3Ab. The 
percentage of proteins recovered from E5PcF3 was 5.36% which was the second lowest 
amount obtained among the RPHPLC fractions of E5Pc. On the other hand, 6.15% of 
proteins were recovered from E3AbF6. It was the third lowest amount of protein 
obtained among the RPHPLC fractions of E3Ab. This may suggest that the active ACE 
inhibitory proteins in P. cystidiosus and A. bisporus were present in low abundance. 
According to Ning et al. (2008), usually the low abundance proteins that plays 
important roles in biological process. Therefore, the low recovery percentage with the 
highest ACE inhibitory activity exhibited by E5PcF3 and E3AbF6 shows that these 
RPHPLC fractions consist of low abundance proteins which could be potential source 
of ACE inhibitory peptides. 
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In the previous studies, different ACE inhibitory peptides had been purified from 
different species of edible mushrooms, namely G. frondosa (Choi et al., 2001), T. 
giganteum (Lee et al., 2004) and P. cornucopiae (Jang et al., 2011). This shows that 
different proteins in the mushroom species were responsible for the ACE inhibitory 
activity. Hence, the RPHPLC fraction with the highest ACE inhibitory activity from P. 
cystidiosus (E5PcF3) and A. bisporus (E3AbF6) were selected for proteomic analysis by 
SDS-PAGE and SELDI-TOF-MS to compare their protein characteristics.  
 
4.6 Proteomic analysis of selected RPHPLC fractions with active ACE 
inhibitory activity 
Proteomic analysis of the two most active RPHPLC fractions from P. cystidiosus 
(E5PcF3) and A. bisporus (E3AbF6) were carried out by SDS-PAGE and SELDI-TOF-
MS. Referring to Figure 4.5, SDS-PAGE of the two RPHPLC fractions revealed the 
majority of proteins present in E5PcF3 and E3AbF6 were of low molecular weight, i.e. 
with molecular masses less than 30 kDa. Some reports from previous studies on food-
derived proteins with ACE inhibitory abilities also feature relatively low molecular 
weight. For example, buckwheat proteins with molecular masses less than 10 kDa has 
exhibited higher anti-ACE activity than its high molecular weight fractions (Ma et al., 
2006). In the current study, E5PcF3 and E3AbF6 have protein bands with molecular 
masses of 7 and 12 kDa as well as 5, 8 and 13 kDa, respectively. Proteins with 
molecular masses of 3 to 10 kDa have been reported to exhibit moderate ACE 
inhibitory activity (Chiang et al., 2006; Jiang et al., 2010). Therefore, it is possible to 
suggest that these low molecular weight proteins could be responsible for triggering the 
ACE inhibitory activity in E5PcF3 and E3AbF6.  
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There were two protein bands common to E5PcF3 and E3AbF6 of molecular 
masses 16 and 18 kDa. A distinct band at 17 kDa was detected in E5PcF3 which was 
not visualised in E3AbF6. On the other hand, E3AbF6 contained eight high molecular 
weight protein bands which are not detected in E5PcF3. According to Natesh et al. 
(2003), large peptide molecules are restricted from fitting into the active site of ACE. 
Therefore the ACE inhibitory activity in E3AbF6 might not be attributable to these high 
molecular weight proteins. 
 
              A                     Marker (kDa)               B                     Marker (kDa) 
  
Figure 4.5: SDS-PAGE analysis of (A) E5PcF3 and (B) E3AbF6. 
: Proteins with similar molecular weight detected in E5PcF3 and E3AbF6. 
 
SELDI-TOF-MS has been reported to be the most effective method for profiling 
low molecular weight proteins and peptides (<30 kDa), providing a complementary 
visualisation technique to SDS-PAGE data (Issaq et al., 2003).
 
SELDI-TOF-MS spectra 
of E5PcF3 and E3AbF6 are shown in Figure 4.6. There were 22 protein clusters 
identified in the EDM analysis of the two RPHPLC fractions as shown in Table 4.4. 
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SELDI peaks lower than m/z 3500 were detected with high intensity in the 
SELDI-TOF-MS spectra of E3AbF6. These peaks were not detected in E5PcF3. In the 
current study, proteins lower than 3,500 Da were expected to be removed during 
dialysis of the protein extracts by snakeskin dialysis tubing (3,500 Da cut-off). As 
reported previously, intact protein structures may become unstable in 50% aqueous-
acetonitrile mixtures (Gekko et al., 1998). Based on the location of E3AbF6 in the 
RPHPLC chromatogram (Figure 4.4D, page 63), the fraction was collected from the 
gradient in a water-acetonitrile mixture close to 50% (water: acetonitrile). Therefore, the 
detection of proteins lower than 3,500 Da in the SELDI spectra of E3AbF6 could 
represent broken-down or fragmented proteins from the unstable proteins in the 
aqueous-acetonitrile mixture. 
There were five common peaks detected in E5PcF3 and E3AbF6 (m/z values 3940, 
4254, 5496, 8300 and 11413). The high intensity of these common peaks shows they 
could play a role in the high levels of ACE inhibitory activity exhibited by the two 
RPHPLC fractions. Besides the five common peaks, there were seven extra peaks with 
m/z values of 5291, 7876 to 8244 and 8516 to 8629 detected only in E5PcF3, while 
E3AbF6 contained three peaks with m/z values of 5906.9, 6022.5 and 8291.8 that were 
not detected in E5PcF3. Interestingly the m/z values of these proteins were in the range 
of 3000 to 10000. Therefore, this range of proteins could be the potential anti-ACE 
agent which played a role in the higher ACE inhibitory activity exhibited in E5PcF3 and 
E3AbF6.  
Based on the proteomic analysis of E5PcF3 and E3AbF6 discussed above, the 
RPHPLC fractions still consist of a mixture of proteins. Therefore, the protein mixtures 
in E5PcF3 and E3AbF6 were further fractionated by SEC column according to 
molecular size to further reduce the complexity of proteins for detection of ACE 
inhibitory proteins. 
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B 
 
Figure 4.6: SELDI-TOF-MS spectra of (A) E5PcF3 and (B) E3AbF6. 
: Proteins with similar molecular weight detected in E5PcF3 and E3AbF6. 
 
Table 4.4: EDM analysis of peak intensities observed in SELDI-TOF-MS spectra of 
E5PcF3 and E3AbF6. 
a
Protein cluster 
m/z 
b
p-value 
c
Peak intensities (µA) 
E5PcF3 E3AbF6 
2552.0 ± 0.9 0.021 ND 59.9 ± 5.7 
2919.2 ± 0.9 0.021 ND 39.4 ± 4.3 
3189.0 ± 1.3 0.021 ND 70.9 ± 11.4 
3223.2 ± 1.1 0.021 ND 60.1 ± 11.9 
3317.7 ± 0.9 0.021 ND 295.7 ± 7.7 
3621.2 ± 1.0 0.021 ND 102.0 ± 19.2 
3940.6 ± 2.8 0.021 66.9 ± 2.8 22.4 ± 2.3 
4254.8 ± 1.0 0.021 42.1 ± 2.6 30.6 ± 3.0 
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Table 4.4 (Continued) 
5291.2 ± 0.5 0.021 25.9 ± 0.5 ND 
5496.6 ± 0.4 0.021 85.0 ± 5.4 35.2 ± 4.0 
5906.9 ± 2.3 0.021 ND 30.1 ± 2.0 
6022.5 ± 0.8 0.021 ND 42.5 ± 7.4 
7876.5 ± 0.6 0.021 226.2 ± 39.4 ND 
8193.5 ± 0.6 0.021 189.2 ± 5.4 ND 
8223.6 ± 1.1 0.021 141.5 ± 4.9 ND 
8244.2 ± 0.6 0.021 284.9 ± 13.5 ND 
8291.8 ± 2.3 0.040 ND 76.5 ± 3.9 
8305.8 ± 1.4 0.021 88.5 ± 2.5 155.3 ± 14.7 
8328.2 ± 22.1 0.021 80.3 ± 2.6 50.1 ± 4.5 
8516.6 ± 0.6 0.021 80.3 ± 13.9 ND 
8629.5 ± 0.7 0.021 95.2 ± 14.9 ND 
11413.5 ± 2.7 0.021 5.0 ± 0.3 39.6 ± 3.4 
a
Proteins with similar molecular mass were clustered during EDM analysis. The m/z 
value for each protein cluster was presented as mean  standard deviation (n=4). 
b
Values with p<0.05 indicate the protein peaks were statistically significant in the two 
samples based on peak intensity. 
c
Peak intensities are presented as mean  standard deviation (n=4). 
 ND: Peaks were not detected. Intensities of ND peaks are only estimated values for 
clustering purposes during EDM analysis. Thus their intensities are not shown.  
Protein clusters highlighted in bold are common proteins detected in E5PcF3 and 
E3AbF6.  
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4.7 Further purification of selected RPHPLC fractions with active ACE 
inhibitory activity by SEC 
Clinical trials have suggested that protein consumption, especially from plant 
sources could reduce blood pressure (Elliott et al., 2006). Low molecular weight 
compounds possess advantages of high absorbability, high permeability and long term 
stability (Arai et al., 2013). Based on the report by Natesh et al. (2003), large protein 
molecules are restricted from fitting into the active site of ACE. Previous studies have 
reported that low molecular weight fractions of filtrates from ultrafiltration exhibited 
higher anti-ACE activity. For example, protein filtrate from tilapia with molecular 
weight cut off lower than 30 kDa showed higher percentages of ACE inhibitory activity 
(Raghavan & Kristinsson, 2009). In addition, potent ACE inhibitory proteins purified 
from water extracts of edible mushrooms such as P. cornucopiae, P. adiposa and T. 
giganteum were exhibited by filtrate of 5000 molecular weight cut-off (Jang et al., 2011; 
Koo et al., 2006; Lee et al., 2004). Therefore, this has intrigued us to further purify the 
proteins with lower molecular weight. In the current study, the mobile phase used for 
SEC, i.e 45% acetonitrile containing 0.1% TFA was an optimised method for the 
separation of low molecular weight proteins (< 20 kDa) provided by the manufacturer 
(McGinley & Knudsen, 2010). 
The SEC chromatograms of E5PcF3 and E3AbF6 are shown in Figure 4.7. There 
were seven fractions collected from each sample and labelled as C1 to C7. Referring to 
Table 4.5, higher recovery rate percentages was collected from SEC fractions of 
E5PcF3 compared to E3AbF6. The total percentages of proteins recovered in E5PcF3 
and E3AbF6 were 83.4% and 21.0%, respectively. As mentioned earlier, the SEC 
profiling has been optimized for the separation of low molecular weight proteins. The 
high percentage of protein recovered in E5PcF3 may suggest that low molecular weight 
proteins dominate in E5PcF3. This is in accordance with the result of SDS-PAGE in 
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Figure 4.5 (page 69), which showed only protein bands with molecular masses lower 
than 30 kDa were visualized in E5PcF3. On the other hand, SDS-PAGE analysis shows 
that E3AbF6 consist of both high and low molecular weight proteins. The lower protein 
recovery in SEC fractionation of E3AbF6 may presume that the extract contained higher 
amount of high molecular weight proteins. 
The ACE inhibitory activity of SEC fractions was tested at 1 µg/ml. Referring to 
Table 4.5, most of the SEC fractions collected from E5PcF3 exhibited higher 
percentages of ACE inhibitory activity compared to E3AbF6. The ACE inhibitory 
activity exhibited by SEC fractions of E5PcF3 was in the range of 5.6-27.4% whereas 
0.9-18.7% of ACE activity was blocked by SEC fractions of E3AbF6. Among the SEC 
fractions, E5PcF3C1, E3AbF6C1 and E3AbF6C4 exhibited the highest ACE inhibitory 
activity. Based on the position of the three peaks in the SEC chromatogram shown in 
Figure 4.7, the molecular masses of peaks C1 and C4 were estimated to be lower than 
20 and 10 kDa, respectively. Previous studies have shown successful purification of 
potent ACE inhibitory peptides from food proteins in this range of molecular masses. 
Protein fraction from sea cucumber below 20 kDa exhibited the highest percentage of 
ACE inhibitory activity (Forghani et al., 2012) whilst protein fraction from tuna with 
molecular masses of 5-10 kDa exhibited high percentage of anti-ACE activity (Lee et 
al., 2010). In addition, ACE inhibitory peptide from G. frondosa was purified from 
filtrate with molecular weight cut off 10,000 (Ohtsuru et al., 2000). Therefore, the three 
SEC fractions, i.e. E5PcF3C1, E3AbF6C1 and E3AbF6C4 could be a potential source 
of potent ACE inhibitory peptides. These three SEC fractions were selected for further 
analysis by LC/MS/MS. 
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Figure 4.7: SEC chromatograms of (A) E5PcF3 and (B) E3AbF6.  
Fractions collected were labelled as C1 to C7. 
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Table 4.5: Percentages of protein recovery yield and percentages of ACE inhibitory 
activity of the SEC fractions. 
SEC fractions 
RPHPLC fractions 
E5PcF3 E3AbF6 
% Recovery 
*
% inhibition % Recovery 
*
% inhibition 
C1 3.6 27.4 ± 2.7 
a
 4.5 18.7 ± 3.2 
e
 
C2 3.9 5.6 ± 2.2 
bc
 2.9 5.8 ± 2.3 
bc
 
C3 24.6 7.5 ± 0.8 
cd
 5.1 0.9 ± 0.6 
f
 
C4 12.8 7.9 ± 4.7 
cd
 4.0 16.1 ± 0.5 
e
 
C5 9.6 5.9 ± 2.2 
bc
 1.7 6.4 ± 1.5 
bcd
 
C6 12.3 8.7 ± 2.5 
cd
 0.7 6.6 ± 2.5 
bcd
 
C7 16.6 10.1 ± 0.52 
d
 2.1 3.4 ± 1.8 
bf
 
Total 83.4 - 21.0 - 
All values are expressed as mean ± standard deviation (n=3).  
*
ACE inhibitory activity of SEC fractions was tested at 1 µg/ml protein. Means with 
different lower case alphabet letters are significantly different (p<0.05).  
SEC fractions highlighted in bold were selected for further analysis. 
 
4.8 LC/MS/MS analysis of potent ACE inhibitor from SEC fractions 
The amino acid sequence of peptides in E5PcF3C1, E3AbF6C1 and E3AbF6C4 were 
determined by LC/MS/MS. The list of all the peptide sequences including the score, 
protein name, molecular masses of the proteins and species of origins were illustrated in 
Appendix C. Most of the proteins identified in the three SEC fractions were 
hypothetical proteins, i.e. proteins predicted from amino acid sequences only and the 
protein functions were unknown. All the three SEC fractions analyzed in the current 
study contain ribosomal protein. It is one of the common proteins found in the cell wall 
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of mushrooms (Chen et al., 2012b). It plays a role in the biogenesis of ribosome for 
different stages of translation process and involved in RNA folding, protein assembly, 
rRNA processing, stabilization of the subunit structure and interacts with protein 
folding factors at the exit tunnel of the ribosome (Ferreira-Cerca et al., 2005). 
Interestingly, peptides from ribosomal protein in rapeseed have been reported as potent 
ACE inhibitor (Marczak et al., 2003). Therefore, the ribosomal proteins in E5PcF3C1, 
E3AbF6C1 and E3AbF6C4 could be a potential source of ACE inhibitory peptide.  
Actin is also a protein commonly found in the mushroom cell wall (Chen et al., 
2012b). In fungi, it is a cytoskeleton protein involved in the initiation of cell wall 
formation and functions in the fundamental processes of cell polarity, cytokinesis and 
endocytosis (Aghamohammadzadeh & Ayscough, 2010). ACE inhibitory peptides have 
been identified in actin from animal sources such as chicken and fish (Fujita et al., 2000; 
Yokoyama et al., 1992). Likewise, peptide isolated from actin of plant, i.e. rapeseed has 
also exhibited potent ACE inhibitory activity. This may suggest actin in E5PcF3C1 
could have contributions in the ACE inhibitory activity exhibited by the particular SEC 
fraction. 
Another common protein in mushroom, guanosine triphosphate (GTP)-binding 
protein has been detected in E5PcF3C1. It is a protein associated with the biosynthesis 
of capsular polysaccharides, i.e. β-glucans and plays a major role in the regulation of 
cell wall morphogenesis (Kang & Cabib, 1986). Glutathione S-transferase found in 
E3AbF6C1 is a protein associated with detoxification processes and participate in the 
cellular response to oxidative stress (Thuillier et al., 2011). Currently, there is no report 
on the association of ACE inhibitory peptides with GTP-binding protein or glutathione 
S-transferase. 
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Due to the detection of mostly hypothetical proteins with unknown function in 
the three SEC fractions, the amino acid sequence of peptides was taken into 
consideration in the selection of peptides with potential ACE inhibitory activity. The 
physicochemical properties of amino acids have been reported to influence the 
biological activity of peptides as ACE inhibitor. For example, hydrophobicity of amino 
acids has been indicated to have the greatest influence on ACE inhibitory activity. In 
other words, amino acid with greater hydrophobicity shows higher ACE inhibitory 
activity (He et al., 2012). According to Pripp and co-workers, hydrophobicity of C-
terminal enhanced the ACE inhibitory activity of potential peptides up to six amino 
acids in length (Pripp et al., 2004; Pripp et al., 2005). Likewise, Curtis et al. (2002) 
indicated bioactive peptides are typically 2-5 amino acids in length. Besides 
hydrophobicity of C-terminal, Wu et al. (2006a) has suggested branched aliphatic 
amino acid for the N-terminal of potential ACE inhibitory peptides. Therefore, in the 
current study, potential ACE inhibitors were selected from the peptide list based on the 
structural requirement of potential ACE inhibitory peptides mentioned above, i.e. less 
than six amino acids and consists of hydrophobic and branched aliphatic amino acid at 
the C- and N-termini, respectively. The physicochemical properties of the twenty amino 
acids, which include hydrophobicity, charge and chemical structure were listed in 
Appendix D.   
Total of ten peptide sequences have been selected as potential ACE inhibitory 
peptides. Two peptides were selected from E5PcF3C1. There were five and three 
peptides chosen from E3AbF6C1 and E3AbF6C4, respectively. The peptide sequences 
and molecular masses were listed in Table 4.6. LC/MS/MS spectra of the peptides were 
illustrated in Appendix E. There is a similar peptide sequence, i.e. AHEPVK detected in 
E5PcF3C1 and E3AbF6C4. It could be a common peptide found in P. cystidiosus and A. 
bisporus. The subsequent analyses were carried out based on nine peptide sequences. 
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The nine selected ACE inhibitory peptides contain five to six amino acids in length. 
This is in accordance with the maximum length of bioactive peptides as mentioned in 
previous reports (Curtis et al., 2002; Pripp et al., 2004).  
 
Table 4.6: List of peptide sequences, molecular masses and IC50 values of the selected 
potential ACE inhibitors.  
SEC fraction Peptide 
(P) 
Peptide 
sequence 
Observed 
mass 
Calculated 
mass 
*
IC50  
(µM) 
E5PcF3C1 1 AHEPVK 679.51 679.37 62.8 ± 5.8 
a
 
2 GPSMR 547.73 546.26 277.5 ± 9.9 
b
 
E3AbF6C1 3 KVAGPK 599.39 598.38 304.9 ± 7.1 
b
 
4 FALPC 549.29 549.26 690.9 ± 5.3 
c
 
5 RIGLF 605.35 604.37 115.9 ± 10.4 
a
 
6 EGEPR 587.80 586.27 728.2 ± 6.6 
c
 
7 APSAK 474.25 472.26 325.7 ± 6.5 
b
 
E3AbF6C4 1 AHEPVK 679.51 679.37 62.8 ± 5.8 
a
 
8 GVQGPM 604.37 603.27 736.7 ± 4.8 
c
 
9 PSSNK 531.24 531.27 129.3 ± 16.6 
a
 
*
IC50 values were expressed as mean ± standard deviation (n=3). Means with different 
lower case alphabet letters are significantly different (p<0.05). 
 
As indicated in the report by Wu et al. (2006a), the N-terminal of potential ACE 
inhibitory peptides usually consist of aliphatic amino acids. This type of amino acids 
have side chains that contain only hydrogen and carbon atoms, which  include alanine, 
glycine, isoleucine, leucine, valine and proline (Betts & Russell, 2003). As shown in 
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Table 4.6, the first two positions of the N-terminal for the nine peptides have either one 
or both position with aliphatic amino acids whereas for the C-terminal, greater 
hydrophobicity of amino acids may increase the ACE inhibitory activity of the 
particular peptide (He et al., 2012), Amino acid with hydrophobic characteristic include 
alanine, isoleucine, leucine, methionine, proline, tryptophan and valine. Referring to the 
peptide sequences shown in Table 4.6, the first two positions of the C-terminal contain 
either one or both residues with hydrophobic amino acids.        
The nine selected peptides were chemically synthesized to determine the IC50 
values of ACE inhibition. The extrapolated graphs for the determination of IC50 values 
for the nine synthetic peptides were illustrated in Appendix F. Referring to Table 4.6, 
the nine synthetic peptides showed variations of IC50 values, ranging from 62.8-736.7 
µM with the lowest IC50 value exhibited by P1. Interestingly, this peptide was detected 
in both E5PcF3C1 and E3AbF6C4. It could be a common peptide in P. cystidiosus and 
A. bisporus. The second potent ACE inhibitory activity was exhibited by P5 with IC50 
value of 115.9 µM. This was followed by P9 with IC50 value of 129.3 µM. The IC50 
values of these three peptides were not significantly different (p<0.05). Peptides P2, P3 
and P7 have also exhibited insignificant differences (p<0.05) with IC50 values in the 
range of 277.5-325.7 µM. The remaining three peptides, P4, P6 and P8 have blocked 50% 
of the ACE activity at a higher concentration, ranging from 690.9-736.7 µM. 
Previous studies have reported on the successful purification of ACE inhibitory 
peptides from edible mushrooms. Among them, peptides from G. frondosa and P. 
adiposa have the same length of amino acids with the peptides in the current study, i.e. 
5-6 amino acids. The IC50 value of peptides VIEKYP and GQGGP from G. frondosa 
and P. adiposa were 129.7 and 254 µM, respectively (Choi et al., 2001; Koo et al., 
2006). Apparently, the three most active peptides tested in the current study, namely P1, 
P5 and P9 has comparable activity with peptide from G. frondosa and more potent 
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activity than peptide from P. adiposa. There were also pentapeptides and hexapeptides 
derived from other food sources that exhibited comparable ACE inhibitory activity with 
the three most potent peptides in the current study. Peptides LVQGS and VTPALR 
from soybean and mung bean blocked 50% of the ACE activity at a concentration of 
43.7 and 82.4 µM, respectively (Li et al., 2006; Rho et al., 2009). Pentapeptides, 
GPCSR and VKAGE from sweet potato exhibited IC50 values of 61.67 and 141.56 µM, 
respectively (Huang et al., 2008; Huang et al., 2011b). There were also pentapeptides 
showing higher ACE inhibitory activity compared to the peptides in the current study. 
For example LKPNM, a peptide from bonita fish which has been commercialized as 
supplement in Canada and Japan. It has the ability to block 50% of the ACE activity at a 
concentration of 2.4 µM (Fujita & Yoshikawa, 1999). Previous studies have also 
reported on the purification of shorter ACE inhibitory peptides. i.e. 2-4 amino acids. 
Some of these peptides have shown higher ACE inhibitory activity than the 
pentapeptides and hexapeptides in the current study. However, there were also peptides 
that exhibited lower ACE inhibitory activity. For example, tripeptides from clam, VKP 
and VKK have IC50 values of 3.7 and 1045 µM, respectively. Nine peptides with 2-4 
amino acids purified from sweet potato exhibited IC50 values of 208.6-849.7 µM 
(Huang et al., 2008). There were also studies reported on the isolation of longer peptide 
sequences with ACE inhibitory activity. For example, two peptides have been extracted 
from P. cornucopiae with 14 and 17 amino acids in length. These peptides exhibited 
IC50 values of 277.3 and 539.9 µM, respectively (Jang et al., 2011). However, shorter 
peptides are preferred due to the advantages of being capable of passing the 
gastrointestinal tract, easily absorbed and reach the peripheral target sites (Quiros et al., 
2005). Therefore, the nine peptides with five to six amino acids tested in the current 
study could be potential ACE inhibitors and warrant further study. 
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The amino acid sequences of the nine peptides tested in the current study were 
compared with the potential ACE inhibitory peptides reported in previous studies. C-
terminal has been reported to have strong influence on the ACE inhibitory activity 
(Cheung et al., 1980; Wijesekara & Kim, 2010). This is because binding of inhibitor to 
the ACE enzyme takes place predominantly via the C-terminal residues (Jao et al., 
2012). Therefore, the comparison of amino acid sequences reported in the current study 
was mostly focused on the C-terminal residue. Pentapeptide from sea squirt, AHIII (Ko 
et al., 2011) has a similar amino acid sequence with P1, AHEPVK. The first two amino 
acids at N-terminal were alanine and histidine. Besides P1, there were three peptides in 
the current study, P3 (KVAGPK), P7 (APSAK) and P9 (PSSNK) which have lysine at 
the C-terminal. Lysine is an aliphatic amino acid. There were reports demonstrated that 
potential ACE inhibitory peptides posses lysine at their C-terminal. Examples include 
VVGAK, YPK, AIYK and VKK from sweet potato, broccoli, wakame and clam, 
respectively (Huang et al., 2011a; Lee et al., 2006; Suetsuna & Nakano, 2000; Tsai et 
al., 2006). Pentapeptide ACE inhibitor from sweet potato, GPCSR (Huang et al., 2011b) 
has a similar peptide sequence with P2, GPSMR. Besides P2, another peptide that has 
arginine at the C-terminal is P6 (EGEPR). Previous reports on ACE inhibitory peptides 
that contain this aliphatic amino acid at the C-terminal include VR and VTPALR from 
salmon and mung bean, respectively (Gu et al., 2011; Li et al., 2006). P5 (RIGLF) 
which has the second lowest IC50 value contains phenylalanine at the C-terminal. 
Peptide with aromatic amino acid at the C-terminal has been reported to exhibit strong 
ACE inhibitory effect (Cheung et al., 1980). Previously reported ACE inhibitory 
peptides with phenylalanine at the C-terminal include VIIF and YYAPF from cuttlefish 
and wine, respectively (Balti et al., 2010; Takayanagi & Yokotsuka, 1999). Cysteine 
has been reported to have modulatory effect on the renin-angiotensin system (Vasdev et 
al., 2009). In the current study, P4 (FALPC) contains cysteine at its C-terminal. A 
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potential ACE inhibitory peptide, GTEKC with cysteine at the C-terminal has been 
isolated from sweet potato (Huang et al., 2008). LKPNM, a peptide from bonita fish has 
been commercialized as supplement in Canada and Japan (Harnedy & FitzGerald, 2012). 
It has strong hydrophobic amino acid, methionine at the C-terminal. Interestingly, 
peptide P8 (GVQGPM) in the current study also contains methionine at the C-terminal. 
In addition, glycine has been reported as one of the major constituent of ACE inhibitory 
peptides (Byun & Kim, 2001; Wu et al., 2013). In the current study, there were five 
peptides, P2, P3, P5, P6 and P8 containing glycine either at the N-terminal or middle 
position. Therefore, the similarity of amino acid residues of the nine peptides in the 
current study with previously reported ACE inhibitors shows the nine peptides from P. 
cystidiousus and A. biposrus could be potential ACE inhibitors. Although the IC50 value 
of the nine peptides were higher compared to some previously reported ACE inhibitory 
peptides from other food sources, the three most active peptides, namely P1, P5 and P9 
have better activity compared to previously reported edible mushrooms (Choi et al., 
2001; Jang et al., 2011; Koo et al., 2006). Besides, mushrooms are easy to cultivate. 
Pleurotus spp. and A. bisporus are among the most cultivated mushrooms worldwide 
(Sanchez, 2010). Hence, a sufficient supply of these mushrooms species could be 
obtained for extraction of potential ACE inhibitory peptides. Additionally, mushroom 
allergy from eating is very rare (Koivikko & Savolainen, 1988). Therefore, these could 
be the added advantages for the production of mushroom as pharmaceutical drugs.       
Table 4.7 summarizes the percentages of ACE inhibitory activity of fractions 
obtained from each purification steps. Water extracts of P. cystidiosus and A. bisporus 
have showed 81.4% and 87.2% of ACE inhibition when tested at 10 mg/ml. The protein 
extracts were tested at a lower concentration than the water extract, i.e. 10 µg/ml and 
the ACE inhibitory activity was maintained at 86.7% and 71.4% for P. cystidiosus and   
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Table 4.7: Summary of the purification steps of ACE inhibitors from P. cystidiosus and 
A. bisporus. 
Purification steps 
(concentration) 
P. cystidiosus A. bisporus 
ACE 
inhibition 
(%) 
*
Purification  
fold 
ACE 
inhibition 
(%) 
*
Purification  
fold 
Water extract 
(10 mg/ml) 
 
81.4 - 87.2 - 
Pooled protein extract 
(10 µg/ml) 
 
86.7 - 71.4 - 
RPHPLC 
(1 µg/ml) 
 
30.8 1.0 25.7 1.0 
SEC 
(1 µg/ml) 
 
27.4 (C1) 0.9 18.7 (C1) 0.7 
  16.1 (C4) 0.6 
 
Synthesised peptides 
(1 µg/ml) 
 
27.5 (P1) 0.9 27.5 (P1) 1.1 
23.9 (P2) 0.8 15.0 (P3) 0.6 
  22.0 (P4) 0.9 
  27.6 (P5) 1.1 
  26.4 (P6) 1.0 
  21.6 (P7) 0.8 
  32.7 (P8) 1.3 
  22.9 (P9) 0.9 
*
Purification fold was determined by dividing the percentage of ACE inhibition from 
each purification step with the percentage of ACE inhibition from RPHPLC. 
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A. bisporus, respectively. The stable ACE inhibitory activity in spite of the reduction of 
concentration by 1000 fold showed proteins in the two mushroom species tested in the 
current study played a major role in ACE inhibition. This is in accordance with the 
report by Barbosa-Filho et al. (2006) that showed protein as the most reported 
compound showing active ACE inhibitory activity.  
The proteins were then fractionated by RPHPLC according to hydrophobicity and 
the concentration used to test their ACE inhibitory activity was reduced to 1 µg/ml. The 
most active RPHPLC fraction from P. cystidiosus and A. bisporus had inhibited 30.8% 
and 25.7% of ACE activity, respectively. Proteins in these RPHPLC fractions were then 
further fractionated based on their molecular size by SEC. The most active SEC fraction 
from P. cystidiosus inhibited 27.4% of the ACE activity at 1 µg/ml. Two SEC fractions 
from A. bisporus have exhibited the highest ACE inhibitory activity, i.e. 18.7% and 
16.1%. The RPHPLC and SEC fractions possessed bioactivities even at a reduced 10 
fold concentration than the concentration of protein extract indicated fractionation of 
proteins has reduced the complexity of protein mixture hence, the potential protein is 
able to better express its ACE inhibitory activity. The enhancement of ACE inhibitory 
activity by fractionation has been reported by Ning et al. (2008). Based on the 
purification fold, a slight reduction in the ACE inhibitory activity of the two SEC 
fractions compared to RPHPLC fraction in A. bisporus may indicate a possibility of 
synergistic activity among the proteins in RPHPLC fraction of A. bisporus,  Synergistic 
activity has been proposed for peptides in cheese, tilapia, pea and whey (Gomez-Ruiz et 
al., 2002; Raghavan & Kristinsson, 2009; Vermeirssen et al., 2005). Fractionation of 
RPHPLC fraction by SEC could have prevented the respective proteins from exhibiting 
their activity.      
Referring to Table 4.7, two peptides have been selected from P. cystidiosus whilst 
eight peptides were chosen from A. bisporus, The ACE inhibitory activity of the two 
 86 
 
peptides from P. cystidiosus have shown similar percentages of inhibition with their 
SEC fraction. Tripeptides from broccoli and buckwheat have also been reported to 
exhibit similar activity with their native proteins in HPLC fraction (Lee et al., 2006; Ma 
et al., 2006). Therefore, the similar ACE inhibitory activity of the P1 and P2 compared 
to SEC fraction in the current study showed that the two peptides may have major 
contribution to the ACE inhibitory activity in SEC fraction of P. cystidiosus. The eight 
peptides from A. bisporus have exhibited a range of percentages of ACE inhibitory 
activity, i.e. 15.0-32.7%. Based on the purification fold, some of the peptides exhibited 
better ACE inhibitory activity compared to their protein precursors in the SEC fractions. 
Increased ACE inhibitory peptides compared to their native proteins have been reported 
in studies from food sources, such as cuttlefish and fish (Balti et al., 2010; Ghassem et 
al., 2011).  
The stability of peptides in terms of their bioactivity after oral administration is of 
high concern in the protein pharmaceutical industry (Mahato et al., 2003). Therefore, 
the nine chemically synthesized peptides in the current study were further analyzed for 
their ACE inhibitory activity after gastrointestinal digestion. Preliminary experiment by 
gastrointestinal enzyme incubation in vitro provides an easy method to evaluate the fate 
of these peptides after oral administration.      
 
4.9 Effect of simulated gastrointestinal digestion on the selected peptides 
4.9.1 ACE inhibitory activity of peptides after gastrointestinal digestion  
Simulated gastrointestinal digestion of the nine synthetic peptides was carried out by in 
vitro assay. Studies have shown that most proteins were emptied from the stomach in 
two hours after ingestion (Chen et al., 1962; Gupta et al., 1958). Besides, at 40
o
C most 
proteins are completely digested by enzymes within a 2 to 3 hours period (Hill & 
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Schmidt, 1962). Prolong hydrolysis time has been reported to cause excessive digestion 
and consequently produced inactive peptides (Zhu et al., 2010). Peptides hydrolysed for 
2 to 3 hours exhibited the highest ACE inhibitory activity (Jiang et al., 2007; Kumar et 
al., 2013). Hence, the peptides in the current study were incubated in the digestive 
enzyme solutions for 2.5 h. There were studies that utilized the same length of 
incubation time used in the current study. This include studies on the purification of 
ACE inhibitory peptides from whey (Bamdad et al., 2009), cotton leafworm 
(Vercruysse et al., 2009) and insect cells (Staljanssens et al., 2011).   
Control consists of percentages of ACE inhibitory activity of the peptides 
incubated in buffer only, without digestive enzymes. Referring to the results obtained in 
Table 4.8, the peptides in control group exhibited variations in the percentages of ACE 
inhibitory activity. The lowest ACE inhibitory activity was exhibited by P6 at 24.5%. 
This was followed by P4 and P8, where 53.3% and 53.8% of ACE was inhibited, 
respectively. P1 and P5 had the highest ACE inhibitory activity. Both of the peptides 
had inhibited 80.3% of the ACE activity.  
A negative control was carried out alongside the experiment which consists of 
the ACE inhibitory activity of the buffer without peptide. The result obtained showed 
the buffer, which contains HCl and potassium phosphate buffer also exhibited a slight 
ACE inhibitory activity by blocking 31.5% of the ACE activity. According to Saboury 
and Moosavi-Movahedi (1995), the state of surrounding solvent such as pH, ionic 
strength, presence of hydrogen bond breaking solutes and amphiphilic compounds could 
disrupt the protein structure which lead to the loss of its biochemical activity. In the 
actual human body, the ACE enzymes work in physiological conditions which are 
optimum for the ACE enzyme. In the current study, ionic strength and pH of the buffers 
could have slightly affected the structure of the ACE and hence inhibit its activity. 
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Therefore, future work can be carried out by in vivo to test the actual ACE inhibitory 
activity of the peptides studied.  
 
Table 4.8: ACE inhibitory activity of the nine selected peptides and negative control 
after simulated gastrointestinal digestion.  
Peptide (P) 
ACE inhibitory activity (%) 
Control Pep Pep + T + C 
1 80.3 ± 7.7 
a
 95.4 ± 0.2 
a
 95.9 ± 0.3 
a
 
2 67.1 ± 4.5 
b
 92.2 ± 2.3 
ab
 96.1 ± 0.5 
a
 
3 70.0 ± 4.2 
b
 93.8 ± 0.8 
ab
 95.8 ± 0.3 
a
 
4 53.3 ± 6.7 
c
 90.9 ± 6.4 
b
 95.3 ± 0.5 
a
 
5 80.3 ± 4.3 
a
 94.3 ± 1.7 
ab
 95.9 ± 0.3 
a
 
6 24.5 ± 6.5 
d
 94.3 ± 1.7 
ab
 95.8 ± 0.3 
a
 
7 68.7 ± 1.4 
b
 92.9 ± 2.1 
ab
 95.2 ± 0.3 
a
 
8 53.8 ± 4.2 
c
 93.5 ± 1.4 
ab
 95.9 ± 0.9 
a
 
9 63.3 ± 8.0 
b
 93.2 ± 0.8 
ab
 91.5 ± 4.7 
b
 
Negative control  31.5 ± 0.1 
d
 63.9 ± 3.0 
c
 84.7 ± 2.0 
c
 
Control: Peptide incubated with buffer only; Pep: Peptide incubated with pepsin;  
Pep + T + C: Peptide incubated with pepsin for 2.5 hours followed by trypsin and 
chymotrypsin. 
Negative controls were carried out without the presence of peptide. 
ACE inhibitory activity was expressed as mean ± standard deviation (n=3). Means with 
different lower case alphabet letters within a column are significantly different (p<0.05). 
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Referring to Table 4.8, all the peptides except P6 have significantly higher ACE 
inhibitory activity than the negative control. This shows the bioactivity of peptides was 
not affected by the acidic and basic pH of buffer which could mimic the pH in the 
stomach and intestine. ACE inhibitory peptides which were pH stable have been 
isolated from protein red deer plasma, algae waste and oyster (Liu et al., 2010b; Sheih 
et al., 2009; Wang et al., 2008).        
 The effect of gastrointestinal digestion on the ACE inhibitory activity of the 
peptides was assessed by two experiments. Evaluation of the ACE inhibitory activity of 
peptides digested with pepsin mimics the bioactivity of these peptides when it reached 
the stomach whilst the ACE inhibitory activity of peptides digested with pepsin for 2.5 
hours followed by trypsin and chymotrypsin mimics the bioavailability of these peptides 
when it reached the intestine. As shown in Table 4.8, all the nine peptides had enhanced 
ACE inhibitory activity after digested by pepsin. The ACE inhibitory activity was 
further increased after digestion by trypsin and chymotrypsin. The ACE inhibitory 
activity of digestive enzymes without peptide was determined and served as negative 
control. The result obtained showed the negative controls also exhibited ACE inhibitory 
activity. Buffer containing pepsin but without peptide has inhibited 63.9% of ACE 
activity whilst buffer containing pepsin, trypsin and chymotrypsin but without peptide 
inhibited 84.7% of ACE activity. As mentioned in the previous paragraph, the buffer 
condition could have affected the molecular structure of some ACE that lead to the loss 
of its bioactivity. Additionally, the pH and ionic strength of the buffers could also cause 
some of the digestive enzymes, i.e. pepsin, trypsin and chymotrypsin to breakdown and 
release amino acid fragments which could have ACE inhibition activity. Currently, 
there were no studies reported on the possible ACE inhibition effect of the digestive 
enzymes. However, based on the report by Tang et al. (1973), the amino acid sequence 
for one of the digestive enzymes, i.e. pepsin contain high amount of hydrophobic amino 
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acid, which could have ACE inhibitory activity. Referring to Table 4.8, even though the 
negative controls also exert ACE inhibitory activity, the percentages exhibited by the 
negative controls were still statistically lower than the percentages obtained by all the 
nine peptides. This may indicate the peptides could still retain their biological activity 
after gastrointestinal digestion. Future work could be done by in vivo study to prove the 
actual ACE inhibitory activity of the peptides after gastrointestinal digestion.  
There were studies reported on the production of pro-drug type ACE inhibitory 
peptides. These peptides are converted to true inhibitors by ACE or gastrointestinal 
proteases and claimed to have long lasting antihypertensive activity after oral 
administration (Fujita et al., 2000; Zhao et al., 2009). Pro-drug type ACE inhibitory 
peptide, LKPNM from fish protein which has been commercialized as supplement was 
reported to exhibit higher ACE inhibitory activity after oral administration. It was 
suggested to be due to the hydrolysis of LKPNM to produce LKP, which has eight-fold 
higher ACE inhibitory activity than LKPNM (Fujita & Yoshikawa, 1999). Likewise, 
ACE inhibitory activity of peptides isolated from fermented milk and sea cucumber has 
intensified inhibitory activity after incubation with gastrointestinal proteases 
(Hernández-Ledesma et al., 2004; Zhao et al., 2009). Terashima and co-workers (2011) 
have reported on the improved ACE inhibitory activity of the peptide derived from 
chicken meat by shortening the peptide length from 10 amino acids to two amino acids. 
Therefore, it is possible to suggest that the nine peptides tested in the current study 
could be further hydrolysed by gastrointestinal proteases to produce di- or tripeptides 
with higher ACE inhibitory activity. Hence, the nine peptides were further analyzed for 
the possible released of fragments during gastrointestinal digestion. 
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4.9.2 Bioinformatic-aided prediction of peptide released during 
gastrointestinal digestion 
There are a number of online programs in peptide science designed to provide 
information such as physicochemical properties of amino acid residues, predictions of 
the peptide structure and proteolytic cleavage sites (Minkiewicz et al., 2008; 
Minkiewicz et al., 2009). BIOPEP database (www.uwm.edu.pl/biochemia) is one of the 
online programs that can serve as a tool to predict the possible proteolysis products 
from a protein or peptide sequence and define the possible biological activity of the 
proteolysis fragments (Iwaniak & Dziuba, 2011). All the nine peptide sequences had 
been analysed by BIOPEP. The predicted fragments released during pepsin and pepsin-
pancreatin digestion were shown in the panel C and D of Figures 4.8-4.16. Referring to 
the result obtained, all the peptides tested, except P4 and P5, were predicted to be stable 
in the stomach before they reach the small intestine.  
The stability of the peptides after simulated gastrointestinal digestion was 
analyzed by injecting the samples into SEC column. The chromatograms obtained were 
illustrated in Figures 4.8-4.16. The chromatograms of negative controls which consist of 
buffers only without gastrointestinal enzymes and peptide were shown in Appendix G (I) 
and G (II). There were two buffer peaks observed in each solution. Peaks at retention 
time of 9.49 and 11.45 min were observed in HCl whilst peaks at retention time of 9.77 
and 11.31 min were observed in potassium phosphate buffer. These may explain the 
extra two peaks obtained in all the chromatograms in panel B of Figures 4.8-4.16, which 
consist of peptide incubated with buffer only. 
The second negative control consists of buffer solutions with gastrointestinal 
enzymes but void of peptide solution. The chromatograms obtained were illustrated in 
Appendix G (III) and G (IV). It is important to note that some of the peptides in the 
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current study have peaks eluted at similar retention time with the gastrointestinal 
enzymes. As shown in Figures 4.8A (page 93) and 4.10A (page 96), peptides P1 and P3 
were eluted at 7.80 min. Based on the chromatograms in Appendix G (III) and G (IV), 
the pepsin and pepsin-pancreatin enzymes also have a peak at 7.80 min with peak height 
16 and 22, respectively. The negative controls were injected into the SEC column at 5-
fold lower concentration than the in vitro peptide digestion assay. Therefore, the pepsin 
and pepsin-pancreatin enzyme peak could be eluted at a height of approximately 80 and 
110, respectively in the chromatograms in panel C and D of Figures 4.8 and 4.10. On 
the other hand, peptides P2 (page 95), P5 (page 100), P6 (page 101), P7 (page 102) and 
P9 (page 105) were eluted at 8.30 min. Based on the SEC chromatograms in Appendix 
G (III) and G (IV), peak height of pepsin and pepsin-pancreatin enzyme at 8.30 min 
were 15 and 43, respectively. As mentioned previously, the pepsin and pepsin-
pancreatin enzymes were injected at 5-fold lower concentration than the peptide 
digestion assay. Therefore, these gastrointestinal enzymes could have a peak height of 
approximately 75 and 215, respectively in the chromatograms in panel C and D of 
Figures 4.9, 4.12, 4.13, 4.14 and 4.16. 
Referring to Table 4.8 (page 88), P1 incubated in buffer without digestive 
enzymes exhibited a high percentage of ACE inhibitory activity, i.e. 80.3%. According 
to Wang et al. (2011b), the preferential parameters for hexapeptides with potent ACE 
inhibitory activity are hydrophobic and stereo properties. In addition, hydrophobic ACE 
inhibitor has been reported to show higher efficiency than hydrophilic ACE inhibitor 
(He et al., 2012; Moskowitz & Johnson, 2004; Sun et al., 2011). Based on the amino 
acid sequence, P1 has high amount of hydrophobic amino acid. This may explain the 
high ACE inhibitory activity of P1. According to the BIOPEP analysis, P1 was not 
hydrolysed by the three digestive enzymes. It remained stable throughout the digestion 
process. As shown in Figure 4.8C and D, the peptide peak at 7.80 min has a peak height  
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Area 4216 
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7.80 
Height 321 
(Enzyme height = 80) 
 
Area 13284 
*
Fragment: AHEPVK 
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7.80 
Height 325 
(Enzyme height = 110) 
 
Area 9179 
*
Fragment: AHEPVK 
Figure 4.8: SEC chromatograms of P1 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion.  
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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of 321 and 325, respectively. Deduction of peak height for digestive enzymes, pepsin 
and pepsin-pancreatin enzyme, i.e. 80 and 110, respectively shows the peptide peak 
were retained at approximately the same height with the peptide incubated in buffer 
only (Figure 4.8B). This may verify the result in BIOPEP analysis that AHEPVK was 
not digested by the digestive enzymes. 
According to BIOPEP analysis, P2 has been predicted to remain stable after 
pepsin digestion. However, referring to Figure 4.9C, the peptide peak at 8.33 min has a 
height lower than the peak of enzyme pepsin, i.e. 75. This suggests that P2 could have 
been hydrolyzed in the simulated pepsin digestion. Referring to Table 4.8 (page 88), P2 
still managed to exhibit ACE inhibitory activity after pepsin digestion. Future work 
could be carried out by in vivo study to prove the actual ACE inhibitory activity of P2 
after gastrointestinal digestion. Besides, 3D structural docking assay could be carried 
out to reveal the clear mechanism of ACE inhibition by P2. BIOPEP analysis revealed 
P2 would be hydrolyzed by pepsin-pancreatin enzymes to release dipeptide sequences, 
GP and SM from its precursor. GP has been previously reported to exhibit ACE 
inhibitory activity with IC50 value of 252.6 µM (Byun & Kim, 2002). There were no 
previous reports on the ACE inhibitory activity of SM. However, dipeptide ACE 
inhibitors with serine at the N-terminus have been isolated from garlic. These dipeptides, 
namely SY and SF have inhibited 50% of ACE activity at concentrations of 66.3 and 
130.2 µM, respectively (Suetsuna, 1998). Based on the peak height detected at 8.33 min 
in Figure 4.9D, i.e. 214 it could be the peak of enzyme pepsin-pancreatin. The detection 
of only the enzyme peak may confirm the hydrolysis of P2 to release the potent ACE 
inhibitors, GP and SM. 
BIOPEP analysis shows P3 would remain stable during pepsin digestion. 
Referring to Figure 4.10C, the peak eluted at 7.79 min has higher height than the 
enzyme peak. It may contain the unhydrolyzed P3. The peptide was predicted to release 
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Figure 4.9: SEC chromatograms of P2 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion.  
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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Figure 4.10: SEC chromatograms of P3 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion. 
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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VAGP from its precursor after digested by pepsin-pancreatin enzymes. The tetrapeptide 
released contain strong hydrophobic aliphatic amino acid, valine at the N-terminus and 
imino acid, proline at the C-terminus. This is in accordance with the requirement of 
peptides with strong ACE inhibitory activity (Cheung et al., 1980; Guang & Phillips, 
2012). Furthermore, a tetrapeptide with similar peptide sequence, i.e. VYAP has been 
isolated from cuttlefish. It was reported to exhibit IC50 value of 6.1 µM (Balti et al., 
2010). Tripeptide, VKP containing amino acid valine and proline at the N-and C-
termini has also exhibited high ACE inhibitory activity with IC50 value of 3.7 µM (Tsai 
et al., 2006). In Figure 4.10D, the peak eluted at 7.80 min has a height of 172, which is 
slightly higher than the enzyme peak, 110. In SEC, protein or peptides are separated 
according to size (Stanton, 2004). The release of lysine from the N- and C-termini of P3 
may not have much effect on its molecular weight. Therefore, VAGP could have been 
eluted at the similar retention time as KVAGPK at 7.80 min.   
BIOPEP analysis of P4 shows dipeptides, AL and PC would be released from the 
precursor after pepsin digestion. Only the dipeptide AL remained after pepsin-
pancreatin digestion. Currently, there were no reported studies on the ACE inhibitory 
activity of dipeptide AL. Based on the amino acid sequence, the dipeptide consists of 
hydrophobic amino acids, alanine and leucine. The release of this hydrophobic peptide 
may have contributed to the higher ACE inhibitory activity of P4 after digestion 
(Vermeirssen et al., 2005). Referring to the SEC chromatogram in Figure 4.11A, the 
peptide was eluted at a retention time of approximately 9.41 min. As illustrated in 
Appendix G (I) and G (II), HCl and potassium phosphate buffer have a peak at 9.49 and 
9.77 min, respectively. Therefore, the peak eluted at approximately 9.61 min in Figure 
4.11B could consist of buffers peak together with peptide P4. The combination of buffer 
and peptide peaks makes it difficult to observe the stability of the peptide by SEC. 
Theoretically, smaller peptides would be eluted from the SEC column at a later time   
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Figure 4.11: SEC chromatograms of P4 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion. 
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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(Stanton, 2004). The peak eluted at 10 to 11 min in Figure 4.11D was higher compared 
to the chromatograms obtained by other peptides after pepsin-pancreatin digestion. 
Therefore, this may confirm the hydrolysis of P4 to smaller fragments by 
gastrointestinal enzymes. 
Based on the result in Table 4.8 (page 88), P5 has exhibited the same high 
percentage of ACE inhibitory activity as P1 when incubated in buffer without digestive 
enzymes. However, unlike P1 which is stable throughout the digestion process, P5 was 
predicted to be further hydrolyzed in the digestive tract. It would release tetrapeptide, 
RIGL after pepsin digestion and further hydrolyzed to release tripeptide, IGL by 
pancreatin enzymes (Figure 4.12). Although there were no previous reports on the ACE 
inhibitory activity of IGL, its amino acid sequence fit the criteria of a potent ACE 
inhibitor. It has branched aliphatic amino acid, isoleucine at the N-terminus and strong 
hydrophobic amino acid, leucine at the C-terminus (Wu et al., 2006a). In addition, 
glycine has been reported as the most favourable amino acid in potent ACE inhibitor of 
tripeptides (Wang et al., 2011b). According to the SEC chromatograms of P5 in Figure 
4.12, peptide digested with pepsin and pepsin-pancreatin enzymes has eluted the peptide 
peak with approximately the same height with enzyme. This shows peak P5 has 
disappeared after digestion which may indicate the peptide has undergone further 
hydrolysis as predicted by the BIOPEP analysis.  
Peptides P6 and P7 were predicted to remain stable during pepsin digestion. 
However, they were predicted to release dipeptide sequences, GE and AP, respectively 
after pepsin-pancreatin digestion. These dipeptide sequences has been reported to block 
50% of the ACE activity at a concentration of 5.4 and 230 µM, respectively (Cheung et 
al., 1980). Besides dipeptide AP, P7 was also predicted to release tripeptide, SAK after 
pepsin-pancreatin digestion. The SEC chromatograms in Figure 4.13C and 4.14C 
showed peak eluted at 8.30 min have a height of 124 and 167, respectively. They were  
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Figure 4.12: SEC chromatograms of P5 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion.  
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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Figure 4.13: SEC chromatograms of P6 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion.  
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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Figure 4.14: SEC chromatograms of P7 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion.  
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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higher than the estimated enzyme peak, i.e. 75. This may suggest the peptides were still 
available and not hydrolyzed after incubation with the enzyme pepsin. In Figures 4.13D 
and 4.14D, the peaks were eluted at almost the same peak height with the digestive 
enzyme, i.e. 215, which indicate the peptides were not detected in the SEC 
chromatograms. Therefore, this may confirm the hydrolysis of the peptides by pepsin-
pancreatin enzymes as predicted by the BIOPEP analysis. 
Peptide P8 was predicted to remain stable after pepsin digestion. It will release 
dipeptide, GP and tripeptide, GVQ after pepsin-pancreatin digestion. Dipeptide, GP has 
been previously reported as potent ACE inhibitor with IC50 value of 252.6 µM (Byun & 
Kim, 2002). Based on the SEC chromatogram of peptide P8 in Figure 4.15A, the 
peptide was eluted at a retention time of approximately 9.38 min. As illustrated in 
Appendix G (I) and G (II), HCl and potassium phosphate buffer have a peak at 9.49 and 
9.77 min, respectively. Therefore, the peak eluted at approximately 9.89 min in Figure 
4.15B could consist of buffers peak together with peptide P8. The combination of buffer 
and peptide peaks makes it difficult to observe the stability of the peptide by SEC. 
Theoretically, smaller peptides would be eluted from the SEC column at a later time 
(Stanton, 2004). The higher peak eluted at 10 to 11 min in Figure 4.15D compared to 
the chromatograms obtained by other peptides after pepsin-pancreatin digestion may 
confirm the hydrolysis of P8 to smaller fragments by gastrointestinal enzymes. 
According to the BIOPEP analysis, P9 was expected to remain stable during 
pepsin digestion. It will release tetrapeptide, SSNK from its precursor after being 
digested by pepsin-pancreatin enzymes. It has been claimed that the most preferential 
characteristic of tetrapeptides with ACE inhibitory activity are stereo and electrical 
amino acid such as lysine (Wang et al., 2011b). Peptides with amino acid serine at the 
N-terminal have been isolated from garlic. These dipeptides, namely SY and SF have  
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Figure 4.15: SEC chromatograms of P8 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion. 
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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Figure 4.16: SEC chromatograms of P9 with retention time (min), peak height (mAU), 
peak area (mAU) and predicted fragments released after digestion. 
(A) Pure peptide (B) Peptide incubated with buffer only, (C) Peptide incubated with 
pepsin and (D) Peptide incubated with pepsin followed by trypsin and chymotrypsin. 
*
Prediction of proteolytic fragment released was carried out based on the BIOPEP 
database (www.uwm.edu.pl/biochemia). 
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exhibited potent ACE inhibitory activity with IC50 values 66.3 and 130.2 µM, 
respectively (Suetsuna, 1998). Therefore, the SSNK which contain serine and lysine at 
its N- and C-termini, respectively may warrant further analysis of this peptide as 
potential ACE inhibitor. Referring to Figure 4.16C, the peak eluted at 8.29 min has a 
higher height than the enzyme peak. It may contain the unhydrolyzed P9. In Figure 
4.16D, the peak eluted at 8.32 min has a height of 253, which is slightly higher than the 
enzyme peak. The release of imino acid, proline from P9 after pepsin-pancreatin 
digestion might not have much effect on its molecular weight. SEC separates protein or 
peptide based on molecular weight (Stanton, 2004). Therefore, SSNK could have been 
eluted at almost the same retention time as PSSNK at 8.3 min.  
 The bioavailability of ACE inhibitory peptides after administration is of high 
concern. The peptides have to reach the blood stream in an active form in order to act as 
ACE inhibitors. Injection has been recognised as an effective way of delivering peptide 
drugs to the body (Brown, 2005). However, patient compliance with drug 
administration regimens by this parenteral route is generally poor due to the pain and 
discomfort associated with injections. Besides, patients may encounter possible 
infections caused by inappropriate use or reuse of needles. Hence, oral route remains the 
most acceptable way of delivering drugs (Shaji & Patole, 2008). 
Several studies have been carried out to investigate the pharmacokinetic 
behaviour of ACE inhibitory peptides. Oral administration of tripeptides IPP and VPP 
have exerted bioavailability of approximately 0.1% in pigs (Pijl et al., 2008). In humans, 
picomolar concentration was detected in plasma following consumption of yoghurt 
enriched with these two tripeptides (Foltz et al., 2007). Furthermore, ACE inhibitory 
peptide from sardine hydrolysate which has been commercialized by the product name 
Valtyron
®
 is claimed to demonstrate efficient blood pressure control by daily intake of 
as low as 0.6 g/serving. There are 31 peptide sequences identified in this product. 
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Among the peptides, dipeptide VY has been determined as the main ACE inhibitor. A 
single dose of 0.6 g of the sardine peptide product contains 0.6-0.96 mg VY (EFSA 
Panel on Dietetic Products Nutrition and Allergies, 2010b). An absolute bioavailability 
of 0.014% was detected in plasma after oral administration of 12 mg of VY (EFSA 
Panel on Dietetic Products Nutrition and Allergies, 2010b). According to Matsui et al. 
(2004), ACE inhibitory peptides preferably to accumulate in organs, such as liver, 
kidneys, heart and lungs rather than in the plasma. This is in accordance with the report 
by Miguel et al. (2007), in which the ACE activity in lung, kidney and aorta is greatly 
inhibited compared to plasma ACE in SHR after treatment with egg white hydrolysate. 
This may suggest that these organs could be a target site associated with the 
antihypertensive action of ACE inhibitory peptides. In addition to ACE inhibitory 
activity, some studies have demonstrated the existence of peptides that exert their blood 
pressure lowering effects through vascular relaxation (Sipola et al., 2002). Based on the 
in vivo studies, these peptides exhibited their antihypertensive action either by direct or 
indirect action on vascular smooth muscle (Kouno et al., 2005; Maes et al., 2004). 
According to Foltz et al. (2007), the oral bioavailability of peptides increases 
with decreasing chain length. Peptides less than 5 amino acids in length have shown 
higher oral bioavailability (Craik, 2006). Several studies have demonstrated significant 
decrease in systolic blood pressure by oral administration of peptides with five to six 
amino acids in length. After oral administration of pentapeptide WVPSV and VVYPW 
at a dose of 10 mg/kg, the systolic blood pressure of spontaneously hypertensive rats 
(SHR) decreased by 22.5 and 9.6 mmHg, respectively (Ren et al., 2011). In another 
study, hexapeptide IPPVPP and VPPIPP lowered the systolic blood pressure by 21 and 
17.4 mmHg, respectively in SHR at a dose of 1.5 mg/kg (Ding et al., 2013). This may 
suggest that the nine peptides in the current study which consisted of five to six amino 
acids in length could have high oral bioavailability as an antihypertensive drug. 
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The main challenge of drug delivery through oral administration has been 
associated with membrane permeability of the peptides in the gastrointestinal tract 
(Shaji & Patole, 2008). The intestinal epithelium selectively controls the entry of 
nutrients and drugs to the systemic circulation. Therefore, it is important to understand 
the mechanism of absorption of substances at the intestinal membrane for designing 
peptides with improve delivery across the barrier and subsequently increase its 
bioavailability to reach the target site. Possible routes of drug transport across the 
membrane include passive diffusion, facilitated transport and carrier-mediated transport 
system (Mahato et al., 2003). Some researchers have carried out investigations to 
predict the intestinal permeability of peptides in the digestive system which involve 
either in silico, in vitro, in situ, ex vivo or in vivo method (Antunes et al., 2013). 
According to Webb (1990), small peptides, mostly di- and tri-peptides have better 
permeability through the intestinal membrane. This is in accordance with the report by 
Mahato et al. (2003) which shows transporters in the membrane are designed to 
transport 2 to 3 amino acid peptides into the cells. Tetrapeptides would be hydrolyzed 
primarily by the membrane peptidases prior to absorption. This may presume that the 
peptides in the current study which have been predicted to undergo further hydrolysis in 
the digestive system to release fragments of 2 to 4 amino acids in length may have 
better absorbability across the intestinal membrane and thereby have high probability to 
reach its target site.    
In the current study, eight peptides were predicted to undergo further hydrolysis 
and released fragments consisting of 2 to 4 amino acids which fit the structural 
requirement of potential ACE inhibitor. Peptide P1 was predicted to remain stable 
throughout the digestion process. BIOPEP database only served as a tool to predict the 
possible proteolysis products from the precursor. Future work can be carried out by in 
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vivo study to prove the actual ACE inhibitory activity of the peptides after 
administration and to investigate the bioavailability of the peptides after digestion. 
 
4.10 Determination of ACE inhibition pattern 
ACE inhibition pattern explains how the peptide binds to ACE and inhibit its activity. 
Based on the IC50 values, three synthetic peptides, namely P1, P5 and P9 which have 
the most potent ACE inhibitory activity were selected to determine their inhibition 
pattern against the ACE. According to the Lineweaver-Burk plot in Figures 4.17A and 
4.17B, P1 and P5 showed competitive inhibition pattern against the ACE. This indicates 
that P1 and P5 bind to the active site of ACE to block it from binding to the substrate. 
ACE has been reported to prefer peptide with competitive inhibition pattern (Chel-
Guerrero et al., 2012; Hong et al., 2008). Besides, ACE has higher affinity to bind with 
peptides containing hydrophobic amino acid especially with aromatic side chain at the 
three positions of the C-terminal (Li et al., 2004). Referring to the amino acid sequence 
of P1 and P5 at Table 4.6 (page 79), the three positions of the C-terminal consist of 
hydrophobic amino acids. Therefore, this may explain the competitive inhibition pattern 
exhibited by these peptides. 
The inhibition pattern exhibited by P1 and P5 are similar with the ACE inhibitory 
peptides purified from edible mushrooms, G. frondosa, P. adiposa, T. giganteum and 
peptide F2-1A of P. cornucopiae (Choi et al., 2001; Jang et al., 2011; Koo et al., 2006; 
Lee et al., 2004). Besides edible mushrooms, there were reports on competitive ACE 
inhibitors from food-derived peptides, such as milk, oyster sauce, cheese and freshwater 
clam (Gobbetti et al., 2000; Je et al., 2005; Ruiz et al., 2004; Tsai et al., 2006). In 
addition, the first orally administered ACE inhibitory antihypertensive drug, captopril 
also inhibited the ACE in a competitive pattern (Bhuyan & Mugesh, 2011). Therefore, 
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these shows P1 and P5 are potential ACE inhibitors which can be developed as 
nutraceuticals. 
Referring to Figure 4.17C, P9 exhibited noncompetitive inhibition pattern against 
the ACE enzyme. This shows that P9 tends to bind together with the substrate to the 
enzyme at any given time. The enzyme-substrate-inhibitor complex formed cannot 
produce product and can only be converted back to the enzyme-substrate complex or 
enzyme-inhibitor complex (Jao et al., 2012). Noncompetitive inhibition pattern has been 
reported in ACE inhibitory peptide derived from edible mushroom, P. cornucopiae 
(Jang et al., 2011). This inhibition mechanism is also observed in food proteins such as 
fermented soybean (Kuba et al., 2003), oyster (Shiozaki et al., 2010; Wang et al., 2008) 
and egg (Memarpoor-Yazdi et al., 2012). 
Structure-activity relationship studies on ACE inhibitory peptides revealed 
positively charged C-terminal, such as arginine and lysine have low affinity with the 
ACE active site (Li et al., 2004). However, these peptides have exhibited potential ACE 
inhibiting activity. Examples of ACE inhibitory peptides with positive charge amino 
acid at their C-terminus include AKK from sardine muscle (Matsufuji et al., 1994) and 
MKR from hen egg white lysozyme (Rao et al., 2012). These peptides were suggested 
to inhibit the ACE by binding to allosteric site that is different from the catalytic site of 
the enzyme (Li et al., 2004). Interestingly, P9 contains a positively charged amino acid, 
lysine at its C-teminus that may explain its noncompetitive inhibition pattern against the 
ACE.   
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Figure 4.17: Lineweaver-Burk plot of ACE inhibitory activity of (A) P1, (B) P5 and    
(C) P9. 
ACE inhibitory activity was determined in the presence (0.05 mg/ml and 0.5 mg/ml) or 
absence of peptide (control). 
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5.0 CONCLUSION 
Edible mushrooms are rich in protein and are potential source of bioactive peptides. 
Compared to previously reported edible mushrooms, the higher inhibition of ACE 
activity by water extracts of nine mushroom species tested in the current study viz. A. 
bisporus, F. velutipes, H. erinaceus, L. edodes, P. citrinopileatus, P. cystidiosus, P. 
flabellatus, P. florida and P. pulmonarius revealed cold water extraction is suitable to 
extract ACE inhibitors. Most of the mushrooms studied have the highest concentration 
of protein precipitated by ammonium sulphate at S50 to S70 indicating that the 
mushrooms contain high amounts of amphipathic proteins. These mushrooms could be 
a good source of ACE inhibitory peptides as previous studies have reported proteins 
containing approximately 50% hydrophobic amino acid as good ACE inhibitors. 
For each mushroom species, the protein fractions were pooled according to the 
similarity of protein bands observed by SDS-PAGE. The ACE inhibitory activity of the 
pooled protein extracts were tested at a concentration of 10 µg/ml. The highest ACE 
inhibitory activity was exhibited by E1Pc and E5Pc from P. cystidiosus, inhibiting 96.2% 
and 86.7% of ACE activity, respectively. This was followed by E1Ab and E3Ab from A. 
bisporus that inhibits 78.4% and 71.4% of ACE activity, respectively. Protein extracts 
from the other mushroom species that exhibited lower ACE inhibitory activity may 
indicate synergistic effect among the proteins or peptides. 
Fractionation based on hydrophobicity by RPHPLC of these four protein 
extracts (E1Pc, E5Pc, E1Ab and E3Ab) yielded six peaks each (F1-F6). Percentages of 
proteins recovered from E1Pc and E5Pc fractions ranged from 6.16-21.78% and 4.95-
17.48%, respectively while fractions from E1Ab and E3Ab ranged from 6.69-19.14% 
and 5.35-17.18%, respectively. The ACE inhibitory activity of the RPHPLC fractions 
was tested at a concentration of 1 µg/ml. The highest ACE inhibitory activity was 
exhibited by E5PcF3 with 30.8% of ACE inhibited. Among the RPHPLC fractions of A. 
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bisporus, the highest ACE inhibitory activity was exhibited by E3AbF6 with 25.7% of 
ACE inhibited. Proteomic analysis of these two RPHPLC fractions revealed the 
majority of proteins present in E5PcF3 and E3AbF6 were of low molecular weight, i.e. 
with molecular masses less than 30 kDa. The detection of SELDI peaks with high 
intensity at m/z ranging from 3-10 kDa shows this range of proteins could be the 
potential anti-ACE agent which has played a role in the higher ACE inhibitory activity 
exhibited in E5PcF3 and E3AbF6.  
E5PcF3 and E3AbF6 were further fractionated by SEC column according to 
molecular size to further reduce the complexity of proteins and seven peaks were 
collected each (C1-C7). The total percentages of proteins recovered in E5PcF3 and 
E3AbF6 were 83.4% and 21.0%, respectively. The ACE inhibitory activity of the SEC 
fractions was tested at a concentration of 1 µg/ml. In E5PcF3, the highest ACE 
inhibitory activity was exhibited by fraction C1 with 27.4% of ACE inhibition. In 
E3AbF6, the most potent ACE inhibitory activity was exhibited by fractions C1 and C4 
with 18.7% and 16.1% of ACE inhibited, respectively. Based on the position of the 
three peaks in the SEC chromatogram, the molecular masses of peaks C1 and C4 were 
estimated to be lower than 20 and 10 kDa, respectively. These three SEC fractions have 
been further analyzed by LC/MS/MS. 
Nine potential ACE inhibitors, AHEPVK, GPSMR, KVAGPK, FALPC, RIGLF, 
EGEPR, APSAK, GVQGPM and PSSNK were selected from the peptide list of 
LC/MS/MS analysis. Selection were based on the structural requirement of potential 
ACE inhibitory peptides, i.e. less than six amino acids and consists of hydrophobic and 
branched aliphatic amino acid at the C- and N-termini, respectively. These nine peptides 
were chemically synthesized and their ACE inhibitory activity was determined by IC50 
values. The result obtained showed the IC50 values varied from 62.8-736.7 µM with the 
three most potent ACE inhibitory activity exhibited by P1 (AHEPVK), P5 (RIGLF) and 
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P9 (PSSNK). Although the IC50 value of these three most potent peptides were higher 
compared to some previously reported ACE inhibitory peptides from other food sources, 
these three peptides have better activity compared to previously reported edible 
mushrooms, G. frondosa, P. adiposa and P. cornucopiae. 
 The effect of gastrointestinal digestion on the ACE inhibitory activity of the 
nine synthetic peptides was determined by in vitro study. The result obtained showed 
the nine peptides were pH stable and they were able to maintain their ACE inhibitory 
activity even after gastrointestinal digestion. BIOPEP analysis of the nine peptides 
showed they could be broken down by digestive enzymes to 2-4 amino acids in length 
which could exhibit better ACE inhibitory activity. This may suggest the peptides may 
have increased ACE inhibitory activity after oral administration. Future work could be 
done by in vivo study to reveal the clear mechanism of ACE inhibition by the peptides. 
Based on the IC50 values, three most active peptides were selected for the 
determination of ACE inhibition pattern. P1 (AHEPVK) and P5 (RIGLF) have 
exhibited competitive inhibition pattern whereas P9 (PSSNK) showed noncompetitive 
inhibition pattern. The inhibition pattern exhibited by P1 and P5 was similar with the 
ACE inhibitory peptides purified from edible mushrooms, G. frondosa, P. adiposa, T. 
giganteum and peptide F2-1A of P. cornucopiae. Noncompetitive inhibition pattern has 
been reported in ACE inhibitory peptide derived from peptide F2-1B of P. cornucopiae. 
In conclusion, the nine peptides tested in the current study, in particular P1, P5 
and P9 could be potential ACE inhibitors. Although captopril and some previously 
reported food derived peptides have stronger ACE inhibition activity than the peptides 
in the current study, the nine peptides were derived from mushrooms which could be 
easily obtained and have very low probability of causing food allergy. These peptides 
could be applied as ingredient in functional foods, dietary supplements or 
pharmaceuticals as an antihypertensive agent. 
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APPENDICES 
Appendix A: Protocols for solutions 
 
I. Solutions for SDS-PAGE 
Solution A: 30% acrylamide: bisacrylamide solution (30.8% T: 2.7% bis) 
Acrylamide 30.0 g 
N, N’-methylenebisacrylamide   0.8 g 
The solution was made up to 100 ml by the addition of distilled water and deionised by 
stirring for 1 hour or overnight with a small quantity of Amberlite IRN-150L. The 
solution was filtered and stored in a dark bottle at 4
o
C. It can be kept for less than 3 
months. 
 
Solution B: 4X running gel buffer (1.5 M Tris-HCl, pH 8.8) 
Tris base 18.17 g 
The Tris base was dissolved with distilled water. After adjusting the pH to 8.8 using 
concentrated HCl, the solution was made up to 100 ml with distilled water. It was kept 
at 4
o
C. 
 
Solution C: 10% (w/v) SDS  
SDS 10.0 g 
The SDS was dissolved with 100 ml of distilled water. The solution can be kept at room 
temperature. 
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Solution D: Stacking gel buffer (0.5 M Tris-HCl, pH 6.8) 
Tris base 6.06 g 
The Tris base was dissolved with distilled water. After adjusting the pH to 6.8 using 
concentrated HCl, the solution was made up to 100 ml with distilled water. It was kept 
at 4
o
C. 
 
10% (w/v) ammonium persulphate (APS) 
APS 0.05 g 
The APS was dissolved in 0.5 ml of distilled water. The solution was prepared fresh 
prior to gel casting. 
 
Volume of solutions required for the preparation of 16% separating gel and 4% 
stacking gel. 
Solutions 
16% Separating gel 
Volume (ml) 
4% Stacking gel 
Volume (ml) 
A 10.68 0.65 
B 5.00 - 
C 0.20 0.05 
D - 1.25 
dH2O 4.02 3.05 
10% APS 0.10   0.025 
TEMED      0.0066   0.005 
The volume of solutions stated above was for the preparation of two gels.  
10% APS and TEMED were added immediately to the solutions prior to casting.   
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Tank buffer : 25 mM Tris, 198 mM glycine, 0.1% (w/v) SDS, pH 8.3 
Tris base  3.03 g 
Glycine  14.4 g 
SDS   1.0 
The solution was made up to 1 L with distilled water and stored at room temperature. 
 
SDS-PAGE sample buffer: 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol, 2% 
(w/v) SDS, 1% (w/v) DTT, 62.5 mM Tris-HCl, pH 6.8 
Bromophenol blue 0.02 g 
Glycerol 2.0 ml 
SDS 0.4 g 
Dithiothreitol (DTT) 0.2 g 
Solution D 2.5 ml 
The solution was made up to 20 ml with distilled water and kept at -20
o
C in aliquots. 
 
II. Solutions for silver staining 
Fixing solution: 40% (v/v) ethanol, 10% acetic acid 
Ethanol 40.0 ml 
Acetic acid glacial 10.0 ml 
The solution was made up to 100 ml with distilled water 
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Sensitizing solution: 30% (v/v) ethanol, 0.13% (v/v) glutaryldehyde, 0.5 M sodium 
acetate, 8 mM sodium thiosulphate 
Ethanol  30.0 ml 
50% (w/v) glutaryldehyde    0.5 ml 
Sodium acetate trihydrate    6.8 g 
Sodium thiosulphate    0.2 g 
The solution was made up to 100 ml with distilled water. Glutaryldehyde was added 
into the solution immediately before use. 
 
Silver solution: 0.25% (w/v) silver nitrate, 0.5% (v/v) formaldehyde 
Silver nitrate  0.25 g 
37% (v/v) formaldehyde  0.50 ml 
The solution was made up to 100 ml with distilled water. Formaldehyde was added 
immediately into the solution before use. 
 
Developing solution: 0.24 M sodium carbonate, 0.04% (v/v) formaldehyde 
Sodium carbonate   2.5 g 
37% (v/v) formaldehyde  40.0 µl 
5% (w/v) sodium thiosulphate    2.8 µl 
The solution was made up to 100 ml with distilled water. Formaldehyde was added 
immediately into the solution before use. 
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Stopping solution: 40 mM ethylenediaminetetraacetic acid 
Ethylenediaminetetraacetic acid   1.46 g 
The solution was made up to 100 ml with distilled water. 
 
Preserving solution: 30% (v/v) ethanol, 4% (v/v) glycerol 
Ethanol   30.0 ml 
87% (v/v) glycerol     4.6 ml 
The solution was made up to 100 ml with distilled water. 
 
III. Solutions for simulated gastrointestinal digestion test 
HCl: (0.1 M, pH 2.0) 
HCl  8.17 ml 
The HCl was dissolved in 500 ml of distilled water. After adjusting the pH to 2.0, the 
solution was made up to 1L by the addition of distilled water. 
 
Potassium phosphate buffer: (0.1 M, pH 8.0) 
Potassium phosphate monobasic   0.52 g 
Potassium phosphate dibasic  16.73 g 
Potassium phosphate monobasic and potassium phosphate dibasic were dissolved in 
distilled water. After adjusting the pH to 8.0, the solution was made up to 1L. 
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Appendix B: SDS-PAGE for pooling 
 
 
 
I. SDS-PAGE analysis of protein fractions from Agaricus bisporus 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into five groups.  
 
 
 
 
II. SDS-PAGE analysis of protein fractions from Flammulina velutipes 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into six groups. 
     10   20  30   40  50  60   70  80  90 100    M 
         1        2     3        4                   5 
           1           2        3        4     5        6 
       10   20   30  40   50   60   70  80   90 100  M 
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III. SDS-PAGE analysis of protein fractions from Hericium erinaceus 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into four groups. 
 
 
 
 
IV. SDS-PAGE analysis of protein fractions from Lentinula edodes precipitated 
at ten percentages of salt saturation. 
*
Protein fractions were pooled into six groups. 
     10   20  30  40  50 60  70   80   90 100       M 
     10   20  30  40  50   60  70 80  90  100       M 
      1           2        3     4       5           6 
           1              2           3              4      
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V. SDS-PAGE analysis of protein fractions from Pleurotus citrinopileatus 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into four groups. 
 
 
 
 
VI. SDS-PAGE analysis of protein fractions from Pleurotus cystidiosus 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into six groups. 
     10   20  30  40 50  60  70  80  90 100       M 
    10   20   30  40  50 60  70  80  90 100       M 
                1             2        3              4 
         1             2          3       4        5    6 
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VII. SDS-PAGE analysis of protein fractions from Pleurotus flabellatus 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into five groups. 
 
 
 
 
VIII. SDS-PAGE analysis of protein fractions from Pleurotus florida precipitated 
at ten percentages of salt saturation. 
*
Protein fractions were pooled into five groups. 
        10  20  30 40  50  60   70  80  90 100      M 
     10   20  30   40  50  60  70  80  90  100        M 
                 1              2     3       4           5 
        1               2        3        4        5     
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IX. SDS-PAGE analysis of protein fractions from Pleurotus pulmonarius 
precipitated at ten percentages of salt saturation. 
*
Protein fractions were pooled into five groups. 
 
 
 
 
       10  20   30  40  50   60   70  80  90 100    M 
           1             2           3     4            5     
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Appendix C: LC/MS/MS Mascot result (score, peptide sequence, protein name, protein molecular mass and origin). 
 
I. Mascot result of E5PcF3C1 
Score Peptide sequence Protein name Mr (Da) Origin 
37 MPASSLLDSLNR Phytanoyl-CoA dioxygenase 44319 Colletotrichum graminicola 
32 NPGALPAPTLSRAK AGL283Wp 39310 Ashbya gossypii 
32 QQKPLVVSSPMPYR + [O] Hypothetical protein 37599 Ajellomyces capsulata 
31 VAPEEHPVLLTEAPINPK Actin 41605 Lipomyces starkeyi 
28 LLAEGKIQVHKPK Hypothetical protein 37041 Nectria haematococca 
28 NATYANNLASLNK Palmitoyl-protein thioesterase 35152 Coprinopsis cinerea 
25 YYPGEVCLRTTDVAIINK Hypothetical protein 32641 Batrachochytrium dendrobatidis 
25 LMLTDLGIVPGKK Hypothetical protein 38234 Puccinia graminis f. sp. tritici 
25 LNPSPLIGGPVPGGR Hypothetical protein 14016 Puccinia graminis f. sp. tritici 
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Mascot result of E5PcF3C1 (Continued) 
24 MTSSSPTAKK + [O] Hypothetical protein 35599 Pyrenophora teres f. teres 
24 IDTVLNAIEAEQAEFR Peroxisomal membrane protein (Pex14p) 38420 Saccharomyces cerevisiae 
24 YLIAGATGGLGAEVLNYFVK Hypothetical protein  34383 Aspergillus terreus 
24 AVMYPNSRIFR + [O] Hypothetical protein 32710 Aspergillus niger 
24 AGSEAIIMKSYR +[O] Hypothetical protein 37932 Batrachochytrium dendrobatidis 
24 RLCGLCGPR Hypothetical protein 24966 Paracoccidioides brasiliensis 
23 TMKPVETVLK +[O] Putative GTP-binding protein 21194 Leucocoprinus cf. zamurensis 
23 MDSSITAMTSWGMAR + [O] Hypothetical protein 37895 Chaetomium globosum 
23 EGEEEGAAGPVK Transcriptional activator 37401 Arthroderma benhamiae 
22 FQHCISQLDK Hypothetical protein 18914 Myceliophthora thermophila 
22 QSLENSMEFPK Hypothetical protein 27371 Phaeosphaeria nodorum 
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Mascot result of E5PcF3C1 (Continued) 
22 MDPGMVWLFYAYR + [O] Hypothetical protein 33262 Hypocrea jecorina 
22 KPEESTSFQSR Hypothetical protein 25957 Ajellomyces capsulata 
22 AIEADPVTTK Hypothetical protein 40215 Mycosphaerella graminicola 
21 TNGGSNKEGGDCAVPLK Hypothetical protein 20474 Arthroderma benhamiae 
21 KCGIFCTDGEQAK Hypothetical protein 29586 Sordaria macrospora 
21 KSADQVPIGLIPR DNA replication licensing factor MCM7 16758 Tephromela atra var. calcarea 
21 RSLVAPPNTQGIAAR Hypothetical protein 34395 Arthroderma otae 
21 QLFQLRDLFK Hypothetical protein 35745 Cordyceps militaris 
21 AGGINAQRPLR Hypothetical protein 21883 Puccinia graminis f. sp. tritici 
21 MMQPESVAR + [O] Hypothetical protein 24774 Moniliophthora perniciosa 
21 ETVAGEPVR Hypothetical protein 15206 Ajellomyces capsulata 
20 ALNGHVTVISVEYR Hypothetical protein 23389 Aspergillus terreus 
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Mascot result of E5PcF3C1 (Continued) 
20 TMPVDIPK + [O] Hypothetical protein 33219 Yarrowia lipolytica 
20 RPVAGMVR + [O] Hypothetical protein 24169 Verticillium albo-atrum 
20 HFYSSLHTMVR + [O] Hypothetical protein 32404 Mycosphaerella graminicola 
20 FASWDIFFADER 6-phosphogluconolactonase 28266 Arthroderma gypseum 
20 RCGHGALFAALAK Hypothetical protein 34511 Moniliophthora perniciosa 
19 FAQLAMK [O] Hypothetical protein  31191 Spathaspora passalidarum 
19 SIYEEAARR Methyltransferase type 11 29475 Grosmannia clavigera 
19 QQGSQAGNQWNEGAR Hypothetical protein 29198 Moniliophthora perniciosa 
18 MSTVPNFK + [O] Hypothetical protein 34274 Postia placenta 
17 AVIVKNFDEGTK 60S ribosomal protein 15700 Batrachochytrium dendrobatidis 
17 KPATATTSK Hypothetical protein 21593 Pyrenophora teres f. teres 
16 AMEQTLLTSAMK+ [O] Hypothetical protein 22803 Nectria haematococca 
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Mascot result of E5PcF3C1 (Continued) 
16 ETEVYAVDFNPSK Hypothetical protein 35034 Encephalitozoon intestinalis 
15 WHAWVAK Hypothetical protein 34243 Arthrobotrys oligospora 
14 IVSPGMGKPPPPMLLQSLK+ [O] Hypothetical protein 29834 Verticillium albo-atrum 
14 QDSFKEFIK Hypothetical protein 16573 Puccinia graminis f. sp. tritici 
14 FEGIMGKK+ [O] Hypothetical protein 34242 Ajellomyces dermatitidis 
12 AHEPVK Hypothetical protein 15610 Pyrenophora teres f. teres 
12 ADDFR FUN81 protein 23426 Arthroderma otae 
10 YTLSC Hypothetical protein 38494 Arthrobotrys oligospora 
10 GMGGPR RAS small monomeric GTPase 31661 Cordyceps militaris 
7 FGGNI Hypothetical protein 36569 Moniliophthora perniciosa 
7 EAFSLFSQKMDGEK+ [O] Hypothetical protein 21281 Sclerotinia sclerotiorum 
7 KPAAP Hypothetical protein 24545 Schizophyllum commune 
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Mascot result of E5PcF3C1 (Continued) 
7 DPAIK NADP-dependent leukotriene B4 12-
hydroxydehydrogenase 
27822 Paracoccidioides brasiliensis 
7 LVESG Hypothetical protein 19524 Ajellomyces capsulatus 
6 YLSHA Hypothetical protein 22569 Schizophyllum commune 
4 GPSMR Hypothetical protein 22519 Paracoccidioides brasiliensis 
 
II. Mascot result of E3AbF6C1 
Score Peptide sequence Protein name Mr (Da) Origin 
30 EPESSSPDVK Hypothetical protein 20199 Colletotrichum graminicola 
29 SLLESEDEGCAR Hypothetical protein 22091 Ajellomyces capsulata 
27 KDISSGGLNLNFVK Hypothetical protein 28662 Candida tenuis 
25 MSDSTPTPSGLAAK + [O] Hypothetical protein 31587 Aspergillus clavatus 
24 QRDDSPDAVR Hypothetical protein 21299 Arthroderma gypseum 
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Mascot result of E3AbF6C1 (Continued) 
22 TPPQGSHGCTHK Hypothetical protein 32448 Botryotinia fuckeliana 
22 AAIDLQLEFKATEK Hypothetical protein 22680 Botryotinia fuckeliana 
22 IEEMYVVMNTPLGLFGER + [O] Hypothetical protein 31698 Botryotinia fuckeliana 
19 LLVGMQHRTPIK+ [O] Hypothetical protein 15998 Puccinia graminis f. sp. tritici 
19 KYHSIEATGGDVNK Whole genome shotgun sequence assembly, 
scaffold_1, strain Mel28 
17044 Tuber melanosporum 
19 DAWMGSSGYPMSFTR+ [O] Hypothetical protein 19549 Nectria haematococca 
18 GSNDSPSLPALATDSK Hypothetical protein 28489 Neurospora tetrasperma 
18 CGPPPSADR Hypothetical protein 20744 Verticillium albo-atrum 
17 QLYCEGILDAFGSK Hypothetical protein 26294 Phaeosphaeria nodorum 
17 GHPHGGIVFSDLK Oxidoreductase, short-chain 
dehydrogenase/reductase family 
32445 Neosartorya fumigata 
17 DMPGQDCR Hypothetical protein 31447 Ajellomyces capsulata 
16 TYVVPEGLAEFK 50S ribosomal protein YmL27 16080 Arthroderma gypseum 
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Mascot result of E3AbF6C1 (Continued) 
16 QPPQSDPK Hypothetical protein 29760 Vanderwaltozyma polyspora 
15 AHAPR Hypothetical protein 21658 Schizophyllum commune 
13 GPVVK Hypothetical protein 20145 Paracoccidioides brasiliensis 
12 RMGEDGTPAK + [O] Hypothetical protein 28755 Pyrenophora teres f. teres 
12 KNPPPER Hypothetical protein 16972 Sclerotinia sclerotiorum 
12 LNPQG DNA repair protein 21460 Arthroderma otae 
10 GPVTLEMR Hypothetical protein 24366 Podospora anserina 
9 RIGLF Hypothetical protein 21335 Sclerotinia sclerotiorum 
9 DFAGK Hypothetical protein 27560 Schizophyllum commune 
9 GPVVQG OB-fold nucleic acid binding domain-containing 
protein 
27408 Verticillium albo-atrum 
9 VAPAN Hypothetical protein 25500 Arthrobotrys oligospora 
8 GGPHR Hypothetical protein 27447 Arthroderma benhamiae 
8 FALPC Hypothetical protein 34031 Arthrobotrys oligospora 
8 KPLGG Hypothetical protein 27214 Neurospora crassa 
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Mascot result of E3AbF6C1 (Continued) 
7 GFHGG Hypothetical protein 22199 Chaetomium globosum 
7 LPSPA Hypothetical protein 16332 Penicillium chrysogenum 
6 APSAK Hypothetical protein 16273 Schizophyllum commune 
6 YSAGK Metallo-beta-lactamase superfamily protein 25992 Paracoccidioides brasiliensis 
6 FGSGN BZIP transcription factor 14497 Magnaporthe oryzae 
6 GCFGA Hypothetical protein 20067 Melampsora larici-populina 
5 KVAGPK Hypothetical protein 28222 Ustilago maydis 
5 FPTSK Hypothetical protein 14585 Puccinia graminis f. sp. tritici 
5 QAFTT Hypothetical protein 17335 Serpula lacrymans var. 
lacrymans 
5 EGEPR Threonine synthase 17893 Pichia angusta 
5 YDCTA Hypothetical protein 15944 Aspergillus terreus 
4 FGAAA Hypothetical protein 26129 Aspergillus terreus 
3 APGPP Acetylcholinesterase 24265 Verticillium albo-atrum 
2 AGGAY Hypothetical protein 19524 Sporisorium reilianum 
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Mascot result of E3AbF6C1 (Continued) 
1 TGGPR Hypothetical protein 15137 Puccinia graminis f. sp. tritici 
0 MGGFG+ [O] Strain CBS138 chromosome E complete 
sequence 
32989 Candida glabrata 
0 AYITL Ribosomal protein 23260 Scheffersomyces stipitis 
0 FSAAS Hypothetical protein 17539 Moniliophthora perniciosa 
 
III. Mascot result of E3AbF6C4 
Score Peptide sequence Protein name Mr (Da) Origin 
32 DPILGGAQNK Hypothetical protein 15263 Botryotinia fuckeliana 
25 GDQLMWFK + [O] Hypothetical protein 14051 Melampsora larici-populina 
24 RPKGLLGGPSAR Hypothetical protein 15151 Arthroderma benhamiae 
24 AARPQPGK Hypothetical protein 13327 Puccinia graminis f. sp. tritici 
24 AILRGQPR Hypothetical protein 11502 Colletotrichum graminicola 
21 QHWRPCEIHGK Hypothetical protein 13479 Neurospora tetrasperma 
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Mascot result of E3AbF6C4 (Continued) 
21 GVQGPM + [O] Hypothetical protein 19893 Melampsora larici-populina 
21 DVLAGPVSVARVRPR Hypothetical protein 7587 Aspergillus niger 
21 ECDPYISK Hypothetical protein 20465 Pichia pastoris 
21 AFLEELK Hypothetical protein 17753 Schizosaccharomyces japonicus 
20 QPRPSANK Hypothetical protein 16815 Magnaporthe oryzae 
20 YSILASWI Hypothetical protein 14227 Ajellomyces dermatitidis 
19 RAPQADLAK Hypothetical protein 18674 Puccinia graminis f. sp. tritici 
18 FQRGNSLSAVTSK Hypothetical protein 11707 Cordycep militaris 
18 VAAGAMLASPKSL + [O] Hypothetical protein 7919 Botryotinia fuckeliana 
18 GPNGSMFK Hypothetical protein 16052 Postia placenta 
18 DFAFGATR Hypothetical protein 14961 Ajellomyces dermatitidis 
15 MDPRMLLEMYMSMAGAR Hypothetical protein 20135 Puccinia graminis f. sp. tritici 
15 HVFNSCKK Hypothetical protein 11324 Leptosphaeria maculans 
11 DIPAC Hypothetical protein 16181 Neosartorya fumigata 
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Mascot result of E3AbF6C4 (Continued) 
13 AHEPVK Hypothetical protein 15610 Pyrenophora teres f. teres 
9 ALPPL Hypothetical protein 14011 Arthroderma otae 
8 PSSNK Hypothetical protein 15080 Botryotinia fuckeliana 
7 DTYGG Hypothetical protein 11396 Ajellomyces capsulata 
7 ENVLFG MRP-like ABC transporter 13589 Botryotinia fuckeliana 
5 DGPID Hypothetical protein 11627 Pyrenophora tritici-repentis 
3 IPMAK + [O] Hypothetical protein 14259 Puccinia graminis f. sp. tritici 
3 PLGPK Hypothetical protein 16453 Ajellomyces dermatitidis 
3 KPLNG Hypothetical protein 17557 Paracoccidioides brasiliensis 
2 AGGAY Hypothetical protein 19524 Sporisorium reilianum 
1 GSAPK 60S ribosomal protein 17831 Ajellomyces dermatitidis 
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Appendix D: Symbol, properties and structure of amino acids 
Amino acid Symbol Properties Structure 
1-Letter 3-Letter 
Alanine A Ala 
Hydrophobic 
Neutral 
 
Glycine G Gly 
 
Isoleucine I Ile 
 
Leucine L Leu 
 
Methionine M Met 
 
Phenylalanine F Phe 
 
Proline P Pro 
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Tryptophan W Trp 
Hydrophobic 
Neutral 
 
Valine V Val 
 
Asparagine N Asn 
Hydrophilic 
Neutral 
 
Cysteine C Cys 
 
Glutamine Q Gln 
 
Serine S Ser 
 
Threonine T Thr 
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Tyrosine Y Tyr Hydrophilic 
Neutral  
 
Arginine R Arg 
Hydrophilic 
Charged (+) 
 
Histidine H His 
 
Lysine K Lys 
 
Aspartate D Asp 
Hydrophilic 
Charged (-) 
 
Glutamate E Glu 
 
 
(Source: http://biomedapps.curtin.edu.au/biochem/tutorials/AAs/AA.html) 
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Appendix E: LC/MS/MS spectra of selected peptides 
 
 
 
I. LC/MS/MS spectra of peptide 1 (AHEPVK) 
 
 
II. LC/MS/MS spectra of peptide 2 (GPSMR) 
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III. LC/MS/MS spectra of peptide 3 (KVAGPK) 
 
 
 
IV. LC/MS/MS spectra of peptide 4 (FALPC) 
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V. LC/MS/MS spectra of peptide 5 (RIGLF) 
 
 
 
 
VI. LC/MS/MS spectra of peptide 6 (EGEPR) 
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VII. LC/MS/MS spectra of peptide 7 (APSAK) 
 
 
 
VIII. LC/MS/MS spectra of peptide 8 (GVQGPM) 
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IX. LC/MS/MS spectra of peptide 9 (PSSNK) 
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Appendix F: Extrapolation of graph for the determination of IC50 value  
 
 
I. Graph for the determination of IC50 value of peptide 1 (AHEPVK). 
 
 
II. Graph for the determination of IC50 value of peptide 2 (GPSMR). 
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III. Graph for the determination of IC50 value of peptide 3 (KVAGPK). 
 
 
IV. Graph for the determination of IC50 value of peptide 4 (FALPC). 
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V. Graph for the determination of IC50 value of peptide 5 (RIGLF). 
 
 
VI. Graph for the determination of IC50 value of peptide 6 (EGEPR). 
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VII. Graph for the determination of IC50 value of peptide 7 (APSAK). 
 
 
VIII. Graph for the determination of IC50 value of peptide 8 (GVQGPM). 
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IX. Graph for the determination of IC50 value of peptide 9 (PSSNK). 
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Appendix G: SEC chromatograms of negative controls 
 
 
Peak No. Ret. Height Area 
1 9.49 24 470 
2 11.45 61 1356 
I. SEC chromatogram of HCl with retention time (min), peak height (mAU) 
and peak area (mAU). 
 
 
Peak No. Ret. Height Area 
1 9.77 50 1710 
2 11.31 76 2769 
II. SEC chromatogram of potassium phosphate buffer with retention time (min), 
peak height (mAU) and peak area (mAU). 
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Peak No. Ret. Height Area 
1 7.45 18 359 
2 7.76 16 206 
3 8.26 15 438 
4 9.60 106 2198 
5 11.44 62 1321 
III. SEC chromatogram of pepsin in HCl with retention time (min), peak height 
(mAU) and peak area (mAU). 
* The concentration used for injection into the SEC column was 5-fold lower than the 
concentration used in the peptide digestion assay. 
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Peak No. Ret. Height Area 
1 7.32 13 221 
2 7.75 22 474 
3 8.31 43 1361 
4 9.76 185 3630 
5 11.37 58 1243 
IV. SEC chromatogram of pepsin, trypsin and chymotrypsin in HCl and 
potassium phosphate buffer with retention time (min), peak height (mAU) 
and peak area (mAU). 
* The concentration used for injection into the SEC column was 5-fold lower than the 
concentration used in the peptide digestion assay. 
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